First syntheses of fluoromuscimols by Abdul Manan, Mohd Abdul Fatah
FIRST SYNTHESES OF FLUOROMUSCIMOLS 
Mohd Abdul Fatah Abdul Manan 
 
A Thesis Submitted for the Degree of PhD 
at the 
University of St Andrews 
 
  
2017 
Full metadata for this item is available in                                     
St Andrews Research Repository 
at: 
http://research-repository.st-andrews.ac.uk/ 
 
 
 
 
Please use this identifier to cite or link to this item: 
http://hdl.handle.net/10023/11029  
 
 
 
 
This item is protected by original copyright 
 
This item is licensed under a 
Creative Commons Licence
 
  
 
First syntheses of fluoromuscimols 
 
 
Mohd Abdul Fatah Abdul Manan 
 
 
 
 
This thesis is submitted in partial fulfilment for the degree of PhD  
at the  
University of St Andrews 
 
 
 
2017 
 
 
 
 
 
 
 
ii 
 
1. Candidate’s declarations: 
 
I, Mohd Abdul Fatah Abdul Manan, hereby certify that this thesis, which is 
approximately 36,800 words in length, has been written by me, and that it is the 
record of work carried out by me, or principally by myself in collaboration with 
others as acknowledged, and that it has not been submitted in any previous 
application for a higher degree.  
 
I was admitted as a research student in September 2013 and as a candidate for the 
degree of PhD in September 2014; the higher study for which this is a record was 
carried out in the University of St Andrews between 2013 and 2017.  
 
Date: ___________________  Signature of Candidate: ________________ 
 
 
2. Supervisor’s declaration: 
 
I hereby certify that the candidate has fulfilled the conditions of the Resolution 
and Regulations appropriate for the degree of Doctor of Philosophy in the 
University of St Andrews and that the candidate is qualified to submit this thesis 
in application for that degree.  
 
 
Date: ___________________  Signature of Supervisor: ________________ 
 
 
 
iii 
 
3. Permission for publication:  
 
In submitting this thesis to the University of St Andrews I understand that I am 
giving permission for it to be made available for use in accordance with the 
regulations of the University Library for the time being in force, subject to any 
copyright vested in the work not being affected thereby.  I also understand that the 
title and the abstract will be published, and that a copy of the work may be made 
and supplied to any bona fide library or research worker, that my thesis will be 
electronically accessible for personal or research use unless exempt by award of 
an embargo as requested below, and that the library has the right to migrate my 
thesis into new electronic forms as required to ensure continued access to the 
thesis. I have obtained any third-party copyright permissions that may be required 
in order to allow such access and migration, or have requested the appropriate 
embargo below.  
 
The following is an agreed request by candidate and supervisor regarding the 
publication of this thesis: 
 
No embargo on print copy. No embargo on electronic copy. 
 
Date: ___________________  Signature of Candidate: ________________ 
 
Signature of Supervisor: ___________________ 
 
 
 
iv 
 
Acknowledgements 
 
I would like to express my sincere thanks to my supervisor Professor David 
O’Hagan for offering me the opportunity to study and work in his group on such 
an interesting and challenging project, and for his guidance, comment, 
encouragement, support and unlimited help. I am very grateful to the entire 
O’Hagan group for their advice and assistance for chemistry matters were 
essential. 
 
I also would like to express my appreciation to Dr David Cordes and Professor 
Alexandra Slawin for their contribution to the single crystal X-ray analyses. Many 
thanks also go to Dr Thomas Lebl and Mrs Melanja Smith for their help with the 
NMR. I am also thankful to Mrs Caroline Horsburgh and EPSRC National Mass 
Spectrometry Service, Swansea for mass spectrometry analyses. Not forgetting, 
our Australian collaborator at the University of Sydney in Australia, Professor 
Mary Collins for biological assays of fluoromuscimols and iodomuscimol.  
 
I wish to extend my deepest gratitude to my family for their constant 
encouragement and support during all the years of my study.  Finally, special 
thanks to Universiti Teknologi MARA and Ministry of Education of Malaysia for 
awarding me the scholarship.   
 
 
 
 
v 
 
Table of Contents 
 
Abbreviations   ix 
Abstract   xv 
Chapter 1: Small molecule agonists of GABA receptors  
1.1 Introduction 1 
1.2 Fluorine in medicinal chemistry 3 
 1.2.1 Some drugs containing isoxazole moiety in the CNS 4 
1.3 Muscimol: Active compound of Amanita muscaria 5 
1.4 GABA: The inhibitory neurotransmitter in CNS 8 
 1.4.1  Synthesis and degradation of GABA via GABA shunt 9 
 1.4.2  GABAA receptors: Synaptic and extrasynaptic receptors 10 
 1.4.3  Phasic and tonic inhibition of GABAA receptors 14 
 1.4.4 GABAA rho receptors 15 
1.5 GABA receptor agonists and partial agonists 17 
1.6 Positron emission tomography and fluorine-18 in nuclear 
medicine 
22 
1.7 Fluorine-18 labelling methods 25 
 1.7.1  Nucleophilic fluorination 25 
 1.7.2  Electrophilic fluorination 28 
1.8 Synthesis and use of [
18
F]FDG in nuclear medicine  31 
 1.8.1  Synthesis of [
18
F]FDG via nucleophilic fluorination  31 
1.9 GABAA receptor radiotracers 33 
 1.9.1 PET radioligands binding to the GABA binding site 33 
 1.9.2  PET radioligands binding to the benzodiazepine binding site 34 
1.10 References 41 
   
Chapter 2: Syntheses and biological studies of fluoromuscimols 
2.1 Introduction 49 
2.2 Previous syntheses of muscimol 50 
2.3 Aims of this project 54 
2.4 Results and discussion 55 
vi 
 
 2.4.1  Approach A-Retrosynthetic approach 55 
 2.4.2  Approach B-Direct fluorination using fluorine gas at  
  Durham University  
62 
 2.4.3  Approach C-Direct fluorination of isoxazole motifs using 
  electrophilic N-F reagents and nucleophilic fluoride sources  
66 
   2.4.3.1 Fluorination attempts on ester (94) 67 
   2.4.3.2 Nitration of methyl ester (94) 70 
   2.4.3.3 Fluorination attempts on nitro ester (100) 72 
   2.4.3.4 Bromination of methyl ester (94) 74 
   2.4.3.5 Fluorination attempts on brominated ester (105) 76 
   2.4.3.6 Bromination of methyl ether (96) 78 
   2.4.3.7 Fluorination of (107) via a lithium-halogen  
   exchange reaction 
79 
   2.4.3.8 Synthesis of brominated di-Boc (108) 82 
   2.4.3.9 Fluorination of (108) via a lithium-halogen  
   exchange reaction 
84 
 2.4.4  Successful route to fluoromuscimol (64) 87 
 2.4.5  Synthesis of trifluoromethylmuscimol (65) 97 
 2.4.6  Biological studies  106 
2.5 Conclusions 111 
2.6 References 113 
   
Chapter 3: Towards the late stage fluorination of muscimol through 
diaryliodonium salts  
3.1 Introduction to hypervalent iodine compounds 118 
3.2 Nomenclature, oxidation state and bonding 120 
3.3 Some of 3-and 5-iodane applications in organic transformations  122 
3.4 Diaryliodonium salts 125 
 3.4.1  Structural features and reactivity 125 
 3.4.2  Synthesis of diaryliodonium salts 125 
 3.4.3  Mechanism of nucleophilic substitution on iodonium salts 129 
 3.4.4  Application of iodonium salts as precursors for nucleophilic 
  fluorination in PET 
131 
3.5 Aims of this project 135 
3.6 Results and discussion 136 
vii 
 
 3.6.1  Synthesis of iodinated precursor (166) 136 
 3.6.2  Synthesis of diacetoxyiodoarene (167) 137 
 3.6.3 Synthesis of diaryliodonium trifluoroacetate salt (171) from 
  diacetoxyiodoarene (167) 
139 
 3.6.4  Fluorination attempts on diaryliodonium tetrafluoroacetate 
  salt (171) 
141 
 3.6.5 Synthesis of 4-iodo ether (173) 144 
 3.6.6 Attempted synthesis of diacetoxyiodoarene (174) 145 
 3.6.7 One-pot synthesis of diaryliodonium tetrafluoroborate salt 
  (176) and (177) 
146 
 3.6.8 Fluorination attempts on diaryliodonium salts (176) and 
  (177) 
151 
 3.6.9 Synthesis of iodomuscimol (165) 153 
 3.6.10 Biological results  158 
3.7 Conclusions 159 
3.8 References 160 
   
Chapter 4: Experimental Section 
4.1 General experimental protocol  165 
 4.1.1 Reagents, solvents and reaction conditions  165 
 4.1.2 Chromatography and mass spectrometry  165 
 4.1.3 Nuclear magnetic resonance (NMR) spectroscopy 166 
 4.1.4 X-ray crystallography  167 
 4.1.5 Other analysis 168 
4.2 Experimental protocols 169 
4.3 References 210 
   
Appendix 
1.1 Crystallographic information for (101) 212 
1.2 Crystallographic information for (105) 213 
1.3 Crystallographic information for (107) 214 
1.4 Crystallographic information for (108) 215 
1.5 Crystallographic information for (120) 216 
1.6 Crystallographic information for (121) 217 
viii 
 
1.7 Crystallographic information for (122) 218 
1.8 Crystallographic information for (64) 219 
1.9 Crystallographic information for (135) 220 
1.10 Crystallographic information for (166) 221 
1.11 Crystallographic information for (171) 222 
1.12 Crystallographic information for (173) 223 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
Abbreviations 
 
 dipole moment  
 nuclear magnetic resonance chemical shift parts per 
million downfield from a standard 
 GABAA -aminobutyric acid type A rho 
3 trivalent 
5 pentavalent 
{
19
F} fluorine decoupled 
{
1
H} proton decoupled 
18-Crown-6 1,4,7,10,13,16-hexaoxacyclooctadecane 
3c-4e 3-centre 4-electron 
Ac acetyl 
Ac2O acetic anhydride 
AcOOH peracetic acid 
ACPCA aminocyclopropanecarboxylic acid 
AmOH amyl alcohol 
APCI atmospheric pressure chemical ionisation 
APS aminopropanesulfonic acid 
aq aqueous  
Ar aryl 
ATR attenuated total reflectance 
BBB blood brain barrier  
BBFO broad band fluorine observation 
BMS borane dimethyl sulfide 
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
br s broad singlet 
Bu butyl 
BuLi butyl lithium 
BZD benzodiazepine 
ca. approximately 
CA1-3 subfield of hippocampus 
x 
 
CACA cis-4-aminocrotonic acid 
CACP cis-3-aminocyclopentane-1-carboxylic acid 
CAMP cis-2-aminomethylcyclopropane-1-carboxylic acid 
CB1 cannabinoid receptor type 1 
CB2 cannabinoid receptor type 2 
cGMP current good manufacturing practices 
CIF crystallographic information file 
conc. concentrated 
CNS central nervous system 
cRNAs cloned ribonucleic acids  
CSA camphorsulfonic acid 
CT computerised tomography 
d doublet 
DBU 1,8-diazabicycloundec-7-ene 
DCE dichloroethene  
DCM dichloromethane 
dd doublet of doublets  
dec. decomposition 
DEPT distortionless enhancement by polarisation transfer 
DHM dihydromuscimol 
dm doublet of multiplets  
DMAP N,N-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMP Dess-Martin periodinane  
DMSO dimethyl sulfoxide 
EC electron capture  
EC50 concentration requires to produce 50% of the response in 
Emax 
EDG electron-donating group 
Emax maximal current produced by a saturating concentration 
of the agonist 
eq equivalent  
ESI electron spray ionisation 
Et ethyl 
xi 
 
EWG electron-withdrawing group 
[
18
F]AH114726 ethyl 7-[
18
F]fluoro-5-methyl-6-oxo-3a,4,5,6-tetrahydro-
3H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
[
18
F]FAZA [
18
F]fluoroazomycinarabinofuranoside 
[
18
F]CB91 N-(4-methylcyclohexyl)-1-(4-[
18
F]fluorobenzyl)-2-oxo-
1,2-dihydro-1,8-naphthyridine-3-carboxamide 
FDA the food and drug administration 
[
18
F]DAA1106 N-(2,5-dimethoxybenzyl)-N-(5-[
18
F]fluoro-2-
phenoxyphenyl)acetamide 
[
18
F]FDG 2-[
18
F]fluoro-2-deoxy-D-glucose 
[
18
F]FEFMZ (5-2’-[18F]fluoroethyl)-5-desmethylflumazenil 
FEP fluorinated ethylene propylene 
[
18
F]FFMZ (3-2’-[18F]fluoro)-flumazenil 
F-GABA fluoro--aminobutyric acid 
[
18
F]GEH120348 tert-butyl 7-[
18
F]fluoro-5-methyl-6-oxo-3a,4,5,6-
tetrahydro-3H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate 
FIBX 2-iodoxy-3,4,5,6-tetrafluorobenzoic acid 
[
18
F]FLT 3’-deoxy-3’-[18F]fluorothymidine 
[
18
F]MFBG meta-[
18
F]fluorobenzylguanidine 
[
18
F]FMZ [
18
F]flumazenil 
FT-IR fourier transform infrared spectroscopy 
[
18
F]UCB-H (R)-1-((3-[
18
F]fluoropyridin-4-yl)methyl)-4-(3,4,5-
trifluorophenyl)pyrrolidin-2-one 
GABA -aminobutyric acid 
GABAA/B/C
 
-aminobutyric acid subclass A/B/C 
GABARc -aminobutyric acid subclass C receptors 
GABA-T -aminobutyric acid transaminase 
GAD glutamic acid decarboxylase 
GAT-1 -aminobutyric acid transporter 1 
h hour 
HEK293 human embryonic kidney cells 293 
HEPES 4-(2-hydroxylethyl)piperazine-1-ethanesulfonic acid  
HMBC heteronuclear multiple bond correlation 
HMPA hexamethylphosphoramide 
HPLC high performance liquid chromatography  
xii 
 
HRMS high resolution mass spectrometry  
HSQC heteronuclear single quantum correlation 
IBX 2-iodoxybenzoic acid 
i-Pr isopropyl  
IR infrared  
IUPAC the international union of pure and applied chemistry 
J coupling constant  
K222 4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane 
KHMDS potassium hexamethyldisilazide  
L ligand 
Lit. literature  
Max. maximum 
m/z mass to charge ratio 
mCBA meta-chlorobenzoic acid 
mCPBA meta-chloroperoxybenzoic acid 
Me methyl 
MFSDA methylfluorosulfonyl difluoroacetate 
Min. minimum 
min minute 
mp melting point  
MRI magnetic resonance imaging 
MTBE methyl tert-butyl ether  
m multiplet 
MW microwave 
N number of valence electrons 
NBS N-bromosuccinimide  
NCA no-carrier-added 
nexp number of repeats  
NFSI N-fluorobenzenesulfonimide 
NIS N-iodosuccinimide  
NSI nanospray ionisation 
Nu nucleophile  
OAc acetate 
xiii 
 
OTf triflate 
Oxone  potassium peroxymonosulfate 
P4S piperidine-4-sulfonic acid 
PET positron emission tomography   
Ph phenyl 
4-PIOL 5-(4-piperidyl)-3-isoxazolol 
PLP pyridoxal-5’-phosphate 
PMA phosphomolybdic acid 
PMP pyridoxamine-5’-phosphate 
ppm parts per million 
py pyridine 
quant.  quantitative 
R substituent 
RCY radiochemical yield 
Rf retention factor 
rt room temperature 
s singlet 
sec second 
sept septet  
SET single electron transfer 
SNAr nucleophilic aromatic substitution  
SPB sodium perborate tetrahydrate 
SPECT single-photon emission computed tomography 
SSADH succinic semialdehyde dehydrogenase 
SV2A synaptic vesicle glycoprotein 2A 
t triplet 
TACA trans-4-aminobut-2-enoic acid 
TACP trans-3-aminocyclopentane-1-carboxylic acid 
TBAF tetrabutylammonium fluoride 
TFA trifluoroacetic acid 
TfOH triflic acid 
THF tetrahydrofuran 
THIP 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol 
xiv 
 
TiCpCl3 cyclopentadienyl(IV) titanium trichloride 
tR retention time 
Ts tosyl 
UDEFT uniform driven equilibrium fourier transform 
uv ultraviolet 
v/v volume per volume 
W Watt 
ZAPA Z-3-[(aminoiminomethyl)thio]prop-2-enoic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
Abstract 
 
Chapter 1 provides a general introduction on the role of bioisosterism of fluorine 
aiming to improve the pharmacokinetics properties of lead compounds. GABAA 
receptors specifically, synaptic GABAA receptors, extrasynaptic GABAA 
receptors and GABAA rho receptors are then presented. Compounds that exhibit 
agonist and partial agonist effects at these receptors are also discussed. The 
applications of some compounds as GABAA receptor PET radiotracers are also 
described.  
 
Chapter 2 details the synthesis of two fluorinated analogues of muscimol, 
fluoromuscimol and trifluoromethylmuscimol. Fluoromuscimol was obtained 
from the lithiation of a Boc-protected isoxazole followed by in-situ fluorination 
using NFSI, whereas trilfuoromethylmuscimol was obtained from the coupling of 
a heteroaryl iodide with trifluoromethylcopper species, which was generated        
in-situ from MFSDA in the presence of CuI. Fluoromuscimol and 
trifluoromethylmuscimol were assessed on human synaptic (122), extrasynaptic 
(42) and 1 subunits of the GABAA receptor. The biological results show that 
fluoromuscimol exhibits greater maximum response in comparison to GABA at 
the extrasynaptic GABAA receptors (42), but lower overall potency, whereas 
trifluoromethylmuscimol was inactive at all the tested GABAA receptors.  
 
 
 
 
 
xvi 
 
Chapter 3 discusses the synthesis and late stage fluorination of diaryliodonium 
salts as precursors to fluoromuscimol. Application of iodonium salts as precursors 
for nucleophilic fluorination in PET studies are also highlighted. The last part of 
this chapter focuses on the synthesis of iodomuscimol as a potential alternative 
SPECT radiotracer to fluoromuscimols in probing GABA binding sites on 
GABAA receptors.           
1 
 
Chapter 1: Small molecule agonists of GABA receptors  
 
1.1 Introduction  
 
Elemental fluorine was first isolated in 1886 by Henri Moissan. His historic and 
courageous efforts focused on its isolation earned him a Nobel Prize in 1906.
1
 
Fluorine (van der Waals radius of 1.47 Å) (Table 1) is the smallest atom after 
hydrogen (van der Waals radius of  1.20 Å) and the most electronegative element 
in periodic table. The substitution of hydrogen with fluorine has proved to be a 
good replacement as it causes a minimal steric change to the host motif. Thus, 
fluorine is a good hydrogen mimic and has been widely employed in medicinal 
chemistry in this regard.
2,3
  
 
Atom I Br Cl O F H 
Van der Waals radii (Å) 1.98 1.85 1.75 1.52 1.47 1.20 
 
Table 1: Fluorine van der Waals radii relative to other electronegative elements.
4
 
 
The high electronegativity (4.0, Pauling scale)
5
 and strong dipole moment            
( C-F = 1.4 D)6  of fluorine result in a significant ionic character to the C-F bond, 
which makes the C-F bond the strongest single bond that carbon can form with 
any other element.
7
 Table 2 summarises the bond length and bond dissociation 
energy of some common elements bound to carbon. This property increases the 
chemical and thermal stability of a fluorinated compound, a feature that is widely 
used to improve drug half-life.
8,9
 
 
2 
 
Bond C-F C-H C-O C-C C-Cl C-N 
Length (Å) 1.35 1.09 1.43 1.54 1.77 1.47 
Energy (kcal/mol) 105.4 98.8 84.0 83.1 78.5 69.7 
 
Table 2: Bond length and bond dissociation energy of some common elements in 
organic compounds.
7
 
 
Bioisosterism is an important concept and strategy in medical chemistry. It refers 
to the capacity of subunits or functional groups with similar sizes or shapes to be 
interchanged without significant perturbation in biological activity,
10
  but may 
have a significant role in the alteration of  pharmacokinetics.
11
 Due to the similar 
steric parameters described above, fluorine acts as a bioisostere of hydrogen and 
the incorporation of fluorine into molecules can significantly affect 
physiochemical properties such as electronegativity, steric size and lipophilicity.
12
  
 
The application of monovalent substitution of hydrogen by fluorine is 
demonstrated by synthetic cannabinoids (Figure 1). Replacement of hydrogen in 
(1a), (2a) and (3a) to give (1b), (2b) and (3b) respectively, resulted in enhanced 
affinity and efficacy towards the CB1 receptor. This greater binding affinity and 
efficacy could be attributed to the activation of the CB1 receptor by the terminal 
fluorine atom of the N-pentyl substituent of these cannabinoids resulting in a 
stronger interaction with the receptor.
13
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Figure 1: Effects of bioisosteric fluorine in synthetic cannabinoids. 
 
1.2 Fluorine in medicinal chemistry 
 
Because of its extreme chemical properties, fluorine has been exploited 
extensively in drug design and development.
14,15
 The discovery of the first 
fluorinated bioactive compound by Fried in 1954 was a major breakthrough in 
medicinal chemistry. Fludrocortisone (4) was found to possess a remarkable 
glucocorticoid activity and has been employed ever since in the treatment of 
Addison’s and congenital adrenal hyperplasia diseases.16 A few year later, 
Heidelberger et al., reported the first synthesis of 5-fluorouracil (5), a drug which 
exhibits profound antitumor-inhibiting activity and one that has been widely used 
in the treatment of solid malignant tumors.
17
  Since then, fluorine has become an 
important and essential tool in drug discovery and has been incorporated to 
numerous blockbuster drugs.  
 
4 
 
1.2.1 Some drugs containing isoxazole moiety acting on the central nervous 
systems (CNS)  
 
Atypical antipsychotic drugs are a class of compounds that are used as medication 
for the treatment of schizophrenia and other related central nervous system 
disorder. They operate by decreasing the dopamine levels in brain.
18
 Among these 
structurally diverse compounds, the 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole 
moiety has received much attention, with risperidone (6) being the first compound 
of this family when it was approved by the FDA in 1993 for the treatment of 
schizophrenia and bipolar disorder.
19
 Risperidone exhibits comparable efficacy 
and is less toxic than haloperidol.
20
 Subsequent studies by Janssen,
21
 led to the 
discovery of its hydroxyl analogue, paliperidone (9-hydroxyrisperidone) (7) 
which appears to be the primary active metabolite of risperidone. With less side 
effects and better pharmacokinetic properties, paliperidone has been regarded as 
an improved drug of risperidone.
22
 It is marketed in tablets form as a racemic 
mixture and was approved by the FDA in 2006 for the treatment of schizophrenia.  
 
Moreover, paliperidone palmitate (8), an injectable new-generation of 
antipsychotic drug has been developed and approved by the FDA in 2009 and in 
Europe in 2011.
23
 It serves as an alternative to oral delivery of paliperidone and 
offers better efficacy and tolerability due to improved adherence and more stable 
pharmacokinetics.
24
 Another member of this family of compound is iloperidone 
(9), which was developed by Vanda Pharmaceuticals for the treatment of acute 
schizophrenia in adults.
25
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1.3 Muscimol: active compound of Amanita muscaria 
 
The mushroom Amanita muscaria (Figure 2) also known as fly agaric has 
powerful psychotropic and hallucinogenic effects. Because of its important effects 
on brain activity, it was one of the first psychoactive drugs used by man.
26
  
 
 
 
Figure 2: Amanita muscaria (fly agaric) (Photo by Onderwijsgek is licenced under              
CC BY-SA 3.0 NL) adapted from 
https://commons.wikimedia.org/wiki/File:Amanita_muscaria_3_vliegenzwammen
_op_rij.jpg, (accessed June 2016).
27
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Numerous efforts have been made to identify and isolate the psychoactive 
constituents of Amanita muscaria. The first active chemical species of Amanita 
muscaria were isolated in 1964 by Takemoto et al.
28
 These compounds, exist in 
zwitterionic form and were shown to be ibotenic acid (10) and muscimol (11). 
Ibotenic acid is biosynthesised by the mushroom, whereas muscimol is formed as 
a consequence of decarboxylation, a process that proceeds without an enzyme 
catalyst. 
26
 Later, two groups independently reported the isolation and structure 
determination of the active amino acids of Amanita muscaria.
29,30
                 
         
 
 
Muscimol (11) is a more potent GABAA receptor agonist than GABA                  
(-aminobutyric acid) (12) and is used as a tool in neurobiology. It binds and is 
capable of activating GABA receptors in a similar mode to that of GABA, altering 
the normal function of the neurones and leading to psychoactive effects. By 
contrast to GABA, muscimol can cross the blood brain barrier on systemic 
administration affecting the central nervous system in various ways. It has also 
been widely used as a selective GABAA receptor agonist of high efficacy. 
Unfortunately, despite its proven efficacy, muscimol is not clinically useful as it is 
toxic and rapidly decomposes in vivo and produces metabolites which may 
contribute to the pronounced toxicity of muscimol.
26,31,32
 Chemically, muscimol 
7 
 
belongs to the isoxazol-3-one family of alkaloids. It contains an electron-rich 
isoxazole ring with a OH at the C-3 and an amino methyl group at C-5. 
 
The protolytic properties of muscimol are comparable to GABA (12) with pKa 
values of 4.8 and 8.4 for muscimol and 4.0 and 10.7 for GABA respectively. 
Therefore, at neutral pH these compounds exist as zwitterions. Unlike GABA, the 
conformational mobility of muscimol (11) is more constrained due to the ring 
(Figure 3).
26
 
 
 
Figure 3: Conformational restriction of muscimol (11) compared to GABA (12). 
 
 
Gaboxadol (THIP) (13), a more conformationally rigid and restricted analogue of 
muscimol is a partial agonist at the synaptic GABAA receptors. Although less 
potent than muscimol, THIP was shown to be a super agonist at extrasynaptic 
GABAA receptors.
33,34
 Moreover, THIP is comparatively non-toxic in animals and 
can cross the blood brain barrier (BBB) after systemic administration.
35,36
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1.4 GABA: The inhibitory neurotransmitter in CNS 
 
Neurotransmitters can be placed in two classes, excitatory and inhibitory. 
Excitatory neurotransmitters are exemplified by acetylcholine and glutamic acid, 
whereas GABA and glycine serve as major inhibitory neurotransmitters. Binding 
of these neurotransmitters to the ligand-gated ion channels receptors can lead to 
either excitatory postsynaptic potentials, resulting in depolarisation or inhibitory 
postsynaptic potentials, resulting in hyperpolarisation.
37
 GABA (12) is the major 
fast inhibitory neurotransmitter in the mammalian central nervous system. It is 
essential in maintaining the overall balance between neuronal excitation and 
inhibition of normal brain. Disturbing the balance between excitatory and 
inhibitory neurotransmission can lead to a range of conditions which include 
convulsions, anxiety, high blood preassure, restlessness and insomnia. Extreme 
imbalance of neurotransmission can result in death.
36
  
 
GABA acts at receptors that can be classed as either ionotropic (receptors that are 
ligand-gated ion channels-GABAA and GABAC receptors) or metabotropic        
(G-protein coupled receptors-GABAB receptors). Cognitive disorder, epilepsies, 
mood disorders, schizophrenia and sleep disorders are all associated with GABA 
imbalances.
38–40
 
 
 
 
 
9 
 
1.4.1 Synthesis and degradation of GABA via GABA shunt 
 
Since GABA cannot cross the blood brain barrier, its supply is biosynthesised in 
the brain through a closed-loop process known as the GABA shunt pathway.
41
 
The first step in GABA biosynthesis involves the transamination of                              
-ketoglutarate (14) which is formed from glucose metabolism in the Krebs cycle 
into L-glutamic acid (15) by the enzyme GABA transaminase (GABA-T) 
(Scheme 1). Glutamic acid decarboxylase (GAD), a PLP-dependent enzyme then 
catalyses the decarboxylation of glutamic acid to form GABA (12). GABA is 
further metabolised by GABA-T, which is also a PLP-dependent enzyme to form 
succinic semialdehyde (16). This process converts PLP to PMP, then PMP is 
recycled back to PLP via transamination with -ketoglutarate (14), regenerating 
L-glutamic acid (15). Succinic semialdehyde (16) is then oxidised by succinic 
semialdehyde dehydrogenase (SSADH) to succinic acid (17). It can then re-enter 
the Krebs cycle to complete the loop (Scheme 1). In order to conserve the supply 
of GABA, transamination only occurs when the parent compound, -ketoglutarate 
(14), is present to accept the amino group removed from GABA to form glutamic 
acid (15). In other words, GABA only can be metabolised in the presence of        
-ketoglutarate (14). 
10 
 
 
Scheme 1: Synthesis of GABA (12) from Krebs cycle.
41
 
 
1.4.2 GABAA receptors: Synaptic and extrasynaptic receptors 
 
GABAA receptors are mostly heteropentameric proteins (Figure 4) that are 
assembled from a family of 19 homologous subunits, six  subunits (1-6), three  
subunits (1-3), three  subunits (1-3), three  subunits (1-3) and one each of the , 
, , and  subunits. Most GABAA receptors are constituted from two copies of         
-subunits, two copies of -subunits and one copy of another subunit (, , or 
).32,33 The diversity of these subunit compositions gives rise to a substantial, 
anatomical, functional and pharmacological heterogeneity. The fast signalling of 
11 
 
brain mediated by GABAA receptors can be classified into two main groups, 
synaptic GABAA receptors and extrasynaptic GABAA receptors.
33
 
 
Figure 4: Heteropentameric GABAA receptor.
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Synaptic GABAA receptors consist of two  subunits (1-4 or 6), two  
subunits and one  subunit (usually 2) and have a relatively low sensitivity to 
GABA. They can be activated by a high concentration of GABA. Extrasynaptic 
GABAA receptors are constituted from two  subunits (1, 4, or 6), two  
subunits and one  subunit. They are highly sensitive to GABA can respond to 
low concentrations of spill-over GABA.
37,43
 In addition, the 5 subunit GABAA 
receptors which do not include the  subunit are also present in the extrasynaptic 
membranes. The  subunit is only found in the extrasynaptic population, which 
distinguish the two receptors classes.
44
 Both synaptic and extrasynaptic subunit 
combinations are shown to be exclusively localised in the brain in various 
neuronal cells (Table 3).
45
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Subunit composition Brain location 
GABA potency 
(EC50)
a
 (M) 
Synaptic   
122 Ubiquitous
46–48
 6.6 
132 Ubiquitous 2.1 
232 
Hippocampus, amygdala, lateral septum 
caudate putamen
46–48
 
13.4 
32/32 Cerebral cortex, thalamus 12.5 
42/32 Hippocampus, thalamus
49
 2.1 
632 Cerebellum 0.17 
Extrasynaptic   
42/3 
Dentate gyrus granule layer,
50,51
 
hippocampus,
50,51
 thalamus
51
 
0.91-1.7 
1 
Dentate gyrus molecular layer,
45,52
 
hippocampal interneurons
52
 
3.7 
532 
Cerebral cortex,
53
 CA1-3 
hippocampus
53,54
 
1.4 
62/3 Cerebellum granule layer
55
 0.17 
 
a
Potency data based on recombinantly expressed receptors HEK293 cells.
56
 
Table 3: GABAA receptor subunit compositions and distribution in the brain. 
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Figure 5 illustrates GABA signalling in the brain. The GABA molecules are 
packaged in small vesicles in the neuronal axon terminus. Activation of 
exocytosis by neuronal activity leads to the release GABA into the synaptic cleft, 
the gap between presynaptic and postsynaptic membrane. Some of these 
molecules bind to synaptic GABAA receptors and activate the receptor, allowing 
the migration of the chloride ions into the neuron. This results in the 
hyperpolarisation of the cell and inhibition of the neuronal activity.
57
 The majority 
of the GABA released is taken up by GABA Transporter 1 (GAT 1), the primary 
reuptake protein and mechanism responsible for transport of the released GABA. 
A lower concentration of GABA molecules diffuse out of the synaptic cleft to 
bind and activate the extrasynaptic GABAA receptors.
43
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: GABA signalling in the brain (adapted from U. Rudolph and                 
B. Antkowiak, Nat. Rev. Neurosci., 2004).
58
 
 
Presynaptic 
Synaptic cleft 
Synaptic 
GABAA receptors 
Extrasynaptic 
GABAA receptors 
Postsynaptic 
GABAergic neuron 
14 
 
1.4.3 Phasic and tonic inhibition of GABAA receptors 
 
Two modes of GABAA mediated inhibition have been identified, phasic and tonic 
inhibition. These are mediated by activation of the synaptic and extrasynaptic 
GABAA receptors respectively. Activation of the synaptic GABAA receptors by a 
high concentration of GABA mediates transient phasic inhibitory currents that 
cease within miliseconds as GABA is mopped up by GABA transporter 1             
(GAT-1) from the synaptic cleft, whereas activation of the extrasynaptic GABAA 
receptors on exposure to a low concentration of GABA, leads to a persistent or 
tonic inhibitory current (Figure 6).
33,59
  
 
Although the concentration of GABA  in the synaptic cleft is high (1-10 mM),         
its low affinity for the synaptic GABAA means it only occupies the receptor for a 
very short duration before being taken up by the primary reuptake mechanism, 
GAT-1. This event results in a fast rise and slow decay waveform that varies 
depending upon the subunit composition and the transmitter profile of the 
synaptic GABAA receptors within the cleft (Figure 6a). On the other hand, an 
exposure to low ambient concentration of GABA, enables the activation of the 
high affinity extrasynaptic GABAA receptors to generate a persistent tonic 
inhibitory potential which sets the threshold for activation and regulates excitatory 
and inhibitory balance in the brain (Figure 6b). This is a fine tuning mechanism 
which the brain uses to discriminate signal from noise.
43,44,59
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Figure 6: Activation of the synaptic and extrasynaptic lead to phasic and tonic 
inhibition (adapted from D. S. Reddy, Front. Endocrinol., 2011).
60
 
  
1.4.4 GABAA rho receptors 
 
GABAC receptors (GABARc) also known as -aminobutyric acid type A rho        
( GABAA) receptors, belong to a subclass of ligand-gated chloride channel that 
mediate fast synaptic inhibition. GABARc receptors can be distinguished from 
GABAA receptors on the basis of their five protein subunits. Unlike GABAA 
receptors, GABARc  or ( GABAA) are formed from five identical homomeric     
 subunits (1-3) or pseudo-heteromeric  subunits comprising a combination of 
(1 and 2 or 1 and 3 subunits) to assemble a single ion channel (Figure 7).
61–63
  
a) Phasic (synaptic) 
current 
b) Tonic (extrasynaptic) 
current 
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Figure 7: Homomeric or pseudo-heteromeric GABA A rho receptors                   
(adapted from B. Frølund et al., Lægemiddelforskning, 2006).
64
  
 
GABAC have distinct different properties to GABAA receptors in term of potency 
and electrophysiological properties. GABAC receptors have higher potency and 
sensitivity for GABA with lower current and they do not desensitise. On the 
single-channel level, these receptors are activated and closed more slowly with 
longer mean channel opening time and lower chloride conductance than GABAA 
ion channels. GABAc receptors are mainly expressed in the retina (strong 1 
subunit expression), hippocampus (strong 2 subunit expression), superior 
colliculus, cerebellum and lateral amygdala.
34,38,39
 Table 4 shows the differences 
between GABAA and GABAC receptors.  
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Property GABAA receptors GABAC receptors 
GABA EC50 5-100 M 1-4  M 
GABA concentrations 10-100 M 1 M 
Channel type Anion (Cl
-
 channel) Anion (Cl
-
 channel) 
Channel composition Heterooligomeric 
Homo/pseudo-
homooligoemeric 
Subunit composition 1-6, 1-3, 1-3, , , ,  1-3 
Conductance 27-30 pS 7-8 pS 
Mean channel open time 25-30 ms 150-200 ms 
Activation/deactivation Fast Slow 
Desensitisation Strong Weak 
Pore size 5.6 Å 5.1 Å 
 
Table 4: Comparisons between GABAA and GABAC receptors.
38,39
 
 
1.5 GABA receptor agonists and partial agonists 
 
A variety of compounds can bind to the GABA receptors and regulate the opening 
or closing of gated chloride ion channels. Agents that induce chloride ion flux are 
GABA receptor agonists, whereas agents that block the flux are antagonists. With 
such important pharmacological properties and therapeutic efficacy, GABA 
receptors have been extensively studied by molecular biologists and medicinal 
chemists.
65,66
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This has led to design and development of a diversity of GABA receptor agonists 
and partial agonists (Figure 8). 
 
 
Figure 8: Structures of GABA analogues that have agonist and partial agonist 
effects at GABAA and GABAC receptors. 
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Muscimol (11) and GABA (12) are potent agonists at GABAA and GABAC 
receptors, however, muscimol is the more potent GABAA receptor agonist. 
Although, the action of muscimol on different subunits of the GABAA receptor  is 
relatively uniform, it acts as a super agonist at the extrasynaptic GABA (43).
67
 
Like muscimol, THIP (13) appears to act as super agonist at the 43 
extrasynaptic GABA receptors. Although THIP (EC50 values of 13 M) is less 
potent than both muscimol (EC50 values of 0.20 M) and GABA (EC50 values of 
0.35 M), it is more efficacious (EMax values of 224%) compared to muscimol                    
(EMax = 120%) and GABA (EMax = 98%), which is in agreement with the data for 
the 42 (Table 5).
44
 The super agonist activity of THIP on these receptors can 
be explained by the reduced desensitisation and increase in the frequency and 
duration of channel opening, resulting in longer burst durations. On the other 
hand, THIP is a partial agonist at the synaptic 132 GABAA receptors                
(EC50 values of 107 M, EMax values of 85%) compared to muscimol                    
(EC50 values of 0.92 M, EMax values of 101%) and GABA (3.4 M, EMax values 
of 100%) respectively (Table 5).
44,67
  
Agonist 
132 
Synaptic 
43 
Extrasynaptic 
422 
Synaptic 
42 
Extrasynaptic 
 
EC50 
(M) 
EMax 
(%) 
EC50 
(M) 
EMax 
(%) 
EC50 
(M) 
EMax 
(%) 
EC50 
(M) 
EMax 
(%) 
GABA (12) 3.4 100 0.35 98 12 100 1.6 97 
Muscimol (11) 0.92 101 0.20 120 2.6 120 0.12 120 
THIP (13) 107 85 13 224 190 76 17 190 
 
Table 5: GABA (12), muscimol (11) and THIP (13) responses at synaptic and 
extrasynaptic GABAA receptors.
44,67
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The 3-fluoro enantiomers of GABA, (3R)-F-GABA (30a) (EC50 values of          
240 M, EMax values of 77%) and (3S)-F-GABA (30b) (EC50 values of 380 M,             
EMax values of 82%) displayed similar agonistic potency at the 122 synaptic 
receptors but an overall reduced potency relative to GABA (EC50 values of                
49 M).68 Based on the structure of THIP and muscimol, several heterocyclic 
GABAA agonists have been developed. Isoguvacine (18), isonipecotic acid (22), 
P4S (26) and 4-PIOL (32) are derived from THIP whereas, thiomuscimol (21) and 
(S)-DHM (25) are derived from muscimol. Isoguvacine is slightly less potent than 
GABA in mediating chloride flux but was found to exhibit approximately the 
same potency as GABA in competing for the binding of [
3
H]GABA.
40,69
 On the 
other hand, 4-PIOL is a partial agonist at GABAA receptors with an EC50 value of 
91 M and it is approximately 200 times less potent than isoguvacine as an 
agonist. As with THIP (13), thio-4-PIOL (33), an analogue of 4-PIOL (32), 
exhibits differences in activity at the synaptic and extrasynaptic GABAA 
receptors. It is a partial agonist with maximal responses up to 30% at the 
extrasynaptic but only 0-4% maximal responses at the synaptic GABAA 
receptors.
70,71
  
 
Both thiomuscimol (21) and (S)-DHM (25) retained the agonism of muscimol, 
despite certain structural modifications. Thiomuscimol was found to be 
approximately equipotent with muscimol whereas, (S)-DHM exhibits the most 
potent agonist activity so far demonstrated in both functional and binding 
assays.
72
 In contrast, replacement of the carboxylic acid group in GABA by a 
sulfonic acid to give 3-APS (28) led to a decrease in potency at inducing         
36
Cl
-
 influx than its parent compound.
73
 However (28) is more potent than GABA 
21 
 
in competing for the binding of [
3
H]GABA suggesting that high-affinity binding 
may not always correlate well with the agonist potency.
74
 On the other hand, the 
conformationally restricted analogues of GABA, ZAPA (31) and TACA (20) are 
potent GABAA agonists. ZAPA (EC50 values of 10.3 M) was found to be more 
potent than GABA on low-affinity GABA banding sites, compared to GABA 
(EC50 value of 12.8 M).
36,75
   
 
The cylopentane (+)-TACP (23) and cylopentene (+)-4-ACPCA (19) analogues of 
GABA, are also potent GABAA agonists.
66
  The cis isomer of TACA, CACA (24) 
serves as a partial but selective agonist at the GABAC receptors. CACA is a 
partial agonist at both 1 (EC50 values of 74 M) and 2 (EC50 values of 70 M) 
with 70-80 efficacy of GABA and weaker agonist at 3 (EC50 values of 139.4 M) 
receptors expressed in Xenopus oocytes (Table 6). Although TACA is not a 
selective agonist for GABA receptors, it is the most potent GABAC agonist 
described so far. The (+)-isomer of CAMP (29), can be regarded as a superior 
GABAC receptor agonist. (+)-CAMP was found to be a selective agonist at both      
1 (EC50 values of 40 M) and 2 (EC50 values of 17 M) and it has been widely 
used as a better tool in neurobiology compared to CACA due to its low effect on 
GABA transporters. (+)-CACP (27a), (-)-CACP (27b) and (+)-TACP (23) are 
also partial agonists at GABAC receptors.
66,76
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Agonist 
1 
(EC50) (M) 
2 
(EC50) (M) 
3 
(EC50) (M) 
GABA (12) 1.0 0.8 4 
CACA (24) 74 70 139.4 
TACA (20) 0.6 0.4 3.8 
(+)-CAMP (29) 40 17 - 
 
Table 6: GABA (12), CACA (24), TACA (20) and (+)-CAMP (29) responses at 
GABAC receptors.
76
 
 
1.6 Positron Emission Tomography (PET) and fluorine-18 in nuclear 
medicine 
 
PET is a non-invasive molecular imaging technique and one of the most powerful 
imaging modalities used to study the fundamental biochemical and physiological 
processes in living organism. It operates by the detection of emitted positrons. 
Unlike other molecular imaging techniques such as MRI, CT, X-rays or 
ultrasound, which only provide limited or no information at all on metabolic or 
molecular events, PET relies on detectable exogenous radioactive probes that have 
the ability to monitor metabolic processes in living patients.
77
 These probes can be 
designed to be tissue or receptor-specific, useful in the diagnosis and early 
detection of diseases such as cancer, heart malfunctioning and disorders of brain 
or neurogenic origin such as epilepsy, stroke and dementia.
78
 Table 7 shows the 
key characteristics of several complementary non-invasive imaging techniques. 
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Imaging 
technique 
Mode 
Spatial resolution 
[ranges] 
Target sensitivity 
[ranges] 
X-ray/CT Anatomical 300.0 m Low [>mM] 
MRI Anatomical 800.0 m Low [>mM] 
Ultrasound Anatomical 800.0 m Medium [nM] 
SPECT Functional + molecular 5.0 – 10.0 mm High [nM-pM] 
PET Functional + molecular 2.0 – 8.0 mm High [nM-pM] 
 
Table 7: Key characteristics of several complementary non-invasive imaging 
techniques.
79,80
 
 
There are four radionuclides which have been used widely as positron emitters. 
These are carbon-11, nitrogen-13, oxygen-15 and fluorine-18. The wide historical 
use of these isotopes in the field of radiochemistry is due to the fact that they can 
be produced in relatively high yields by commercially available cyclotrons and 
their decay mode is close to 100% positron emission (Table 8).
78
  
 
Radionuclide Half-life (min) Decay mode 
Fluorine-18 110 97% +, 3% EC 
Carbon-11 20.4 100% + 
Nitrogen-13 9.97 100% + 
Oxygen-15 2.04 100% + 
 
Table 8: Physical characteristics of fluorine-18, carbon-11, nitrogen-13 and 
oxygen-15.
78
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Among these four PET isotopes, fluorine-18 is the most widely used, especially 
for clinical application. This is because fluorine-18 has ideal properties for      
high-resolution PET imaging.
81
 It has a short and manageable 110 minutes            
half-life which allows sufficient time for multistep synthesis labelling reactions 
and then transportation of doses to sites several hours away. Secondly, the 
positron decay of fluorine-18 (97% +), lower energy (640 keV maximum) and 
short travel distance (2.4 mm positron linear range in tissue) before its 
annihilation with an electron, are particularly advantageous in term of spatial 
resolution compared to other available positron emitters.
82
  
 
Additionally, the higher achievable specific activity of fluorine-18 produced by 
proton irradiation of 
18
O-enriched water is very important, especially for high 
affinity receptor and gene-expression related PET studies.
81
  
 
Table 9 shows the theoretical and specific activity values of carbon-11 compared 
to fluorine-18. One of the important advancements in scanner technology is the 
incorporation of PET and CT (X-ray) into one device which allows the 
complementary data of metabolism and anatomy to be merged into a unique 
image to form the final result.
83
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Nuclide 
Common 
production 
method 
Max 
energy 
(keV) 
Mean 
energy 
(keV) 
Max. range 
in water 
(mm) 
Theoretical and 
(practical) 
radioactivity 
(GBq/mol) 
C-11 14N(p,)11C 960 386 4.1 mm 
3.4  105 
(110-2600) 
F-18 
18
O(p,n)
18
F 640 250 2.4 mm 
6.3  104 
(180-3700) 
 
Table 9: The relationship of positron energy and positron travel range  of             
carbon-11 and fluorine-18.
84–86
 
 
 
1.7 Fluorine-18 labelling methods  
 
Direct and indirect fluorination methods offer two distinct strategies which can be 
employed for fluorine-18 labelling. Direct fluorination requires the fluorine-18 
isotope to be introduced directly into the target molecule in one step, whereas 
indirect fluorination requires so-called fluorine-18 prosthetic groups (small 
fluorine-18 labelled alkyl or aryl groups) in a multistep synthetic approach. Direct 
fluorine-18 can be divided into nucleophilic and electrophilic approaches. Of 
these two methods, nucleophilic fluorine-18 reactions have been found to be very 
important due to the ease of access to 
18
F-fluoride and its high specific activity.
78
  
 
1.7.1 Nucleophilic fluorination 
 
Nucleophilic fluorination is the most common and routinely used approach                  
to produce radiolabelled [
18
F]-organofluorine compounds. [
18
F]-Fluoride is 
generated through the nuclear reaction of 
18
O(p,n)
18
F, in which 
18
O-enriched 
water is irradiated with a high energy beam of protons. This nuclear reaction is 
intrinsically high yielding at low proton energies (<16 MeV) and produces the 
26 
 
fluorine-18 as [
18
F]F
-
 ion in aqueous solution. This “no-carrier-added”           
(NCA) method produces [
18
F]F
-
 ion with a high specific radioactivity                            
(exceeding 5 Ci/mol).81 In order to render the fluoride ion as a reactive 
nucleophilic, several pre-activation steps are required. The first step is to remove 
the bulk [
18
O]water and solubilise the fluoride-18 in organic solvent. This can be 
achieved by adsorption of the [
18
F]F
-
 onto an ion exchange column which allows 
the recovery of expensive [
18
O]water. The trapped [
18
F]F
-
 is then eluted from the 
column with a small volume of aqueous potassium carbonate. The aqueous 
fluoride is a poor nucleophile because of a high degree of solvation, therefore 
addition of a phase transfer reagent (e.g.: aminopolyether kryptofix K222), 
followed by removal of water improves the reactivity of [
18
F]F
-
 in two ways. First, 
the aminopolyether forms a strong complex with potassium cation, consequently 
exposing the [
18
F]F
-
. Second, the complex is readily soluble in organic solvents, 
where the [
18
F]F
-
 is not solvated and remains reactive.
81
 Alternatively, the 
irradiated target [H2
18
O] can be directly subjected to azeotropic evaporation cycles 
in the presence of base and kryptands or other phase-transfer catalysts. However, 
this method is unable to recycle the 
18
O-enriched water for further use           
(Figure 9).
81
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Figure 9: Two alternative methods for the preparation of reactive [
18
F]F
-
 through 
the formation of [
18
F]F
-
/K222/K
+
-complex (“kryptofix-complex”);81 n may be as 
great as 15 in fully hydrated fluoride ion;
87
 m is expected to be < n. 
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1.7.2 Electrophilic fluorination 
 
Electrophilic fluorine-18 labelling can be achieved through the nuclear reaction of 
20
Ne(d,)18F carried out in a neon gas target with carrier addition of [19F]F2(g) at a 
pressure up to 25 bar in a nickel target. This approach is less favorable nowadays 
for several reasons.
82
 The nuclear reaction only gives labelled products with low 
achievable specific radioactivities (Table 10) due to the highly exothermic 
reaction, and electrophilic fluorine-18 may exchange with added fluorine or 
diffuse to the target wall to be adsorbed as nickel fluoride.
88,89
 Moreover, the high 
reactivity of the generated [
18
F]F2(g), resulting in poor  selectivity giving mixtures 
of 
18
F-labelled products. One of the advantages of this approach is that the 
resultant radiolabelled [
18
F]F2 can be used directly without any pre-activation 
procedures.
81
  
 
 
Nucleophilic fluorine-18 
approach 
Electrophilic fluorine-18 
approach 
Nuclear reaction 
18
O(p,n)
18
F 20Ne(d,)18F 
Target Enriched H2
18
O(aq) Ne2(g) (0.1% F2) 
Main product form [
18
F]F
-
(aq) [
18
F]F2(g) 
Specific activity 
[MBq/mol] 
600  103 100 
 
Table 10: Nucleophilic and electrophilic approaches for fluorine-18 
labelling.
80,84,90
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Intravenous injection or inhalation is required in order to introduce the PET probe 
into the subject (animal or human). During decay, 
18
F emits a positron (+) with a 
maximum energy of 640 keV. The emitted positrons travel at a specific range 
before colliding with an electron (annihilation event) in the surrounding tissue. 
The collision of positron and electron results in an annihilation to give rise to two 
gamma ray photons () of equal energy (511 keV), that travel at 180 to each 
other. The simultaneous detection of these two gamma ray photons allows the 
radioactive events and PET probe in the body to be located (Figure 10). The raw 
data is then converted into quantified data such as flow, consumption tracer, 
affinity and/or density of receptor information using a mathematical model.
77,82
    
 
 
Figure 10: Positron emission tomography (adapted from D. Le Bars, J. Fluor. 
Chem., 2006).
82
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For example, some of the most important fluorine-18 PET radiotracers               
(Figure 11) produced from nucleophilic 18 fluorination reactions include 
[
18
F]FDG (34) and 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) (35). These 
tracers are used in oncology investigations.
91–93
 [
18
F]Fallypride (36),
94
 
[
18
F]haloperidol (37) and [
18
F]spiperone (38) are used in dopamine receptor                              
studies,
95,96
 while [
18
F]fluoroazomycinarabinofuranoside ([
18
F]FAZA (39) and 
[
18
F]fluoromisonidazole ([
18
F]FMISO (40) are used for imaging tissue 
hypoxia.
97,98
 
 
 
 
Figure 11: Some of the most important clinical [
18
F]-PET radiotracers. 
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1.8 Synthesis and use of [
18
F]FDG in nuclear medicine   
 
The development of the first PET tracer [
18
F]FDG (34) was a major breakthrough 
in the field of radiopharmaceuticals.
99
 This glucose mimic has been employed in 
neurological, cardiovascular and oncology investigations. Unlike glucose, the 
phosphorylation of FDG generates FDG-6-phosphate by the action of hexokinase, 
which cannot be further metabolised and accumulates in cells at a rate 
proportional to glucose. This allows the identification and characterisation of 
diseases related to the alterations in the metabolism of glucose. For example, the 
uptake of FDG in cancerous cells correlates with the rate of tumour growth and 
degree of metastasis. Therefore, [
18
F]FDG (34) plays an important role in locating 
a tumor prior to surgery or radiotherapy.
82,99
   
 
 
 
1.8.1 Synthesis of [
18
F]FDG via nucleophilic fluorination 
 
The most reliable method for producing [
18
F]FDG (34) in a high radiochemical 
yield (RCY) is through nucleophilic fluorination.
78,100,101
 With the current 
methods available, the radiochemical yield (purified product radioactivity over 
total starting radioactivity) of this procedure could reach up to 70-73%.
78,101
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The modified glucose, mannose triflate (41) serves as a substrate for a 
nucleophilic reaction. Displacement of the tiflate by [
18
F
-
] ion through 
nucleophilic substitution leads to formation of tetra-acetylated 
fluorodeoxyglucose (42) which is then treated with HCl affording the                  
18
F labelled FDG (34) (Scheme 2).
100
 
 
 
Scheme 2: Synthesis of [
18
F]FDG (34) via nucleophilic fluorination.
100
  Reagents: 
a) [
18
F]F
-
, kryptofix K222/K2CO3, MeCN; b) HCl.                                   
 
 
[
18
F]FDG is by far the most commonly employed radiotracer in PET imaging. The 
ability of [
18
F]FDG PET to quantify in vivo pathological processes allows the 
early detection of some neurodegenerative diseases before clinical symptoms 
appear. Thus this technique appears to be an ideal tool in neurobiology for 
monitoring the efficiency of drugs to the targeted pathological sites and could 
serve as a platform and starting point for future research in drug development to 
treat neurological diseases.  
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1.9  GABAA receptor radiotracers 
 
Due to the role of GABA as the major inhibitory neurotransmitter in CNS and 
taking advantage of PET as a powerful imaging tool, various radiotracers that 
specifically bind and target the GABA receptors have been designed and 
developed as useful tools in neurobiology.   
 
1.9.1 PET radioligands binding to the GABA binding site   
 
Despite extensive research on the pharmacology of GABAA receptors, there are 
only a few examples in the literature of GABA radiotracers that have been 
reported.
102
 [4-
11
C]GABA (45) was labelled starting with hydrogen [
11
C]cyanide 
prepared from [
11
C]CO2. Michael addition with ethyl acrylate (43) followed by a 
selective reduction and hydrolysis of the resulting amino ester (44) afforded        
[4-
11
C]GABA (45) (Scheme 3).
103
  
 
 
Scheme 3: Radiosynthesis of [4-
11
C]GABA (45).
103
 Reagents: a) K
11
CN, 
kryptofix K222, THF; b) CoCl2/NaBH4, MeOH; c) NaOH.                                                                   
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Schiff bases of benzophenone derivatives have been reported to displace GABA 
from the GABAA receptor by mimickling the binding properties of GABA. In this 
category, [
11
C]methoxyprogabidic acid (47) was radiolabelled by reacting              
5-fluoro-2-hydroxy-4’-hydroxybenzophenone (46) with [11C]methyl iodide 
through a Schiff reaction with an excess of GABA (12) in the presence of sodium 
methoxide as a catalyst (Scheme 4). Although the biodistribution of this 
radioligand in mice has been reported, no human PET data is reported.
104
  
 
 
Scheme 4: Radiosynthesis of [
11
C]methoxypropagidic acid (47).
104
 Reagents:              
a) 
11
CH3I; b) GABA (12), NaOMe.  
 
1.9.2 PET radioligands binding to the benzodiazepine binding site 
 
Benzodiazepines have been prescribed as psychotropic drugs for the treatment of 
epilepsy, sleep disorders, anxiety and symptoms of depression for more than four 
decades.
105
 Chemically, benzodiazepines are a class of compound that contain an 
aryl ring fused to a seven membered diazepine (often 1,4-diazepine) ring. Some of 
the most common benzodiazepine psychotropic drugs are illustrated in Figure 12. 
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Figure 12: Common benzodiazepine psychotropic drugs.
105
 
 
The classical benzodiazepines are agonists with similar affinity to GABA for 
GABAA receptors. The binding site of benzodiazepines, however, is slightly 
different. In GABA, the binding site is located between the  and  subunits, 
whereas the binding site of benzodiazepines is located between the  and  
subunits (Figure 13).
42
 Due to this different location, benzodiazepines do not 
trigger chloride ion channel opening, but they enhance the activity of the channel 
once it is opened. Therefore, benzodiazepines are inactive without the presence of 
GABA.
42
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Figure 13: Binding sites of GABA and benzodiazepine on GABAA receptor.  
 
[
11
C]Flunitrazepam (48) and [
11
C]diazepam (49) were the first examples of 
radiolabelled benzodiazepines.
106,107
 Both of these compounds were labelled by   
N-[
11
C]-methylation on the amide nitrogen using [
11
C]methyl iodide. Later, 
[
11
C]fludiazepam (50), which is the 2’-fluoro analogue of  [11C]diazepam, was 
also labelled using the same approach (Scheme 5). The low specificity and 
binding affinity of these compounds on the benzodiazepine receptors was a major 
drawback for progressing them for PET imaging.
108
  
 
 
 
Scheme 5: Radiosyntheses of [
11
C]flunitrazepam (48) (R
1 
= NO2, R
2 
= F, R
3 
= H),     
[
11
C]diazepam (49) (R
1
=Cl, R
2
=R
3
=H), and [
11
C]fludiazepam (50) (R
1 
= Cl,              
R
2 
= F, R
3 
= H). Reagent: a) 
11
CH3I.  
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As benzodiazepines are prone to be metabolised by 3-hydroxylation,
109
                                             
3-[
18
F]fluorodiazepam (53) was explored as a potential tracer. It was prepared 
from   diazepam (51) by electrophilic fluorination of [
18
F]F2 or using the milder 
fluorinating agent [
18
F]acetyl hypofluorite.
110
 It was suggested that the 
radiolabelled compound is formed through a concerted cyclic mechanism from the 
enol form of diazepam (52) as illustrated in Scheme 6.
110
  
 
 
Scheme 6: Radiosynthesis of 3-[
18
F]fluorodiazepam (53). Reagent: a) [
18
F]F2. 
 
Due to accumulated pharmacological problems associated with the classical 
benzodiazepines such as [
11
C]flunitrazepam (48) and [
11
C]diazepam (49), a potent 
benzodiazepine antagonist bearing an imidazole ring system was designed. The 
imidazobenzodiazepine flumazenil (Ro 15-1788) (54) was labelled with               
carbon-11 on the N-methyl carbon using [
11
C]methyl iodide
111–113
 or [
11
C]methyl 
triflate
114
 (Scheme 7). [
11
C]-N-Methyl-flumazenil (55) has been extensively used 
to quantify benzodiazepine binding in the human brain,
115
 to measure changes in 
GABA levels,
116,117
 as well as to investigate some neurological disorders such as 
epilepsy and neuronal loss in stroke.
118,119
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Scheme 7: Radiosynthesis of [
11
C]flumazenil (55). Reagents: a) 
11
CH3I or 
11
CH3OTf, acetone, NaOH. 
 
 
Incorporating fluorine 18 into the structure of flumazenil was challenging because 
of the unactivated aromatic ring. The first reported synthesis of  [
18
F]flumazenil 
(57) involved nucleophilic substitution of [
18
F] fluoride ion with the nitro 
precursor (56), under both conventional and microwave irradiation heating 
methods (Scheme 8).
120,121
  
 
 
Scheme 8: Synthetic routes to obtain [
18
F]flumazenil (57). Reagents and 
conditions: a) [
18
F]F
-
, kryptofix K222/K2CO3, DMF, 160 C, 30 min; b) [
18
F]F
-
, 
kryptofix K222/K2CO3, DMF, 160 C, 5 min. 
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More recently, Rodnick et al.,
122
 introduced the new flumazenil analogue 
radiotracers [
18
F]AH114726 (60) and [
18
F]GEH120348 (61) with high chemical 
and radiochemical purities and high specific activities. The syntheses of these 
radiotracers were carried out by nucleophilic aromatic substitution using [
18
F] 
fluoride ion with the nitro aromatic precursors (58) and (59) (Scheme 9). Both 
radiotracers showed good activities on GABAA/benzodiazepines receptors, and 
are comparable to [
11
C]flumazenil (55), offering an option for imaging the 
GABAA receptor.
122
   
 
 
Scheme 9: Radiosynthesis of [
18
F]AH14726 (60) and[
18
F]GEH120348 (61). 
Reagents and conditions: a) [
18
F]F
-
, kryptofix K222/K2CO3, DMF, 130 C, 30 min.   
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Some other examples of the [
18
F] labelled radiotracers of the flumazenil analogues 
include [
18
F]FFMZ (62) and [
18
F]FEFMZ (63). However, neither of these     
labelled radiotracers exhibited satisfactory in vivo properties compared to                     
[
18
F]FMZ (57).
123,124
  
 
 
 
Since the fluorination of muscimol has never been achieved before, 
fluoromuscimol would be of great interest for its agonist activity against GABAA 
receptors. A first synthesis of fluoromuscimol and its biological effect on GABAA 
receptors is the subject of Chapter 2.  
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Chapter 2: Syntheses and biological studies of fluoromuscimols 
 
2.1 Introduction 
 
As discussed in Chapter 1, despite extensive research on the development of novel 
radiotracers that target the GABAA receptor, most do not locate at the GABA 
binding site.
1–5
 In addition, there are currently no suitable radiotracers that have 
been specifically designed to locate at the synaptic and extrasynaptic GABAA 
receptors. Therefore, the fluoro analogues of a compound known to locate at the 
GABA binding site of GABAA receptors could be of value. If the fluoro analogues 
retained similar properties to its non-fluorinated parent, it could then serve as a 
starting point for the development of a PET radiotracer for GABA receptors. In 
this context, the fluorination of muscimol (11), a naturally occurring toxin isolated 
from the mushroom Amanita muscaria, was chosen as a research focus. 
Specifically, syntheses of fluoromuscimol (64) and trifluomethylmuscimol (65) 
were addressed.  
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2.2 Previous syntheses of muscimol  
 
Since the isolation of muscimol from Amanita muscaria, a number of syntheses 
have been reported.
6–11
 However, the preparation and investigations of muscimol 
and its derivatives have been restricted due to the limited availability of both 
natural and synthetic material. Despite a number of approaches, the synthesis of 
muscimol suffers from the number of steps, availability of starting materials, and 
poor reproducibility of yields.  
 
Among the several synthetic approaches, the route reported by Pevarello and 
Varasi is one of the most convenient,
6
 particularly for large scale synthesis of 
muscimol (Scheme 10). In this synthesis, the bromo(chloromethyl)isoxazole (69) 
intermediate was obtained in a high yield (81%) through a 1,3-dipolar 
cycloaddition reaction between bromonitrile oxide (68) generated in situ from 
stable and easily available dibromoformaldoxime (66) and 2,3-dichloropropene 
(67). Substitution reactions with ammonia and methanol afforded methyl ether 
protected muscimol (70), which was then deprotected using HBr in AcOH 
furnishing muscimol (11).  
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Scheme 10: Pevarello and Varasi synthesis of zwitterionic muscimol (11).
6
  
Reagents and conditions: a) KHCO3, EtOAc, H2O, 25 C, 20 h, 81%;                    
b) 30% NH3, H2O, dioxane, 025 C, 5 h; 90%; c) MeOH, KOH, H2O, reflux,   
48 h, 66%; d) 33% HBr, AcOH, reflux, 15 min, 62%. 
 
On the other hand, McCarry and Savard reported a facile approach to the 
synthesis of muscimol starting from propargyl chloride (71) (Scheme 11).
7
 The 
first step of this reaction involved the deprotonation of propargyl chloride by 
methyllithium and then treatment with ethyl chloroformate, to generate ethyl 
chlorotetrolate (72). Further reaction with hydroxylamine in basic methanolic 
solution produced hydroxamic acid (73) which underwent in situ cyclisation to 
afford 5-chloromethyl hydroxyisoxazole (74). Finally, the conversion to muscimol 
(11) was accomplished by heating (74) in a methanolic solution of anhydrous 
ammonia.  
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Scheme 11: McCarry and Savard synthesis of muscimol (11).
7
 Reagents and 
conditions: a) CH3Li, ClCO2Et, Et2O, -40 C, 70%, b) NH2OH, MeOH (aq),              
-35 C, 15 min, 41%; c) NH3, MeOH, 050 C, 5 h, 65%. 
 
The shortest and convenient synthesis of muscimol was reported by Frey and 
Jäger (Scheme 12).
8
 The reaction involved three straightforward steps, 
progressing through stable crystalline intermediates. The synthesis began with a 
DBU induced condensation of hydroxyurea (75) and dimethyl 
acetylenedicarboxylate (76) to form methyl 3-hydroxyisoxazole-5-carboxylate 
(77).  Treatment of (77) with ammonia, followed by amide reduction of (78) using 
borane dimethyl sulfide (BMS), furnished muscimol (11) as a white crystalline 
solid after acidic ion-exchange resin work up.  
 
 
Scheme 12: Frey and Jäger synthesis of muscimol (11).
8
 Reagents and conditions:                
a) DBU, MeOH, 0-10 C, 60%; b) NH3(aq), MeOH, 1 h, quant.; c) BMS, THF, 
reflux, 8 h, 51%. 
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A proposed mechanism for the formation of methyl ester (77) in Scheme 13 
involves an initial deprotonation of the OH group of hydroxyurea (75) by DBU 
forming (79). Michael addition of (79) to dimethyl acetylenedicarboxylate (76) 
results in the formation of intermediate (80), which then undergoes intramolecular 
cyclisation through nucleophilic displacement of the methoxyl group, to generate 
the five-membered heterocycle (81). The final product (77), is obtained via the 
loss of methyl carbamate and subsequent enolisation of (82).
12
 
 
 
Scheme 13: Proposed mechanism for the formation of the heterocycle (77).
12
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2.3 Aims of this project 
 
The objective of this project was to prepare two fluorinated analogues of 
muscimol and, subsequently, assay their agonist activities against the GABAA 
receptors in order to study their relative efficacy compared to muscimol itself. If 
the interesting properties of muscimol, such as the ability to cross the blood brain 
barrier
13
 and high affinity
14
 for the GABA binding site are preserved in 
fluoromuscimol (64) and trifluoromethylmuscimol (65), this opens opportunities 
for future PET application, specifically [
18
F]-fluoromuscimol and                   
[
18
F]-trifluoromethylmuscimol. They could indeed serve as a starting point to 
probe GABA binding sites on GABAA receptors; something that remains 
unresolved with the current GABAA receptor radiotracers, as they bind almost 
exclusively at the benzodiazepine binding site.
15–18
 If such properties are 
conserved in these fluorine containing compounds, a synthesis suitable for PET 
will require development.  
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2.4 Results and discussion 
 
2.4.1 Approach A-Retrosynthetic approach 
 
Our first approach towards the synthesis of fluoromuscimol (64) envisioned the 
retrosynthetic route shown in Scheme 14. According to the proposed 
retrosynthetic route, the desired fluoromuscimol (64) could be approached 
through azide (83). This intermediate might be formed by cyclisation of -fluoro-
-keto-hydroxamic acid (84). The reactive -ketohydroxamic acid (84) could be 
obtained from the corresponding fluorinated ketoester (85) which is accessible via 
fluorination of ketoester (86).    
 
 
 
Scheme 14: Retrosynthetic approach to fluoromuscimol (64). 
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In order to address this approach, ketoester (86) was synthesised through 
nucleophilic substitution on the commercially available chloroacetoaetate (87) 
with sodium azide in THF/water mixture (Scheme 15). Fluorination of (86) was 
carried out at room temperature using Selectfluor as an electrophilic 
fluorination reagent, as shown in Scheme 15. The reaction used a catalytic amount 
of cyclopentadienyl(IV) titanium trichloride (TiCpCl3) in acetonitrile. The catalyst 
was chosen on the basis of the previously reported fluorination reactions on 
several -ketoesters which showed that the use of TiCpCl3 induced a clean 
fluorination with high selectivity towards the monofluorinated product.
19,20
        
The reaction was not clean and purification by column chromatography proved to 
be challenging as some impurities co-eluted together with ketoester (85).  
However, after careful chromatography, the desired fluorinated product (85) was 
successfully isolated, albeit in low yield (37%). A control experiment indicated 
that the reaction did not occur in the absence of catalyst. 
 
 
 
Scheme 15: Synthesis and fluorination method of (85). Reagents and conditions:                           
a) NaN3, THF/water, 0 Crt, overnight, 67%, b) Selectfluor, TiCpCl3, MeCN, 
15 h, 37%. 
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The mechanism proposed for this fluorination reaction is depicted in Scheme 16 
and starts with the coordination of substrate (86) to TiCpCl3 (88) followed by 
enolisation within the coordination sphere of the catalyst. Subsequent SET 
interaction with Selectfluor (89) gives rise to the formation of radical cation 
intermediate (90), which then captures a fluorine atom from the reagent forming 
the new C-F bond.
21
 Displacement of product (85) from the catalyst by exchange 
with another molecule of substrate (86) completes the catalytic cycle.
22,23
  
 
 
Scheme16: Proposed catalytic cycle for the fluorination of (86).
22,23
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As shown in Figure 14, the 
1
H NMR spectrum of (85) exhibits three proton 
signals. The methyl group at 3.88 ppm is assigned to H-5 and the methine proton 
H-2 appears  as a doublet at 5.39 ppm, with a geminal fluorine coupling constant 
of  
2
JHF =  48.4 Hz. The methylene protons (H-4) are diastereotopic and display an 
AB-pattern at 4.31 ppm (
2
JHH = 19.2 Hz, 
4
JHF = 2.2 Hz) and at 4.26 ppm           
(
2
JHH = 19.2 Hz, 
4
JHF = 1.6 Hz) respectively.  
 
 
Figure 14: 
1
H NMR spectrum of (85). 
 
A representative fluorine decoupled 
1
H{
19
F}experiment of (85) is shown in     
Figure 15. The spectrum clearly shows that the doublet for the H-2 collapses to a 
singlet, while that of the AB-pattern simplifies with the removal of fluorine 
coupling.  
 
H-4 
H-2 
CDCl3 
H-5 
H-2 
H-4a H-4b 
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Figure 15: Partial 
1
H NMR spectra of (85) with and without {
19
F}. 
 
The 
19
F-NMR spectrum of (85) (Figure 16) has a signal at -199.5 ppm. It appears 
as doublet of multiplets with a geminal coupling constant of 
2
JHF = 48.4 Hz. This 
signal becomes a singlet in the proton-decoupled 
19
F{
1
H} NMR spectrum, as 
expected.  
 
Figure 16: Partial 
19
F NMR spectra of (85) with and without {
1
H}.  
1
H{
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1
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The 
13
C NMR analysis of (85) (Figure 17) reveals three sets of doublets. The 
signals at 199.5 ppm and 163.7 ppm have coupling constants of 
2
JCF 24.2 Hz and 
2
JCF 23.6 Hz, are assigned to C-3 and C-1 carbonyl carbons respectively, whereas 
that at 90.5 ppm with a large 
1
JCF coupling constant of 197.4 Hz is assigned to the 
CHF C-2. 
 
Figure 17:
13
C NMR spectrum of (85). 
 
With compound (85) in hand, a conversion to -ketohydroxamic acid (84) was 
required. Since the carbonyl group of a ketone is more susceptible to nucleophilic 
attack than that of an ester, it was necessary to protect this group in order to avoid 
formation of hydroxyl-imine (91) rather than the desired ketohydroxamic acid 
(84).  
 
 
C-3 C-1 
C-2 
CDCl3 
C-5 
C-4 
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Protection of ketone (85) as an acetal (Scheme 17) was attempted using ethylene 
glycol. However, despite exploring various sets of conditions (boron trifluoride 
diethyl etherate, or tosic acid as catalyst, molecular sieves or Dean-Stark 
apparatus), none of the desired acetylated product (92) was formed, and only 
starting material was recovered at the end of the reaction period. An attempt to 
protect ketone (85) as dimethyl acetal (93) was carried out using trimethyl 
orthoformate in DCM in the presence of a catalytic amount of CSA (Scheme 17). 
However, again, this reaction was unsuccessful and no new organic fluorine 
signals were apparent in 
19
F NMR spectrum beyond the starting material (85). It is 
not clear why the protection -fluoro--ketoester (85) did not proceed as 
expected. 
 
Scheme 17: Attempted protection of (85) as acetal (92) and dimethyl acetal (93).                                 
Reagents and conditions: a) Ethylene glycol, BF3OEt2 or TsOH, DCM,                                      
b) HC(OMe)3, CSA, DCM. 
 
 
Since the attempted syntheses of (92) and (93) failed, this route was discontinued, 
and a new synthetic strategy for the synthesis of fluoromuscimol was explored.  
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2.4.2 Approach B–Direct fluorination using fluorine gas at Durham 
University  
 
An alternative approach towards the fluorinated isoxazole was envisaged via 
direct fluorination using fluorine gas of an already-formed isoxazole ring. Similar 
fluorination has been reported for pyrazole derivative.
24
 These compounds were 
obtained in acceptable yields (40–46%) after purification (Scheme 18).   
 
 
 
Scheme 18: Synthesis of monofluoropyrazoles using fluorine gas.
24
 
 
Three isoxazole precursors (77), (94) and (96) were chosen as representative 
substrates for this investigation. These substrates were prepared according to the 
synthetic route outlined in Scheme 19. Treatment of hydroxyurea (75) with 
dimethyl acetylenedicarboxylate (76) under basic conditions, afforded                  
3-hydroxyisoxazole-5-carboxylate (77), which was subsequently converted to 
methyl ester (94) with methyl iodide and potassium carbonate. Ester (94) was 
obtained as a colourless crystalline solid in good yield (66%) after column 
chromatography. Reduction of (94) with NaBH4 in MeOH afforded alcohol (95) 
in good yield and then conversion of (95) to its methyl-ether derivative (96) was 
carried out with methyl iodide and sodium hydride. This reaction afforded (96) in 
acceptable yield (57%). 
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Scheme 19: Synthesis of isoxazole derivatives (77), (94) and (96): Reagents and 
conditions: a) DBU, MeOH, 41%; b) MeI, K2CO3, DMF, 14 h, 66%; c) NaBH4, 
MeOH rt, overnight, 85%; d) NaH (60% dispersion oil), MeI, THF, 0 Crt, 1h, 
57%. 
 
 
These compounds were subjected to direct fluorination conditions using formic 
acid as a solvent and were carried out at the University of Durham. An image 
from the experimental setup is shown in Figure 18. Accordingly, in a glass 
reaction vessel fitted with a mechanical stirrer, an FEP thermocouple well, an FEP 
gas delivery tube and an exit tube to a scrubber filled with soda lime was charged 
with substrate (1.0 eq) and formic acid (4 ml) before being cooled to ca. 10 C. 
The vessel was purged with nitrogen, and then fluorine gas (4.0 eq) diluted at    
10% v/v in nitrogen, was passed through the stirred solution over 1 h. When the 
fluorine supply had been turned off, the reaction vessel was purged with 
nitrogen.
25,26
  The reaction mixture was poured into water and extracted with ethyl 
acetate. The extracts were dried and the solvent was removed under reduced 
pressure to afford dark brown oil.  
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Figure 18: Experimental setup for direct fluorination using elemental F2                                      
(the reaction was carried out with assistance from Dr Tony Harsanyi at the 
University of Durham). 
 
Unfortunately, all three reactions afforded a complex mixture of products that 
could not readily be characterised (Scheme 20). These findings clearly indicated 
that fluorine gas was too reactive, resulting in significant decomposition of 
substrates (77), (94) and (96), particularly when the reagent is present in excess. 
This approach was not pursued.  
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Scheme 20: Direct fluorination of (77), (94) and (96) using elemental F2.  
 
In order to tackle the drawback associated with the apparent reactivity of fluorine 
gas, the use of less reactive electrophilic fluorinating agents such as Selectfluor 
(89) and NFSI (97) was explored.  
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2.4.3 Approach C–Direct fluorination of isoxazole motifs using electrophilic                        
N-F reagents and nucleophilic fluoride sources 
 
 
Direct C-4 fluorination of a series of 3,5-diphenylisoxazoles by electrophilic 
fluorination using the N-F reagent, Selectfluor has been reported by                  
Stephens et al.,
27
 (Scheme 21) and Sato et al.,
28
 (Scheme 22). Following these 
successful examples, it was decided to investigate the fluorination of (94) and (96) 
using the N-F electrophilic fluorination agents, as these class of reagents are 
commonly employed by medicinal chemists due to ease of handling and are 
commercially available.
29–34
  
 
 
Scheme 21: Direct C-4 fluorination of series of 3,5-diphenylisoxazoles as reported 
by Stephens et al.
27
 Reagents and conditions: a) Selectfluor (1.05 eq), MeCN, 
reflux, overnight; b) Selecfluor (1.05 eq), sulfolane, 120 C, 396 h. 
  
 
 
 
 
Scheme 22: Direct C-4 fluorination of series of 3,5-diphenylisoxazoles as reported 
by Sato et al.
27
 Reagents and conditions: a) Selectfluor (1.0 eq), sulfolane,      
120 C (oil bath), 1 h. 
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2.4.3.1 Fluorination attempts on ester (94) 
 
The first attempt to fluorinate methyl ester (94) was carried out according to a 
protocol reported in the literature.
27,28
 Accordingly, a mixture of methyl ester (94) 
(1.0 eq) and Selectfluor (1.0 eq) in dry acetonitrile was heated under reflux 
(Scheme 23). However, the reaction failed to produce any new organofluorine 
products. Increasing the amount of Selectfluor to 4.0 equivalents, or changing 
the solvent to sulfolane did not improve the outcome of the reaction. There was no 
apparent consumption of starting material and no fluorinated products were 
observed by 
19
F NMR.  
 
 
 
Scheme 23: Fluorination attempts of (94) with Selectfluor. Reagents and 
conditions: a) Selectfluor, MeCN, reflux; b) Selectfluor, sulfolane, 130 C. 
 
Heating the compound under forcing conditions in a microwave assisted reaction 
in both acetonitrile and sulfolane (Scheme 24) was also investigated. Again, these 
strategies did not afford any fluorinated compound, and only the unreacted 
starting material was recovered at the end of the reaction.  
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Scheme 24: Fluorination attempts of (94) via microwave assisted reaction. 
Reagents and conditions: a) Selectfluor, MeCN, MW, 50 W, 90 C;                     
b) Selectfluor, sulfolane, MW, 50 W, 150 C. 
 
 
It has been reported that the reactivity of the 4-position of the isoxazole ring 
towards electrophilic reagents is sensitive to the electronic properties of its 
neighbouring substituents.
27,28,35,36
 The presence of electron withdrawing groups 
at C-3 or C-5 of the isoxazoles leads to a decrease in their nucleophilicity.
35,36
       
A possible approach to circumvent this problem is to replace the ester moiety with 
an ether group. This should increase reactivity towards electrophilic fluorination 
reagents such as Selectfluor and NFSI. Attempts to fluorinate (96)                   
(Schemes 25 and 26) were carried out according to the conditions described in 
Schemes 23 and 24. However again, this reaction was unsuccessful and no new 
organic fluorine signals were apparent in the 
19
F NMR, except for those of the 
tetrafluoroborate groups of Selectfluor.  
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Scheme 25: Fluorination attempts of (96) with Selectfluor. Reagents and 
conditions: a) Selectfluor, MeCN, reflux; b) Selectfluor, sulfolane, 130 C. 
 
 
Scheme 26: Fluorination attempts of (96) via microwave assisted reaction. 
Reagents and conditions: a) Selectfluor, MeCN, MW, 50 W, 90 C;                    
b) Selectfluor, sulfolane, MW, 50 W, 150 C. 
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2.4.3.2 Nitration of methyl ester (94) 
 
It was hypothesised that the fluorination of the 4-position of (94) could be 
achieved using a nucleophilic fluorination reagent via addition-elimination 
reaction by taking advantage of the electron withdrawing effect of methyl ester 
(94). In order to facilitate nucleophilic attack by fluoride, a suitable activating 
group with good leaving ability required to be placed at C-4. It was therefore 
decided to explore the introduction of a nitro group at this position. Moreover, the 
nitro group of (100) also has the potential to be converted to a reactive cationic 
quaternary ammonium species such (102) as shown in Scheme 27.  
 
 
 
Scheme 27: C-4 fluorination strategies of nitro (100) and quaternary ammonium 
salt (102) using nucleophlic fluorination reagents.  
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Nitration of methyl ester (94) was accomplished in a one-pot procedure using the 
nitronium triflate reagent (103). This reagent was generated in situ from 
tetramethylammonium nitrate and triflic anhydride in DCM (Scheme 28).
37
  
 
 
Scheme 28: In situ formation of, nitronium triflate (103).
37
 
 
Addition of substrate (94) to the in situ generated nitronium triflate (103), 
furnished the corresponding nitro product (100) as a yellow oil, in acceptable 
yield (70%) (Scheme 29).  
 
 
 
Scheme 29: One-pot nitration of (94). 
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2.4.3.3 Fluorination attempts on nitro isoxazole (100) 
 
Fluorinations of nitro isoxazole (100) were attempted using CsF and KF as 
fluoride sources (Scheme 30). These reagents were dried under vacuum at 150 C 
prior to use.  Accordingly,  a mixture of nitro (100) (1.0 eq) and fluoride reagent 
(2.0 eq) in dry DMF were heated under reflux. However, despite exploring 
various conditions (increasing fluoride to 4.0 equivalents, heating under 
microwave, and addition of the phase transfer reagent kryptofix K222 to KF), none 
of the attempted procedures furnished the desired fluorinated heterocycle (98). 
Moreover, there was no new signal observed by 
19
F NMR and the starting 
material did not react. Thus the nitro group was not sufficient to induce the 
addition-elimination reaction. 
 
 
 
Scheme 30: Fluorination attempts of (100) using nucleophlic fluorination 
reagents. Reagents and conditions: a) CsF, DMF, 150 C; b) KF, DMF, 150 C. 
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Although the fluorination of (100) was disappointing, the fact that quaternary 
ammonium salts are widely employed as precursors for nucleophilic fluorinations, 
particularly in PET studies, prompted further investigation.
38–40
  Reduction of the 
nitro group of (100) to the corresponding free amine (101) was achieved using 
iron powder under acidic conditions (Scheme 31). Purification by column 
chromatography afforded (101) as a colourless crystalline solid in good yield 
(83%). The structure of (101) was confirmed by X-ray crystallography                
(Figure 19).  
 
 
 
Scheme 31: Reduction of nitro (100) to free amine (101). Reagents and 
conditions: a) Fe powder, AcOH/H2O, 50 C, 2 h, 83%.                                            
 
 
 
Figure 19: X-ray structure of (101). 
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An attempt to transform the free amine (101) into the N-methylated quaternary 
ammonium salt (102) was carried out using an excess methyl iodide in basic 
methanolic solution (Scheme 32). Disappointingly, even after a prolonged 
reaction time of 24 hour and elevated temperature (reflux), the reaction failed to 
produce the desired product (102), and only the unreacted starting material was 
recovered at the end of reaction period. The lack of success is presumably due to 
the mesomeric electron-withdrawing effect of the ester moiety, resulting in a 
poorly nucleophilic amine.  
 
 
 
Scheme 32: Unsuccessful synthesis of quaternary ammonium salt (102) from free 
amine (101). Reagents and conditions: a) MeI, Ca2CO3, MeOH.                                            
 
 
2.4.3.4 Bromination of methyl ester (94) 
 
It was decided to explore further the fluorination of methyl ester (94). Therefore, a 
lithium-halogen exchange reaction was envisaged. In order to facilitate carbanion 
formation at C-4, a halogen substituent, in this case bromine was introduced at the 
4-position. Bromination of methyl ester (94) proved to be straightforward and was 
achieved using NBS in TFA. TFA enhances the electrophilicity of the Br through 
NBS protonation (104) (Scheme 33).
41
 Moreover, TFA was shown to be an 
effective and useful solvent for bromination and iodination of very unreactive 
aromatic compounds.
36,42–44
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Scheme 33: Strategy to introduce a bromine atom at C-4 of (94). 
 
Accordingly, a solution of ester (94) in TFA was treated with an excess of NBS 
under reflux. A relatively long reaction time (>24 h) was required to achieve an 
acceptable conversion, suggesting that the presence of an electron withdrawing 
group at the 5 position of the isoxazole ring decreases its nucleophilicity. In order 
to expedite the reaction, substrate (94) was subjected to microwave irradiation at 
150 C for 3 hours, affording clean and complete conversion to the desired 
product (105) (Scheme 34). Compound (105) was obtained as a colourless 
crystalline solid in 85% yield after column chromatography and its structure was 
confirmed by single crystal X-ray crystallography (Figure 20).  
 
 
Scheme 34: Synthesis of (105) via microwave assisted reaction. Reagents and 
conditions: a) NBS, TFA, MW, 50 W, 150 C, 3 h, 85%. 
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Figure 20: X-ray structure of (105). 
 
2.4.3.5 Fluorination attempts on brominated ester (105) 
 
With compound (105) in hand, an attempt to fluorinate the 4 position of isoxazole 
ring (105) in two stages via a lithium-halogen exchange reaction using t-BuLi and 
NFSI as an electrophilic source of fluorine, was made. As shown in Scheme 35,         
t-BuLi (2.0 eq) was added at -78 C to a solution of substrate (105) in THF.           
The mixture was stirred for 1 h and a solution of NFSI in THF was added. TLC 
and 
19
F NMR analyses of the product showed a complex mixture of products 
containing several fluorine signals. Due to the poor yield and low concentration of 
the fluorinated product, no further attempt was made at isolation. Furthermore, the 
1
H NMR analysis showed evidence for the presence of ketone (106) as a major 
product, which could clearly arise from direct nucleophilic attack of the                 
t-butylithium to the ester carbonyl.  
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Scheme 35: Attempt to fluorinate (105) using t-BuLi and NFSI. Reagents and 
conditions: a) n-BuLi, NFSI, THF, -78 C. 
 
In order to avoid direct nucleophlic attack by the base at the ester moiety of (105), 
a reaction was carried out using a weaker non nucleophilic base, KHMDS on          
ester (94) (Scheme 36). Analysis of the 
1
H NMR of the product showed unreacted 
starting material. However, 
19
F NMR analysis indicated a new organofluorine 
product at F = -166.1 ppm. An attempt to isolate this product for further 
characterisation was not possible due to its low concentration in the resulting 
mixture.  
 
 
 
Scheme 36: Attempt to fluorinate (94) using non nucleophilic base, KHMDS and 
NFSI. Reagents and conditions: a) KHMDS, NFSI, THF, -78 C. 
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2.4.3.6 Bromination of methyl ether (96) 
 
The bromination of ether (96) represents a possible strategy to overcome the 
limitation of direct fluorination of C-H. Moreover, this approach allows the 
fluorination reaction via two stages using organolithium bases followed by the 
addition of NFSI, to be fully utilised without having to consider the complication 
of direct nucleophilic attack of these reagents to the electrophilic carbon. Methyl 
ether (96) was brominated, as outlined in Scheme 33. This was achieved by 
adding an excess NBS to a solution of ether (96) in TFA. Purification by column 
chromatography afforded (107) as a colourless crystalline solid in 85% yield 
(Scheme 37). The structure of (107) was confirmed by X-ray crystallography 
(Figure 21).  
 
 
Scheme 37: Synthesis of brominated compound (107). Reagents and conditions:                   
a) NBS, TFA, rt, 48 h, 85%. 
 
 
Figure 21: X-ray structure of (107). 
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2.4.3.7 Fluorination of (107) via a lithium-halogen exchange reaction 
 
The fluorination of (107) via a lithium-halogen exchange reaction was 
investigated using n-BuLi and NFSI (Scheme 38). Ether (107) was subjected to 
lithiation with n-BuLi (1.1 eq) at -78 C in THF, followed by quenching with 
NFSI (2.0 eq). This afforded a complex mixture of products containing several 
fluorine signals (
19
F NMR). Of these, one was of particular interest in                 
that the 
19
F NMR signal (F = -187.4 ppm), appeared in the expected region                 
(from F(CDCl3) = -173 ppm to F(CDCl3) = -185 ppm)
27,45
 for fluorination at the 
C-4 of the isoxazole.  
 
 
 
Scheme 38: Fluorination approach of (107) via halogen-exchange reaction. 
Reagents and conditions: a) n-BuLi, NFSI, THF, -78 Crt, overnight, <10%. 
 
An attempt to isolate this compound was performed by careful chromatography. 
In the event, the desired fluorinated methyl ether (99) was isolated, albeit in very 
low yield (<10%).            
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The 
1
H NMR spectrum of (99) (Figure 22) shows that the methylene signal of H-6 
is coupled to fluorine, as a doublet (J = 1.6 Hz), consistent with 
4
JHF coupling.
45
 
This signal collapses to a singlet in the fluorine-decoupled 
1
H{
19
F}                 
NMR spectrum. Moreover, the proton signal assigned to the 4-position of (96)             
is not present in the 
1
H NMR spectrum, suggesting the successful incorporation of 
fluorine atom into the isoxazole ring.  
 
 
Figure 22: Partial 
1
H NMR spectra of (99) with and without {
19
F}. 
 
The incorporation of fluorine at the 4-position was further confirmed by 
19
F NMR               
(Figure 23). The 
19
F NMR exhibits a triplet at -187.4 ppm, with a 
4
JHF coupling 
constant of 1.6 Hz. A proton-decoupled 
19
F{
1
H} NMR experiment resulted in the 
collapse of this signal.  
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Figure 23: Partial 
19
F NMR spectra of the (99) with and without {
1
H}. 
 
In view of this promising result, it was decided to prepare compound (108) in 
order to optimise the metal exchange and fluorination reactions. Moreover, (108) 
is structurally closer to the desired fluoromuscimol (64) and thus, fewer steps are 
required to complete the synthesis, if fluorination is successful.   
 
 
 
 
 
 
 
19
F NMR 
19
F{
1
H} NMR 
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2.4.3.8 Synthesis of brominated di-Boc (108) 
 
As illustrated in Scheme 39, the synthesis of (108) was achieved in 8 steps 
starting from (77). It is worth mentioning that, initially (77) was synthesised via 
the method reported by Frey and Jäger.
12
 However, upon becoming commercially 
available, it was subsequently purchased from Fluorochem. The methylation of 
(77) followed by reduction of (94) to alcohol (95) was carried out under similar 
conditions as described in Scheme 19. Alcohol (95) was brominated using Appel 
conditions, in DCM at 0 C to yield (109) in 83% yield after column 
chromatography. The latter was then subjected to nucleophilic substitution using 
NaN3 in DMF at 80 C to obtain (110) in 90% yield. Bromination of intermediate 
(110) was accomplished according to the standard conditions outlined in    
Scheme 37, adding an excess of  NBS to a solution of the substrate in TFA at      
30 C to acquire (111) in 85%. Reduction of the azide using Staudinger’s 
conditions produced the corresponding protected bromomuscimol (112), as a 
yellowish oil after purification by column chromatography. The route was 
progressed by monoprotection of the amine moiety of bromoisoxazole (112) by 
treatment with Boc anhydride under basic conditions at room temperature. This 
afforded (113) as a colourless crystalline solid in good yield (72%). The second 
Boc group was introduced by dissolving (113) in the aprotic solvent, MeCN and 
heating the mixture under reflux after addition of Boc anhydride and a catalytic 
amount of DMAP. Di-Boc protected (108) was obtained as a colourless crystalline 
solid in excellent yield (91%). Structure (108) was confirmed by X-ray 
crystallography (Figures 24).  
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Scheme 39: Synthetic route to (108). Reagents and conditions: a) MeI, K2CO3, 
DMF, rt, 14 h, 66%; b) NaBH4, MeOH, 0 Crt, overnight, 85%; c)  PPh3, CBr4, 
DCM 0 C, 2 h, 83%; d) NaN3, DMF, 80 C, 3.5 h, 90%; e) NBS, TFA, 30 C,     
27 h, 85%; f) PMe3, THF, H2O, 0 C, 30 min, 66%; g) Boc2O, Et3N, DCM, rt,         
15 h, 72%; h) Boc2O, DMAP, MeCN, reflux, 3 h, 91%. 
 
 
 
 
Figure 24: X-ray structure of (108). 
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2.4.3.9 Fluorination of (108) via a lithium-halogen exchange reaction 
 
Fluorination of (108) was conducted in a similar manner to that illustrated in 
Scheme 38, by adding n-BuLi (1.1 eq) into a solution of (108) in THF at -78 C, 
followed by quenching with NFSI (2.0 eq) (Scheme 40). This reaction was not 
clean and gave rise to a complex mixture of products as evidenced by TLC 
analysis. Nevertheless, the crude material showed a clear fluorine signal, which 
was found to be consistent with fluorination at C-4 of the isoxazole, as it appeared 
in the same region to that observed in the fluorinated methyl ether (99).              
Despite the difficulty of separation by column chromatography, the desired 
product (114) was isolated cleanly, but in low yield, <10%.   
 
 
 
Scheme 40: Fluorination approach of (108) via a halogen-exchange reaction.  
Reagents and conditions: a) n-BuLi, NFSI, THF, -78 Crt, overnight, <10%. 
 
 
Analysis of the 
1
H NMR spectrum (Figure 25) shows that the methylene proton 
(H-6) of (114) resonates as a doublet at 4.84 ppm with a 
4
JHF coupling constant of 
1.8 Hz.  This collapses to a singlet upon 
19
F decoupling. Moreover, the fluorine 
signal (Figure 26), which appears as a triplet at F -187.9 ppm has a similar 
coupling constant (
4
JHF = 1.8 Hz) to that observed in the 
1
H NMR spectrum. This 
signal becomes a singlet in the proton-decoupled 
19
F{
1
H} experiment and in 
agreement with previous results on the fluorination of methyl ether (99).  
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Figure 25: Partial 
1
H NMR spectra of (114) with and without {
19
F}. 
 
 
 
Figure 26: Partial 
19
F NMR spectra of (114) with and without {
1
H}. 
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The formation of (114) was further confirmed by HRMS (NSI
+
) analysis                   
(Figure 27), with the appearance of characteristic peaks at m/z 369.1435 and 
715.2965, assigned to the [M+Na]
+
 and [2M+Na]
+ 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: HRMS (NSI
+
) analysis of (114). 
 
Although fluorination of (108) was successful, due to the large number of steps 
and the poor overall yield, this route was abandoned. Once again, a new approach 
to fluoromuscimol was required. This time, it was decided to begin the synthesis 
by switching the protecting group of the 3-position of (94) from methyl to 
isopropyl (115), as it appeared that it may be easier to deprotect this ether.
46–48
  
 
 
 
[M+Na]
+
 
[2M+Na]
+
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2.4.4 Successful route to fluoromuscimol (64) 
 
The successful route to fluoromuscimol (64) built on previous experience 
involved nine steps (Scheme 41), starting from the protection of (77) as an 
isopropyl ether (115). Reduction of the ester group of (115) was achieved using an 
excess of NaBH4 and gave alcohol (116). Bromination of (116) using the Appel 
reaction generated bromide (117), which was subjected to nucleophilic 
substitution with sodium azide affording (118). The resultant azide was 
transformed into the desired amine (119) via a Staudinger reaction using PMe3 at 
0 C in water/THF mixture. Protection of the amino group was achieved by 
addition of Boc anhydride and Na2CO3 to a solution of the free amine (119) in 
dioxane/water mixture. The mono-Boc protected product (120) was then isolated 
in excellent yield (90%) as a colourless viscous oil that crystallised in time. Its 
structure was confirmed by X-ray crystallography (Figure 28).  
 
 
Figure 28: X-ray structure of (120). 
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Scheme 41: Successful route to fluoromuscimol (64). Reagents and conditions:                                   
a) i-PrBr, K2CO3, DMF, 55 C, overnight, 77%; b) NaBH4, MeOH, 0 Crt, 
overnight, 90%; c) PPh3, CBr4, rt, 12 h, 58%; d) NaN3, DMF, 80 C, 3.5 h, 91%; 
e) PMe3, THF, H2O, 0 C, 1 h, 65%; f) Boc2O, Na2CO3, dioxane/H2O, rt, 
overnight, 90%; g) n-BuLi, NFSI, THF, -78 Crt, overnight, 30%; h) TFA, 
DCM, rt, 98%; i) 33% HBr in AcOH, 60 °C, 17 h, 36%. 
 
 
The key fluorination step of (120) was successfully achieved by addition of          
n-BuLi (2.2 eq) to a solution of (120) in THF at -78 C followed by addition of 
NFSI (1.1 eq). The proposed mechanism of this reaction is outlined in Scheme 42 
and starts with abstraction of a proton from carbamate (120) by the first 
equivalent of n-BuLi to generate lithium enolate (123). The nitrogen of (123) then 
acts as a ligand and coordinates to the second equivalent of n-BuLi via ortho-
directed lithiation, thus facilitating the deprotonation at the 4-position of the ring 
89 
 
and formation of a pseudo five-membered di-lithio chelate (124).
49
 This latter 
carbanion is more reactive towards electrophiles and results in the formation of 
intermediate (125) after addition of NFSI (97). Intermediate (125) then collapses 
to furnish the desired fluoro compound (121) upon warming to room temperature. 
After work-up and purification, (121) was obtained in 30% yield as a colourless 
viscous oil that crystallised in time. The structure of (121) was confirmed by              
X-ray crystallography (Figure 29). 
 
  
Scheme 42: Proposed mechanism for the fluorination of (120). 
 
 
Figure 29: X-ray structure of (121). 
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Analysis of the 
1
H NMR spectrum of (121) (Figure 30) is not straightforward, as 
the chemical shift of the NH proton cannot be properly assigned due to 
overlapping of its broad signal with the septet of the isopropyl group H-7 at      
4.92 ppm. Moreover, the 4-J (
4
JHF) coupling between the methylene group of H-6 
and fluorine is not observed due to the strong and more intense 3-J (
3
JHH) vicinal 
coupling of this group with the adjacent NH moiety. Nevertheless the                    
19
F NMR (Figure 31) gives clear evidence for the formation of the desired 
compound with the presence of a singlet at -188.0 ppm. 
 
 
 
Figure 30: 
1
H NMR spectrum of (121). 
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Figure 31: 
19
F NMR spectrum of (121). 
 
Further characterisation by 
13
C NMR (Figure 32) reveals that compound (121) 
exhibits three distinct doublets at 161.5 ppm (C-3), 152.3 ppm (C-5) with 
2
JCF 
coupling constants of  12.5 and 19.2 Hz respectively, while the third doublet 
signal appears much further upfield at 134.3 ppm (C-4) with a large 
1
JCF coupling 
constant of 254.6 Hz. The carbonyl carbon (C-9) and one sp
3
 quaternary carbon 
(C-10) appear at 155.5 ppm and 80.5 ppm respectively. Two upfield signals 
resonate at 28.4 ppm and 22.0 ppm are assigned to the methyl carbons of C-11 
and C-8 respectively. The remaining signals at 74.6 ppm and 35.0 ppm are 
attributed to methine carbon of C-7 and methylene carbon of C-6 respectively.  
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Figure 32: 
13
C NMR spectrum of (121). 
 
Removal of the Boc protecting group of (121) with TFA furnished the TFA salt of 
(122) in excellent yield (98%), after purification by column chromatography. A 
single crystal suitable for X-ray diffraction studies was grown from DCM and 
Et2O and the resultant structure is shown in Figure 33.  
 
 
Figure 33: X-ray structure of (122). 
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Final deprotection of the isopropyl group of (122) with 33% HBr in acetic acid, 
followed by subsequent preparative HPLC purification afforded (64) as a 
colourless solid in 36% yield after freeze-drying. A suitable crystal for X-ray 
diffraction was grown from water and Et2O. The structure is shown in Figure 34.  
 
 
Figure 34: X-ray structure of fluoromuscimol (64). 
 
 
The purity of fluoromuscimol (64) was determined by analytical HPLC on a 
reverse phase column. HPLC gave a single peak (tr = 1.97 min) corresponding to 
fluoromuscimol (64), and indicating a high purity (>99%) (Figure 35).  
 
 
Figure 35: HPLC chromatogram of fluoromuscimol (64) showing greater than 
99% purity.  
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In the 
1
H NMR spectrum of fluoromuscimol (64) (Figure 36), the methylene 
proton of H-6 appears as a doublet at 4.21 ppm with a 
4
JHF coupling constant of 
1.5 Hz, which collapses to a singlet upon 
19
F decoupling, while the 
19
F NMR 
spectrum exhibits a singlet resonance at  -185.2 ppm (Figure 37).  
 
Figure 36: 
1
H NMR spectra of fluoromuscimol (64). 
 
Figure 37: 
19
F NMR spectrum of fluoromuscimol (64). 
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The 
13
C NMR spectrum of fluoromuscimol (64) (Figure 38) exhibits four sets of 
doublets corresponding to 
13
C-
19
F couplings, whose coupling constants are        
for one bond 
1
JCF 257.1 Hz, two bonds 
2
JCF 21.8 Hz, 11.0 Hz and three bonds   
3
JCF 3.1 Hz. These are assigned to 139.1 ppm (C-4), 145.6 ppm (C-5), 167.8 ppm 
(C-3) and 32.5 (C-6) respectively. Analysis of the 
1
H-
13
C HMBC spectrum 
(Figure 39) indicates that H-6 has a 
4
J correlation with C 167.8 ppm (C-3),             
a 
3
J correlation with C 139.1 (C-4) and a 
2
J correlation with C 145.6 ppm (C-5) 
respectively.  
 
 
Figure 38: 
13
C NMR spectrum of fluoromuscimol (64). 
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Figure 39: 
1
H-
13
C HMBC spectrum of fluoromuscimol (64). 
 
A synthesis of muscimol (11) was carried out as a control for biological 
assessment.  Deprotection of the isopropyl group of (119) with 33% HBr in acetic 
acid, followed by purification using preparative HPLC afforded muscimol (11) as 
colourless solid in 34% yield after freeze-drying (Scheme 43).  
 
 
Scheme 43: Synthesis of muscimol (11) from (119). Reagents and conditions:                                
a) 33% HBr in AcOH, 60 °C, 17 h, 34%. 
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2.4.5 Synthesis of trifluoromethylmuscimol (65) 
 
Introduction of trifluoromethyl (CF3) group to an organic molecule has attracted 
much interest particularly in the field of pharmaceuticals and agrochemicals.
50–56
 
In addition, this structural moiety presents in a range of commercially available 
drugs and is known to dramatically alter the solubility, lipohilicity, bioavailability, 
metabolic stability etc of organic molecules.
57–59
 Importantly, due to the lipophilic 
nature of the trifluoromethyl group, it can increase the lipid solubility of drugs, 
thus enhancing their ability to penetrate the blood-brain barrier, an important 
structural feature that has to take into account when designing novel CNS 
drugs.
60–63
 Hence, it was of interest to synthesise the trifluoromethyl analogue of 
muscimol and evaluate its agonist activities against GABAA receptors. It is 
anticipated that replacing the fluorine for trifluoromethyl group should 
significantly increase the lipophilicity of the muscimol analogue. 
 
The synthetic route to trifluoromethylmuscimol (65) is illustrated in Scheme 44,    
a synthesis which took eleven steps, starting from the commercially available 
(77). The first four steps of the route were similar to that previously described for 
the synthesis of fluoromucimol (64) outlined in Scheme 41. Iodination at C-4 of 
isopropyl azido (118) was accomplished in a similar manner to that described in 
Scheme 37, replacing NBS with NIS as the electrophilic halogen source. 
Reduction of the azide group of (126) to amine (127) via the Staudinger process 
followed by direct protection with Boc anhydride afforded the N-doubly protected 
amino (129) in 87%. With this compound in hand, the next task was to install the 
trifluoromethyl group at C-4 of intermediate (129). The key step for 
98 
 
trifluromethylation was achieved using methyl fluorosulfonyldifluoroacetate 
(MFSDA) as a nucleophilic triluoromethylating reagent. This approach enabled 
the incorporation of the trifluoromethyl group at a late stage in the synthetic 
sequence, an aspect which is attractive for PET studies.  
 
 
Scheme 44: Successful route to trifluoromethylmuscimol (65). Reagents and 
conditions: a) i-PrBr, K2CO3, DMF, 55 C, overnight, 77%; b) NaBH4, MeOH,            
0 Crt, overnight, 90%; c) PPh3, CBr4, rt, 12 h, 58%; d) NaN3, DMF, 80 C,   
3.5 h, 91%; e) NIS, TFA, rt, overnight, 86%; f) PMe3, THF, H2O, 0 C, 1 h, 83%; 
g) Boc2O, Na2CO3, dioxane/H2O, rt, overnight, 81%; h) Boc2O, DMAP, MeCN, 
reflux, 3 h, 87%; i) MFSDA, CuI, HMPA/DMF, 80 C, 24 h, 34%; j) TFA, DCM, 
rt, 6 h; k) 33% HBr in AcOH, 60 °C, 48 h, 36% over two steps. 
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The proposed mechanism for the trifluoromethylation of (129) is shown in 
Scheme 45.  The process starts with the reaction of MFSDA (131) with CuI by 
elimination of methyl iodide to generate copper salt (132). Decarboxylation of salt 
(132) leads to the formation of difluorocarbene and a fluoride ion, which are in 
equilibrium with trifluoromethyl anion (133). In the presence of CuI,                   
the equilibrium shifts to afford the active cuprate species (134).
60,64,65
 
Subsequently, the oxidative addition to the cuprate (134) of aryl iodide (129), 
followed by reductive elimination gives the desired cross-coupling 
trifloromethylated product (130) along with the release of CuI and iodide ion,  
thus completing the catalytic cycle.
66
  
 
 
Scheme 45: Proposed mechanism for the trifluoromethylation of (129).
60,64–66
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The structure of trifloromethylated product (130) was elucidated by NMR 
analyses. As can be seen in Figure 40, the methylene proton of H-6 resonates as a 
quartet at 4.97 ppm and shows a coupling to the trifluormethyl group                    
(
5
JHF = 1.0 Hz). This signal collapses to a singlet in the 
1
H{
19
F} NMR spectrum.  
In the 
19
F NMR (Figure 41), the trifluoromethyl group is found to resonate as a 
triplet at -57.7 ppm with the same 
5
JHF coupling constant of 1.0 Hz. This triplet 
collapses to a singlet in the 
19
F{
1
H} experiment confirming the presence of 
coupling between the trifluoromethyl group and methylene proton H-6.   
 
 
 
Figure 40: 
1
H NMR spectra of (130) with and without {
19
F}. 
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Figure 41: 
19
F NMR spectra of (130) with and without {
1
H}. 
 
13
C NMR analysis of compound (130) is shown in Figure 42. Two quartets appear 
at 121.2 ppm (
1
JCF = 254.6 Hz) and 99.2 ppm (
2
JCF = 39.4 Hz) are attributed to 
13
C-
19
F coupling associated with the trifluoromethyl group. These signals are 
assigned to the CF3 carbon and C-4 respectively. The carbonyl group of C-9 is 
assigned to 169.4 ppm, while the other three quaternary carbons of C-3, C-5 and 
C-10 which appear more upfield are assigned to 167.4 ppm, 151.6 ppm and      
83.8 ppm respectively. Other signals such as that 28.1 ppm and 21.8 ppm 
correspond to methyl carbons of C-11 and C-8. The rest of the signals at 74.9 ppm 
and 42.2 ppm are attributed to the methine carbon of C-7 and methylene carbon of 
C-6 respectively.  
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Figure 42: 
13
C NMR spectrum of (130). 
 
Deprotection of the Boc protecting groups was conducted according to the 
standard protocol, adding an excess TFA to a solution of substrate (130) in DCM. 
This reaction afforded a colourless crystalline solid containing the TFA salt (135) 
upon removal of solvent under reduced pressure. Unfortunately, attempts to purify 
the product by chromatography were unsuccessful due to its instability on silica 
gel. Nevertheless, the crystalline material was found to be stable enough to 
perform single-crystal X-ray diffraction analysis (Figure 43), thus confirming the 
formation of the desired compound.  
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Figure 43: X-ray structure of (135). 
 
 
Due to the suspected instability of (135) it was submitted directly to further 
deprotection conditions in order to remove the isopropyl group. Thus the 
colourless crystalline solid was treated with an excess of HBr (33% in acetic acid) 
for 48 hours at 60 C. The final trifluoromethylmuscimol (65) was obtained as a 
colourless solid in 36% yield after purification by preparative HPLC. The purity 
of (65) was assessed by analytical HPLC on a reverse phase column. HPLC gave 
a single peak (tr = 2.27 min) corresponding to (65), and indicating a high purity 
(>98%) (Figure 44).  
 
Figure 44: HPLC chromatogram showing greater than 98% purity of 
trifluoromethylmuscimol (65). 
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As shown in Figures 45 and 46, both 
1
H NMR and 
19
F NMR spectra of 
trifluoromethylmuscimol (65) exhibit one sharp singlet resonating at 4.38 ppm 
and -58.9 ppm respectively, readily recognisable as arising from methylene proton 
H-6 and trifluoromethyl CF3 group respectively. With respect to 
13
C NMR  
(Figure 47), the signal corresponding to the trifluoromethyl CF3 group appears as 
a quartet at 121.6 ppm, showing clear 
13
C-
19
F coupling (
1
JCF of 267.8 Hz), 
whereas the quaternary sp
2
 carbon (C-4) adjacent to the trifluoromethyl group 
appears as an apparent doublet at 103.2 ppm (
2
JCF of 39.5 Hz), rather than a clear 
quartet. Besides these characteristic signals, the remaining three carbon signals are 
assigned to methylene carbon of C-6 at 34.5 ppm and quaternary carbons of C-3 
at 172.2 ppm and C-5 at 163.7 ppm respectively.  
 
Figure 45: 
1
H NMR spectrum of trifluoromethylmuscimol (65). 
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Figure 46: 
19
F NMR spectrum of trifluoromethylmuscimol (65). 
 
 
Figure 47: 
13
C NMR spectrum of trifluoromethylmuscimol (65). 
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2.4.6 Biological studies  
 
Biological evaluation was performed at the Faculty of Pharmacy, the University 
of Sydney in Australia. Compounds were tested on human synaptic (122), 
extrasynaptic (42) and (1) subunits of the GABAA receptor, expressed in 
Xenopus laevis frog oocytes. Oocytes were injected with a mixture of cRNAs 
encoding the desired GABAA receptor subunits and incubated for 3-7 days at        
18 C in modified Barth’s solution (96 mM NaCl, 2.0 mM KCl, 1.0 mM MgCl2, 
1.8 mM CaCl2, 5.0 mM HEPES, 2.5 mM sodium pyruvate, 0.5 mM theophylline, 
100 g/ml gentamycin, pH 7.4).  
 
The activities of GABA agonists were measured by recording induced currents at 
a holding potential ranging from -60 to -80 mV using an Axon Geneclamp 500B 
amplifier (Molecular Devices). Responses and data acquisition were recorded by 
using two-electrode voltage-clamp electrophysiology. In the data presented in 
Table 11, Emax refers to the maximal current produced by a saturating 
concentration of the agonist and EC50 refers to the concentration of agonist that is 
required to produce 50% of the response in Emax.  
 
GABA was reassayed as a control in this study. The potency of GABA was 
approximately 7-fold higher at the extrasynaptic (42) than synaptic (122) 
receptors, with  EC50 values of 2.8 and 20 M respectively (Table 11, Figures 48a 
and 48b), and was found to be comparable with previous reports.
67–70
 Synthetic 
muscimol was also compared with fluoromuscimol and trifluoromethylmuscimol. 
Fluoromuscimol (64) and muscimol (11) both evoked current responses at 
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synaptic (122) (Table 11, Figures 49a and 49b) and extrasynaptic (42) 
(Table 11, Figures 49d and 49e) receptors that appeared similar to those                  
of GABA (12). Fluoromuscimol (64) was between 9- and 17-fold less potent than 
GABA at both receptors types. However, it displayed higher efficacy at saturating 
concentrations than GABA at extrasynaptic (42) receptors, with 
Emax(fluoromuscimol) 1.6-fold greater than Emax(GABA). The Emax was lowered 
at synaptic (122) receptors, reaching 77% of GABA. On the other hand, the 
introduction of fluorine increased the EC50 values of muscimol (11) by 56-fold for 
the synaptic (122) receptors and by 112-fold for the extrasynaptic (42) 
receptors, thus reducing the potency, although the maximal efficacy (Emax) had 
been maintained for the extrasynaptic (42) receptors, and a little reduced for 
the synaptic (122) receptors. The trifluoromethyl analogue of muscimol (65) 
was inactive and did not evoke any current responses at all the tested GABAA 
receptors at concentrations up to 300 M (Figures 49c).  
 
Table 11: Potency and relative efficacy of GABA (12), muscimol (11), 
fluoromuscimol (64) and trifluoromethylmuscimol (65) at synaptic (122), 
extrasynaptic (42) and (1) GABAA receptors.  
Agonist 
122 
Synaptic 
42 
Extrasynaptic 
1 
 
EC50 
(M) 
EMax 
(%) 
nexp 
EC50 
(M) 
EMax 
(%) 
nexp 
EC50 
(M) 
EMax 
(%) 
nexp 
GABA (12) 20 100 5 2.8 100 9 1.1 100 8 
Muscimol (11) 3.1 120 6 0.43 160 9 1.6 75 6 
Fluoromuscimol 
(64) 
175 77 5 48 160 5 
not 
active 
not 
active 
 
6 
Trifluoromethyl
muscimol (65) 
not 
active 
not 
active 
3 
not 
active 
not 
active 
3 
not 
active 
not 
active 
 
3 
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Figure 48: Activities of GABA (12), muscimol (11) and fluoromuscimol (64) at 
synaptic (a)(122) and extrasynaptic (b)(42) GABAA receptors. 
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Figure 49: Current responses of GABA (12), muscimol (11), fluoromuscimol (64) 
and trifluoromethylmuscimol (65) at synaptic (a)(b)(c)(122) and extrasynaptic 
(d)(e)(42) GABAA receptors. 
122 42 
a d 
b e 
c 
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With respect to the 1 GABAA receptors, both GABA (12) and muscimol (11) 
were characterised as full agonists, with EC values of 1.1 M for GABA and           
1.6 M for muscimol respectively (Table 11 and Figure 50). Of the agonists 
tested, fluoromuscimol (64) was an inefficient agonist at 1 GABAA receptors, 
only evoking 33% response at the highest tested concentration (1 mM)           
(Figure 50).  
 
 
 
 
 
 
 
 
 
 
Figure 50: Activities of GABA (12), muscimol (11) and fluoromuscimol (64)          
at 1 GABAA receptors 
 
 
The biological assessment has shown that, introduction of one fluorine atom or a 
trifluoromethyl group into muscimol (11) did not improve the potency at the 
GABAA receptors. The best result was achieved on the extrasynaptic (42) 
receptors, where fluoromuscimol (64) showed higher potency than GABA (12)       
at saturating concentrations.  
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2.5 Conclusions 
 
The first syntheses of fluoromuscimol (64) and trifluoromethylmuscimol (65) 
have been achieved in nine and eleven steps respectively. The key fluorination 
step in the synthesis of fluromuscimol (64) was achieved via lithiation of (120) 
with n-BuLi followed by addition of NFSI.  
 
 
 
 
 
Fluoromuscimol (64) showed greater maximum response in comparison to GABA 
at the extrasynaptic GABAA receptors (42), but lower overall potency. 
Therefore, the substitution of hydrogen atom by fluorine in muscimol resulted in a 
decrease in potency relative to reference compounds, GABA and muscimol.  
 
The introduction of trifluoromethyl group onto muscimol was accomplished 
through the coupling of heteroaryl iodide (129) with trifluoromethylcopper 
species (134), which was generated in situ from MFSDA (131) in the presence of 
catalytic amounts of CuI. Trifluoromethylmuscimol (65) was inactive and did not 
evoke any current responses at all the tested GABAA receptors.  
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With the non-radioactive [
19
F] reference compound (64) in hand, the immediate 
challenge is to develop a late stage synthesis suitable for PET studies. One of the 
approaches that could be employed is by using diaryliodonium salts as precursors. 
Alternatively, the iodination of muscimol may offer an alternative to 
fluoromuscimol (64), as this compound could be labelled using the longer half-life 
iodine-124. The syntheses of diaryliodonium salts and iodomuscimol are the 
subjects of Chapter 3.  
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Chapter 3: Towards the late stage fluorination of muscimol through 
diaryliodonium salts. 
 
3.1 Introduction to hypervalent iodine compounds 
 
The first organic hypervalent iodine compound, (dichloroiodo) benzene (137) was 
prepared in 1885 by German chemist Conrad Willgerodt by reacting iodobenzene 
(136) with ICl3. One year later, Willgerodt reported an improved and                 
high-yielding approach for the preparation of (dichloroiodo) benzene (137) by 
passing Cl2 gas through a vessel containing an ice-cold iodobenzene solution. 
(Dichloroiodo) benzene (137) precipitated as yellow needles from the solution 
(Scheme 46).
1
 
 
 
 
 
 
 
 
 
Scheme 46: Willgerodt synthesis of (dichloroiodo) benzene (137).
1
 
 
This was rapidly followed by the discovery of other new important hypervalent 
iodine compounds such as (diacetoxyiodo) benzene (138) and iodosylbenzene 
(139) in 1892,
2
 2-iodoxybenzoic acid (IBX) (140) in 1893
3
 and diaryliodonium  
salts(141) in 1894.
4
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The next major contributor to the field was Beringer and co-workers, with their 
pioneering work to improve synthetic routes and applications of hypervalent 
iodine compounds for various organic transformations.
5
 For example, the first 
synthetic application of hypervalent chemistry in the -arylation of enolisable 
carbonyl compounds with diaryliodonium salts was reported Beringer and          
co-workers in 1960.
6
 This synthesis involved the use of diphenyliodonoium 
chloride (142) in promoting the transformation of diketone (143) into the 
corresponding mono- and bis-phenylated products of (144) and (145)                
(Scheme 47).  
 
 
 
Scheme 47: The first reported -arylation of diketone (143) using 
diphenyliodonoium chloride (142).
6
 Reagents and conditions: a) NaOtBu,             
t-BuOH, 83 C, 4 h.  
 
 
The discovery of Dess-Martin periodinane (DMP) (146) as a mild and non-toxic 
oxidation reagent by Dess and Martin in the 1980s was a major breakthrough in 
hypervalent iodine chemsistry.
7
 Since then, synthetic chemistry related to such 
compounds has received considerable attention. For example, although IBX was 
known since 1893, its utility in oxidation reactions was not unveiled until 1994.
8
 
Both DMP and IBX are frequently used in mild and selective oxidative 
transformations synthesis in organic and medicinal chemistry.
9,10
  Recently, Wirth 
and co-workers developed a tetra-fluorinated analogue of FIBX (147).              
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This reagent exhibits greater solubility in organic solvent compared to IBX, thus 
improving the reactivity of a reaction.
11
  
 
 
 
3.2 Nomenclature, oxidation state and bonding 
 
The definition of a hypervalent state according to Musher is when an atom 
commonly in group 15-18 of the periodic table expands its valence shell beyond 
the limits of the Lewis octet rule.
12
 The general oxidation process of iodine 
compounds is described according to the Martin-Arduengo N-X-L designation for 
hypervalent molecules and is shown in Scheme 48, where N is the number of 
valence electrons assignable to the valence shell of the central atom X, either as 
unshared pairs of electrons or as pairs of electrons in the sigma bonds joining a 
number, L, of ligands to the atom X.
13,14
 
 
 
 
Scheme 48: Oxidation levels of iodine compounds described according to the                        
Martin-Arduengo N-X-L designation for hypervalent molecules.
13,14
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According to IUPAC nomenclature, hypervalent iodine compounds are generally 
classified according to the oxidation state of the iodine and are denoted with a 
lambda notation.
15
 For examples, iodine compounds with the oxidation state of 
+III and +V are referred to as 3- and 5-iodanes respectively. The bonding in 
hypervalent iodine species can be demonstrated by using a 3-iodane (Figure 51). 
Iodine(III) compounds (ArIL2) have 10 electrons at the iodine atom and the 
geometry is best depicted as a pseudotrigonal bipyramid (T-shape) with two of the 
heteroatom ligands L occupying the apical positions and the less electronegative 
aryl moiety and two free electron pairs occupy the equatorial positions.
16
                 
The linear (L-I-L) bond in ArIL2 is a three-centre four-electron (3c-4e) bond 
derived from the doubly occupied 5p orbital with two electrons from iodine and 
one each from the apical ligands. This results in a highly polarised, longer and 
weaker bond compared to others and the iodine is electrophilic.
16,17
 Moreover, the 
electron withdrawing ligands also contribute to the electrophilicity of the 
iodine(III) centre.  
 
 
 
Figure 51: (a) Pseudotrigonal bipyramid geometry of ArIL2 
3
-iodane.                
(b) Molecular orbitals of the hypervalent bond. 
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It follows that, hypervalent iodine(III) compounds react with nucleophiles by first 
forming the Nu-I bond with release of one of the ligands (Scheme 49). Subsequent 
nucleophilic substitution or reductive elimination yields the Nu-L product and 
releases ArI.
18
 
 
Scheme 49: General reactivity of ArIL2 
3
-iodane with nucleophiles.
18
 
 
3.3 Some of 3- and 5-iodane applications in organic transformations 
 
Hypervalent iodine compounds exhibit attractive features of low cost, mild and 
selective reagents in organic synthesis.
19,20
 These reagents serve as 
environmentally benign alternatives to toxic heavy-metal based oxidants and 
expensive organometallic catalysts.
21,22
 The application of iodine(V) reagents 
such as DMP, IBX and their derivatives is vast, encompassing areas such as 
oxidations, C-C, C-heteroatom, heteroatom-heteroatom bond formation, 
rearrangements and radical reactions.
8,23–25
 Unlike DMP, IBX is much more stable 
and less expensive than DMP. It has been widely employed as a precursor of 
DMP as a versatile reagent capable for (a) dehydrogenating aldehydes and ketones 
to their corresponding ,-unsaturated carbonyl compounds,26 (b) oxidising 
oximes to the corresponding carbonyl compounds,
27
 (c) oxidising alcohols to 
carbonyl compounds,
8
 (d) oxidising phenols to o-quinones,
28,29
 (e) oxidising 
primary amides to the corresponding nitriles,
30
 (f) deprotecting of thioketals to 
aldehydes,
31
 (g) affecting the oxidation of benzylic sites
32
 and (h) oxidising 
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sulfides to their sulfoxides counterparts.
33
 The versatility of IBX reagent in 
organic transformations is illustrated in Figure 52. 
 
 
Figure 52: Transformations of IBX reagent (140). 
 
The first hypervalent iodine(III) compounds used as electrophilic 
trifluoromethylation reagents were developed in 2006 by Togni.
34
                      
Two compounds, 1-(trifluoromethyl)1-2-benziodoxol-3(1H)-one (148) and 
trifluoromethyl-1,3-dihydro-3,3-dimethyl-1,2-benziodoxole (149) (Figure 53) 
have been widely employed as trifluoromethylation reagents for a variety of 
substrates.
35
   
 
 
Figure 53: Electrophilic trifluoromethylation iodine(III) reagents developed by 
Togni.
34
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Liu and co-workers recently utilised Togni’s reagent in a one-pot, two-step 
process for the synthesis of trifluoromethylated isoxazoles. The reaction proceeds 
via copper catalysed trifluoromethylation of the Meyer-Schuster rearrangement. 
Addition of hydroxylamine to the reaction mixture led to the corresponding -CF3 
substituted compounds in acceptable yields (Scheme 50).
36
   
 
 
 
Scheme 50: One-pot synthesis of trifluoromethylated isoxazoles from propargylic 
alcohols.
36
 Reagents and condtions: a) (148) (1.8 eq), CuI (20 mol%), DCE,         
80 C; b) NH2OHHCl, py, t-AmOH, 90 C. 
 
 
Diaryliodonium salts are one of the most important 3 hypervalent compounds. 
They have been widely employed as a precursors in fluorination reactions 
especially in the field of positron emission tomography.
37
 The synthesis and 
application of these diaryliodonium salts for fluorination reactions is discussed in 
the following section. 
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3.4 Diaryliodonium salts 
 
3.4.1 Structural features and reactivity  
 
The general structure of 3-iodane diaryliodonium salts is shown in Figure 54. It 
is referred to as a symmetrical salt if R
1 
= R
2
 and unsymmetrical salt if R
1  R2 
and can be classified as 8-I-2 cationic species according to the Martin-Arduengo 
N-X-L rule, with two aryl moieties associated with an anion X
-
.
13,14
  
 
 
Figure 54: General structure of diaryliodonium salts. 
 
Since it has only 8 electrons in its valence shell, diaryliodonium salts are not 
formally hypervalent compounds. However, X-ray structural data demonstrate 
that they have similar features to a typical hypervalent iodine species exhibiting a 
pseudotrigonal bipyramid (T-shape) with a strong secondary interaction between 
the counterion and the iodine centre. Moreover, the L-I-L bond angle is about 90, 
which is consistent with a hypervalent iodine species and they can be considered 
as 10-electron hypervalent compounds.
16
  
 
3.4.2 Synthesis of diaryliodonium salts 
  
Diaryliodonium salts can be prepared by several different approaches.               
The majority are carried out under acidic conditions and are summarised in               
Scheme 51. The most widely employed strategy requires two or three steps, with 
initial oxidation of the aryl iodide to an iodine(III) compound followed by ligand 
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exchange reaction with an arene or organometallic reagent to afford a 
diaryiodonium salt (strategy a). In many cases, anion exchange is required in 
order to obtain a suitable anion for further reaction.
5,38
  
 
 
 
Scheme 51: General strategies for synthesis of diaryiodonium salts. 
 
Examples of how diphenyliodonium triflate (151) is prepared from iodobenzene 
(136) and benzene (150) via some of these strategies are illustrated in Scheme 52. 
(Diacetoxyiodo) benzene (138) was obtained in excellent yield and a short 
reaction time after oxidizing iodobenzene (136) with peracetic acid in acetic acid  
(route a).
39
 Treatment of (138) in aqueous NaOH furnishes iodosylbenzene (139) 
(route b).
40
 Kitamura and co-workers have successfully developed a route 
whereby this compound is converted to diphenyliodonium triflate (151), after 
treatment of (139) with TfOH, followed by the addition of benzene                
(route c and d).
41
 Bielawski and co-workers reported that this route can be 
shortened by employing a one-pot oxidation and ligand exchange. They found that 
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iodobenzene (136) could be treated directly with mCPBA and TfOH before the 
addition of benzene (150) to obtain diphenyliodonium triflate (151) in excellent 
yield (route h). They also showed that the reaction of benzene (150) and iodine 
with the same oxidant (mCPBA) and acid (TfOH) could deliver diphenyliodonium 
triflate (151) in 93% yield (route g).
42
  The same approach was also reported by 
Kitamura’s group by employing K2S2O8 as an oxidant. Diphenyliodonium triflate 
(151) was obtained in 78% yield after anion exchange with NaOTf (route e).
43
 
Alternatively, diphenyliodonium triflate (151) could also be obtained by treating 
benzene (150) in the presence of molecular iodine with K2S2O8 (route f).
44
   
 
 
Scheme 52: Example of how diphenyliodonium triflate (151) can be synthesised 
by employing the general strategies outlined in Scheme 51. Reagents and 
conditions: a) AcOOH, AcOH, 25-30 C, 4 h, 92%; b) NaOH(aq), rt, 1 h, 85-93%; 
c) TfOH, DCM, rt, 2 h; d) (150), rt, 17 h, 65%; e) K2S2O8, TFA, (150), 36-38 C, 
20 h; f) I2, K2S2O8, TFA, 40 C, 72 h; g) I2, mCPBA, TfOH, 80 C, 10 min, 93%; 
h) mCPBA, TfOH, (150), DCM, rt, 10 min, 92%. 
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The pre-formed iodine(III) compounds can also be employed as a starting 
materials and further reacted with silanes,
45,46
 stannanes
46–48
 or boron
49,50
 reagents 
to yield diaryiodonium salts. The purpose of using these organometallic reagents 
is to provide a nucleophilic coupling partner for subsequent reaction with a 
diacetoxyiodoarene. Luke and co-workers recently demonstrated that by reacting 
the preoxidised diacetoxyiodo (138), with the corresponding stannanes and silanes 
reagents, iodonium trifalte (152) and trifluoroacetate (153) are obtained in 
acceptable yields (Scheme 53).
46
 
 
Scheme 53: Route to iodonium triflate (152) and trifluoroacetate (153).
46
 
Reagents and conditions: a) TfOH, DCM -30 Crt.  
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3.4.3 Mechanism of nucleophilic substitution on iodonium salts 
 
The selectivity of the nucleophilic substitutions of diaryliodonium salts tend to 
proceed according to the so-called “ortho-effect” (Scheme 54) with the most 
bulky and more sterically demanding aryl ligand and two electron lone pairs 
occupying equatorial positions for steric reasons. This effect results in the 
reductive elimination of PhI and preferential transfer of the nucleophile to the 
ortho substituted aryl group, situated in the equatorial position, even though if it is 
a more electron rich ring.
37,51,52
 
 
 
Scheme 54: Ortho-effect of diaryliodonium salts. 
 
If there is no ortho substituent present on either aryl ring, the ring with the lowest 
electron density will preferentially transfer to the nucleophile with varying 
selectivities. The initial ligand exchange gives rise to hypervalent iodine(III) 
intermediates (154) and (155) with the nucleophile occupying the axial position 
(Scheme 55). The fast pseudorotation of these intermediates lead to two different 
transition states (156) and (157).
37,53
 Transition state (157) is more favourable 
than (156) due to stabilisation of the partial negative charge developed on the 
aromatic ring by the more electron-deficient aryl group. Moreover, the electron 
rich aryl group can also stabilise the enhanced positive charge on iodine(III) more 
effectively than an aryl substituent bearing an electron deficient group.
37,54,55
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Scheme 55: General mechanistic for the reactions of diarylidodonium salts with 
nucleophiles. 
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3.4.4 Application of iodonium salts as precursors for nucleophilic 
fluorination in PET 
 
The first [
18
F]radiofluorination using diaryliodonium salts as precursors was 
reported in 1995,
56
 and since then they have become a valuable approach for the 
late stage introduction of fluorine into a diversity of aromatic compounds.
57
 
Furthermore, by using diaryliodonium salts, both electron-deficient and electron-
rich rings can be fluorinated, allowing access to all regioisomers of a particular 
arene over standard SNAr chemistry.
58
 Moreover, these types of reactions 
typically require milder condition than standard SNAr, and they can even take 
place in wet solvents.
59
  
 
One of the limitations of nucleophilic aromatic substitution in the field of PET is 
that it is poor for labelling electron-rich arenes, and poor at accessing all 
regioisomers due to mechanistic considerations. This limitation can be 
circumvented using diarylidodonium salts as a precursor.
60
                                  
For example, the synthesis of N-(2,5-dimethoxybenzyl)-N-(5-[
18
F]fluoro-2-
phenoxyphenyl)acetamide ([
18
F]DAA1106 (159),  an imaging agent 
benzodiazepine receptors in the brain was achieved by nucleophilic 
radiofluorination of diphenyliodonium tosylate salt (158) as a precursor. 
[
18
F]DAA1106 was produced in high chemical yield (65%) (Scheme 56).
61
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Scheme 56: Synthesis of PET imaging [
18
F]DAA1106, (159).
61
 Reagents and 
conditions: a) 
18
F
-
, nBu4NHCO3, DMSO, 80 C, 20 min. 
 
 
Recently, Manera and co-workers have reported the synthesis and evaluation of a 
potent and selective candidate marker of the CB2 cannabinoid receptor. 
[
18
F]CB91 (161) is used to monitor the therapeutic efficacy of anti-inflammatory 
drugs in neurological diseases. The radioligand was obtained by nucleophilic 
fluorination of diaryliodonium salt (160) in good radiochemical yield (42%) 
(Scheme 57).
62
 
 
 
Scheme 57: Radiosynthesis of [
18
F]CB91 (161) from a diaryliodonium salt 
precursor (160).
62
 Reagents and conditions: a) K
18
F, kryptofix K222, DMSO,              
190 C, 25 sec, microfluidics. 
 
133 
 
Despite extensive research dedicated to developing novel radiotracers, there have 
been few studies reported in the literature pertaining to the synthesise of imaging 
agents bearing meta substituents due to the difficulties associated with accessing 
these regioisomers by standard nucleophilic means. In this regard, diaryliodonium 
offer an opportunity and has been employed by Warnier and co-workers for the 
preparation of a fully automated cGMP compliant radiosynthesis of [
18
F]UCB-H 
(162), a PET tracer for imaging synaptic vesicle glycoprotein 2A (SV2A). SV2A 
plays a pivotal role in neurotransmission processes and its role in epilepsy has 
rendered it an important PET target for neurological disorders related to epilepsy 
and Alzheimer’s disease (Scheme 58).37,63   
 
 
Scheme 58: Automated cGMP compliant radiosynthesis of [
18
F]UCB-H (162).
63
 
Reagent and condition: a) 
18
F
-
, automated cGMP.  
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Practical radiofluorination using this approach has been demonstrated in the 
synthesis of meta-[
18
F]fluorobenzylguanidine, ([
18
F]MFBG) (164), which was 
achieved via a two-step automated method by thermolysis of diaryliodonium salt 
(163) and subsequent acid mediated deprotection. [
18
F]MFBG was obtained in 
31% radiochemical yield and is currently ongoing clinical imaging trials for 
neuroendocrine tumors (Scheme 59).
64
  
 
 
Scheme 59: Two-step automated synthesis of [
18
F]MFBG (164).
64
 Reagents and 
conditions: a) K
18
F, kryptofix K222, toluene/MeCN, 120 C; b) 6 M HCl, 120 C.  
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3.5 Aims of this project 
 
This aspect of the study can be divided into two objectives. The first involved the 
synthesis and late stage fluorination of diaryliodonium salts, as precursors to 
fluoromuscimol (64). The second objective focused on the synthesis of an 
iodinated analogue of muscimol (11) and to assess the agonist activity of this 
compound against GABAA receptors. Good agonist activity of iodomuscimol 
(165) would offer an alternative SPECT radiotracer to extend the tools for GABA 
receptor imaging. 
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3.6 Results and Discussion 
 
3.6.1 Synthesis of iodinated precursor (166) 
 
The synthesis of (166) is illustrated in Scheme 60. Ester (94) was synthesised 
from the isoxazole (77). Protection of (77) as a methyl ether afforded methyl ester 
(94) which was then iodinated in good yield (80%) using NIS in TFA. Crystals 
suitable for X-ray studies of this product were obtained and the structure is shown 
in Figure 55.   
 
 
Scheme 60: Synthesis of (166). Reagents and conditions: a) MeI, K2CO3, DMF, 
14 h, 66%; b) NIS, TFA, MW, 50 W, 150 C, 3h, 80%. 
 
 
 
Figure 55: Crystal structure of 4-iodo ester (166). 
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3.6.2 Synthesis of diacetoxyiodoarene (167) 
 
There are many oxidising agents that have been widely employed in the 
transformation of iodoarenes to diacetoxyiodoarenes. These include sodium 
perborate tetrahydrate,
65,66
 sodium periodate,
67
 hydrogen peroxide-urea,
66,68
 
Selectfluor,66,69 and m-chloroperoxybenzoic acid.66,70 The most general 
methodology for diacetoxyiodoarene preparation uses sodium perborate 
tetrahydrate as an oxidant in acetic at 45 C.65 The first attempt to synthesise 
diacetoxyarene (167) was carried out using this approach (Scheme 61). However, 
no consumption of aryliodide (166) was observed when following the reaction by 
1
H NMR or TLC. Increasing the temperature of the reaction to 60 C and with a 
reaction time of 24 h did not facilitate the reaction. Additional methods were 
explored, including changing the oxidant from sodium perborate tetrahydrate to 
hydrogen peroxide-urea and sodium periodate. However, these were also 
unsuccessful. 
 
 
 
Scheme 61: Attempted synthesis of diacetoxyiodo (167). Reagents and conditions: 
a) NaBO34H2O, AcOH, 45 C; b) CO(NH2)2H2O2, AcOH, Ac2O, Na2SO4, 40 C; 
c) NaIO4, NaOAc, AcOH, Ac2O, reflux.   
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A further method was considered using mCPBA in acetic acid as the oxidant 
(Scheme 62). This was successful, however, 
1
H-NMR of the crude product 
mixture showed that it consisted of a 1.5:1 mix of starting material (166) and 
diacetoxyiodo compound (167) (Figure 56). Purification of diacetoxyiodo 
compound (167) by column chromatography or recrystallisation failed to separate 
the diacetoxyiodoarene as the product decomposed back to the starting material. 
Additionally, prolonged reaction times up to 96 h did not facilitate a complete 
conversion to the desired product (167). 
 
Scheme 62: Synthesis of diacetoxyiodo compound (167). Reagents and 
conditions: a) mCPBA, AcOH, 55 C, 96 h. 
 
Figure 56: Crude product NMR of diacetoxyiodo compound (167). 
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The mechanism for the synthesis of diacetoxyiodo (167) has not been fully 
established but a rationale is shown in Scheme 63. The iodoarene attacks the 
protonated mCPBA, forming a reactive iodine(III) species (168). Further 
activation of the OH of (168) in the acidic medium leads to the formation of 
oxonium intermediate (169), which enables a subsequent nucleophilic substitution 
with acetate to give diacetoxyiodo (167).  
 
 
Scheme 63: Proposed mechanism for diacetoxyiodo (167) formation.  
 
3.6.3 Synthesis of diaryliodonium trifluoroacetate salt (171) from 
diacetoxyiodoarene (167) 
 
 
The difficulty in purifying diacetoxyiodo (167), coupled with its apparent 
instability forced a direct synthesis approach to diaryliodonium salt (171). This 
synthesis was carried out by dissolving diacetoxyiodo (167) in dry DCM at            
-30 C, followed by drop wise addition of TFA (2.0 eq). The resulting solution 
was stirred with the exclusion of light for another 30 min, followed by 1 h                   
at room temperature. The solution was then re-cooled to -30 C, when                             
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tributyl(4-methoxyphenyl)stannane (170) (1.0 eq) was added. The solution was 
warmed to room temperature for a second time and left to stir overnight.            
The reaction solvent was then removed, followed by the addition of Et2O to 
crystallise iodonium salt (171) (Scheme 64). 
 
Scheme 64: Direct synthesis of diaryliodonium salt (171). Reagents and 
conditions: a) mCPBA, AcOH, 55 C, 96 h; b) TFA, (170), DCM, -30 Crt, 
overnight, 10%. 
 
The nucleophilic coupling of arylstannene (170) with diacetoxyiodo (167) can be 
explained on the basis of the polarisation of the C-Sn bond. This polarisation 
enhances the reactivity of arylstannane towards the electrophilic iodine(III) centre. 
Subsequent TFA anion exchange, yielded diaryliodonium salt (171) (Scheme 65). 
The structure of the salt was confirmed by X-ray crystallography (Figure 57).  
 
 
 
Scheme 65: Nucleophilic coupling of arylstannane (170) with diacetoxyiodo 
(167). 
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Figure 57: X-ray structure of diaryliodonium salt (171). 
 
3.6.4 Fluorination attempts on diaryliodonium trifluoroacetate salt (171) 
 
As previously discussed, if there is no ortho substituent present on either ring, the 
most electron-deficient aryl moiety on the diaryliodonium salt will generally be 
fluorinated. In the context of diaryliodonium trifluoroacetate salt (171), the 
isoxazole moiety bearing the ester group, is clearly the most electron-deficient 
relative to the anisole counterpart. Therefore, it was anticipated that selective 
fluorination at C-4 of the isoxazole moiety should be observed.   
 
Fluorination of diaryliodonium salt (171) (1.0 eq) was performed in DMF using 
caesium fluoride (2.0 eq) as a nucleophilic fluorination reagent (Scheme 66). 
Caesium fluoride was chosen on the basis of previous studies reported by             
Nairne et al., on several fluorination reactions of trifluoroacetate diarylidodonium 
salt using various nucleophilic fluorination reagents. The yield of the                     
fluorinated compounds obtained with respect to the reagents used                         
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are as follow CsF>KF(18-crown-6)>KF(K222)>KF=TBAF.
71
 However, despite 
exploring various sets of conditions (heating under microwave, addition of CuOTf 
as catalyst and addition of phase transfer reagent, kryptofix K222 to KF), none of 
the desired fluorinated isoxazole (98) could be isolated. 
1
H NMR analysis of the 
crude mixture showed evidence of reductive degradation of the aryliodonium salt 
(171) to the corresponding isoxazoles (94), (166) and iodoanisole (172) in 
different ratios (Scheme 67).  
 
 
Scheme 66: Fluorination attempts on diaryliodonium trifluoroacetate salt (171). 
Reagents and conditions: a) CsF, DMF, rt130 C. 
 
 
 
Scheme 67: Products from CsF treatment of (171). Reagents and conditions:        
a) CsF, DMF, rt130 C. The ratios are given in parentheses and were 
determined from 
1
H NMR analysis of the crude mixture.  
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It has been reported that diaryliodonium salts can interact in an intra-molecular 
manner thus forming dimers, trimers and so on.
46
 This is observed in the X-ray 
crystal structure of compound (171) (Figure 58). Furthermore, the presence of 
intra-molecular IO interactions between the carbonyl of the ester attached to the 
isoxazole moiety and the iodine(III) centre could make the adduct more stable and 
thus less amenable to fluorination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: X-ray crystal structure of (171) showing the formation of dimer (left)                      
and the intra-molecular IO interaction (right). 
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3.6.5 Synthesis of 4-iodo ether (173) 
 
To address the limitation of carbonyl complexation, it was decided to prepare the 
iodonium salt from methyl ether (96). Scheme 68 shows the synthesis of 
iodoisoxazole (173), which was prepared starting from isoxazole (77). Iodination 
of methyl ether (96) was carried out again with NIS in TFA. The desired product 
(173) was isolated in good yield (88%) and its structure was confirmed by X-ray 
crystallography (Figure 59). 
 
 
Scheme 68: Synthesis of iodoisoxazole (173). Reagents and conditions:                                   
a) MeI, K2CO3, DMF, 14 h, 66%; b) NaBH4, MeOH rt, overnight, 85%;                
c) NaH (60% dispersion oil), MeI, THF, 0 Crt, 1 h, 57%; d) NIS, TFA, rt, 
overnight, 88%. 
 
 
Figure 59: Crystal structure of 4-iodo ether (173). 
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3.6.6 Attempted synthesis of diacetoxyiodoarene (174) 
 
Attempts to oxidise (173) to the diacetoxyiodo (174) according to the standard 
condition outlined in Scheme 62 proved unsuccessful. Despite exploring various 
sets of reaction conditions as shown in Table 12, none of the desired product 
(174) could be isolated. Mass spectroscopy analysis of the crude mixture revealed 
the presence of iodoxy compound (175) along with unreacted starting material 
(173) (Scheme 69).  
 
 
Scheme 69: Attempted synthesis of diacetoxyiodo compound (174). 
 
Oxidant Solvent Additive Temperature Outcome 
mCPBA AcOH - 55 C (173) + (175) 
SPB AcOH - 55 C 
No reaction. 
Only (173) recovered 
Oxone TFA/CHCl3 - rt 
No reaction. 
Only (173) recovered 
mCPBA AcOH TFA 55 C (173) + (175) 
mCPBA AcOH TfOH 55 C (173) + (175) 
mCPBA CHCl3  rt (173) + (175) 
 
Table 12: Conditions for oxidation of (173). 
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3.6.7 One-pot synthesis of diaryliodonium tetrafluoroborate salts (176) and 
(177) 
 
A one-pot synthesis of the tetrafluoroborate iodonium salt was investigated.           
Such a protocol has been shown to be efficient in generating such salts without 
anion-exchange step.
72
 Accordingly, a solution of mCPBA (1.3 eq) in DCM was 
treated with iodoisoxazole (173) (1.0 eq) and boronic acid precursors (1.1 eq)              
in the presence of boron trifluoride (2.5 eq) at room temperature. Diaryliodonium 
tetrafluoroborate salts (176) and (177) were obtained in acceptable yields upon 
precipitation with diethyl ether (Scheme 70).  
 
 
Scheme 70: One-pot synthesis of iodonium tetrafluoroborate salts (176) and 
(177). Reagents and conditions: a) mCPBA, BF3OEt2, rt, 2 h; b) 4-OMePh-
B(OH)2, rt, 2 h, 50%; c) 2,4,6-TriMePh-B(OH)2, rt, 2 h, 45%. 
 
Despite a wide level of interest over many years in the one-pot synthesis of 
diaryliodonium salts, the exact mechanism remains unclear. A possible 
mechanism, shown in Scheme 71, starts with nucleophilic attack of iodoisoxazole 
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(173) on mCPBA to generate iodo oxide (175). Further activation of (175) by 
Lewis acid BF3 followed by loss of fluoride of (178), leads to intermediate (179). 
The free fluoride can then attack BF3 to generate BF4
-
. Intermediate (179) then 
undergoes nucleophilic addition at the electrophilic iodine centre to give (180) 
which then collapses to afford the desired iodonium tetrafluoroborate salts.   
 
 
Scheme 71: Putative mechanism for one-pot synthesis of diaryliodonium 
tetrafluoroborate salts (176) and (177). 
 
 
Complete assignments of 
1
H NMR, 
13
C NMR and 
19
F NMR spectra of 
diaryliodonium salts (176) and (177) are shown in Figures 60-63. 
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Figure 60: 
1
H NMR of iodonium salt (176). 
 
 
Figure 61: 
13
C NMR of iodonium salt (176). 
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Figure 62: 
1
H NMR of iodonium salt (177). 
 
 
Figure 63: 
13
C NMR of iodonium salt (177). 
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19
F NMR spectra of (176) and (177) are shown to exhibit two fluorine signals  
with different intensities at (-148.17 and -148.23 ppm) for (176) and                             
(–148.16 and -148.21 ppm) for (177). These signals correspond to the fluorines in 
the BF4
-
 group. The different intensities of the resonances are due to different 
natural abundance of the two isotopes of boron (
11
B and 
10
B).
72–74
                           
A representative 
19
F NMR spectrum of (176) is shown in Figure 64.  
 
 
Figure 64: 
19
F NMR of iodonium salt (176). 
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3.6.8 Fluorination attempts on diaryliodonium salts (176) and (177) 
 
Fluorinations of the diaryliodonium salts (176) and (177) were attempted 
according to the standard conditions outlined in Scheme 66. Unfortunately, 
despite exploring various sets of conditions (heating under microwave, addition of 
CuOTf as catalyst and addition of the phase transfer reagent, kryptofix K222 to 
KF), none of the attempted procedures furnished the desired fluorinated isoxazole 
(99) (Scheme 72). Again, 
1
H NMR analyses of the crude mixtures showed 
evidence of reductive degradation of the aryliodonium tetrafluoroborate salts 
(176) and (177) to the corresponding iodoisoxazole (173) and 4-iodoanisole (172) 
or iodomesitylene (181) in different ratios (Scheme 73).  
 
 
 
Scheme 72: Fluorination attempts on diaryliodonium tetrafluoroborate salts (176) 
and (177). Reagents and conditions: a) CsF, DMF, rt130 C. 
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Scheme 73: Products formed from fluorination of iodonium salts (176) and (177).                   
Reagents and conditions: a) CsF, DMF, rt130 C. Ratios are given in 
parentheses and were determined from 
1
H NMR analyses of crude mixtures. 
 
 
It has been reported that the selectivity and distribution of the organofluorine 
compounds obtained from fluorination of non-symmetrical iodonium salts 
depends on the stereoelectronic properties of the aryl rings.
37
 These results clearly 
suggest that diaryliodonium salts containing the isoxazole moiety do not meet the 
stereoelectronic requirements necessary for the fluorination reactions to occur. 
Moreover, the lack of precedent pertaining to the fluorination of these types of 
substrates perhaps reinforces their unsuitability.   
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3.6.9 Synthesis of iodomuscimol (165)  
 
As discussed in Chapter 1, the most commonly employed radionuclides for PET 
imaging include 
11
C and 
18
F. These radiotracers suffer from a major limitation 
because of their short half-lives (20.4 min for 
11
C and 110 min for 
18
F) which may 
limit both the synthesis protocols and the time frame for PET studies. This 
limitation can be addressed by using iodine-124.  With a half-life of 4.2 days, 
iodine-124 serves as an alternative PET radionuclide which allows extended 
radiosynthesis procedures and longitudinal PET imaging studies.
75
 Therefore, it 
was decided to synthesise the iodo analogue of muscimol to investigate its agonist 
activity against GABA receptors. If good agonist activity is observed, a synthesis 
suitable for SPECT becomes an attractive prospect.  
 
The synthesis of iodomuscimol (165) is illustrated in Scheme 74. It was 
developed based on the route to trifluoromethylmuscimol as described in              
Chapter 2. The synthesis was similar, except that the last two steps involved the 
reduction of compound (126) according to Staudinger conditions to form 
isopropyl protected iodomuscimol (127), followed by HBr deprotection to provide 
iodomuscimol (165), after preparative HPLC purification. A low yield was 
attributed to significant deiodination which was evident due to the recovery of 
muscimol (11) (Scheme 75). This product could result from competition between 
the rate of deiodination and the slower rate of the deprotection of the isopropyl 
group.  
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Scheme 74: Successful route to iodomuscimol (165). Reagents and conditions:         
a) i-PrBr, K2CO3, DMF, 55 C, overnight, 77%; b) NaBH4, MeOH, 0 Crt, 
overnight, 90%; c)  PPh3, CBr4, rt, 12 h, 58%; d) NaN3, DMF, 80 C, 3.5 h, 91%; 
e) NIS, TFA, rt, overnight, 86%; f) PMe3, THF, H2O, 0 C, 1h, 83%; g) 33 % HBr 
in AcOH, 60 °C, 17 h, 19%. 
 
 
 
 
 
Scheme 75: Putative mechanism for deiodination of isopropyl protected 
iodomuscimol (127) yielding muscimol (11), as a side reaction. 
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The purity of iodomuscimol (165) was determined by analytical HPLC on a 
reverse phase column. HPLC gave a single peak (tr = 2.19 min), corresponding to 
iodomuscimol (165) and indicating high purity (>99%) (Figure 65).  
 
 
Figure 65: HPLC chromatogram showing greater than 99 % purity iodomuscimol 
(165).  
 
The 
1
H-NMR spectrum of iodomuscimol (165) (Figure 66) shows the methylene 
signal at 4.21 ppm (H-6). Analysis of the 
1
H-
13
C HMBC spectrum (Figure 67) 
indicates that H-6 has 
4
J correlation with C 176.4 ppm (C-3), 
3
J correlation with  
C 61.6 ppm (C-4) and 
2
J correlation with C 163.2 ppm (C-5) respectively, as 
expected.  
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Figure 66: 
1
H NMR of iodomuscimol (165). 
 
 
Figure 67: 
1
H-
13
C HMBC spectrum of iodomuscimol (165). 
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The 
13
C NMR spectrum (Figure 68) has the expected three heteroaromatic ring 
signals [176.4 ppm (C-3), 163.2 ppm (C-5) and 61.6 ppm (C-4)] and a methylene 
carbon [35.3 ppm (C-6)].  
 
 
Figure 68: 
13
C NMR of iodomuscimol (165). 
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3.6.10 Biological results 
 
Iodomuscimol (165) was sent to our collaborator, Professor Mary Collins at the 
Faculty of Pharmacy, University of Sydney, in Australia for biological evaluation 
against GABAA receptors in order to assess its agonist activity. Unfortunately, 
iodomuscimol (165) was inactive and did not evoke any current responses at all 
the tested GABAA receptors relative to the reference compounds, GABA (12) at 
concentrations up to 1000 M (Figure 69). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Current responses of GABA (12) and iodomuscimol (165) at synaptic 
(a)(122) and (b)(1) GABAA receptors. 
 
122 1 a b 
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3.7. Conclusions 
 
The syntheses of three isoxazole diaryiodonium salts bearing anisole and 
mesitylene moieties were achieved. Diaryliodonium trifluoroacetate (171) was 
obtained by a direct synthesis of diacetoxyiodoarene (167) with aryl stannane 
(170) whereas the diaryliodonium tetrafluoroborate salts (176) and (177) were 
successfully prepared using a one-pot protocol from 4-iodo ether (166). 
Fluorination reactions of these compounds resulted in the reductive degradation to 
their corresponding isoxazole analogues and 4-iodoanisole or iodomesitylene in 
different ratios. Hence, these diaryliodonium salts are not suitable substrates for 
the preparation of fluoroisoxazole motifs.  
 
 
 
 
The first synthesis of iodomuscimol (165) was achieved in seven steps and high 
purity (>99%). Iodomuscimol (165) was inactive at all the tested GABAA 
receptors. 
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Chapter 4: Experimental Section 
 
4.1  General experimental protocol 
 
4.1.1 Reagents, solvents and reaction conditions  
 
All commercially available reagents were purchased from Acros UK, Sigma 
Aldrich, Fluorochem UK or Alfa Aesar UK and were used without further 
purification. n-BuLi was purchased from Sigma Aldrich as a 2.5 M solution in 
hexanes and was titrated against diphenylacetic acid prior to use. Anhydrous 
solvents (THF, DCM) were obtained from the MBraun MB SPS-800 solvent 
purification system, by passage through two drying columns and dispensed under 
an argon atmosphere. Anhydrous MeOH and MeCN were distilled from calcium 
hydride in recycling still.
1
 Anhydrous DMF and dioxane were available 
commercially. If not stated otherwise, all non-aqueous reactions were performed 
in a flame-dried flask under an inert atmosphere of argon, using a double vacuum 
manifold with the argon passing through anhydrous calcium sulphate. Microwave 
reactions were performed using a CEM Discover microwave reactor with infrared 
pyrometer and pressure control system.  
 
4.1.2  Chromatography and mass spectrometry  
 
Thin layer chromatography (TLC) was performed using Merck silica gel                               
60F254  aluminium-supported thin layer chromatography sheets. Compounds were 
visualised by either UV light (254 nm) or thermal development after dipping in 
ethanolic solution of phosphomolybdic acid (PMA), basic aqueous solution of 
potassium permanganate (KMnO4) or ninhydrin. Column chromatography was 
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performed using Merck Geduran silica gel 60 (250-400 mesh), eluting with 
solvents as supplied, under a positive pressure of compressed air. Reverse phase 
column chromatography was performed using C18 (Varian Mega Bond Elut C18) 
prepacked cartridges. High resolution mass spectra were recorded at the EPSRC 
National Mass Spectrometry Service, Swansea or at the University of St Andrews 
by Caroline Horsburgh on a Waters Micromass LCT time of flight mass 
spectrometer coupled to a Waters 2975 HPLC system. Values are reported as a 
ratio of mass to charge (m/z). 
 
4.1.3  Nuclear magnetic resonance (NMR) spectroscopy  
 
NMR spectra were acquired on either Bruker Avance 400 (
1
H at 400 MHz, 
13
C at 
100 MHz, 
19
F at 376 MHz) equipped with BBFO probe, Bruker Avance III HD 
500 (
1
H at 500 MHz, 
13
C at 125 MHz, 
19
F at 470 MHz) equipped with BBFO 
probe, Bruker Avance III 500 (
1
H at 500 MHz, 
13
C at 125 MHz) equipped with 
TCI cryoprobe or Bruker Avance III 700 (
13
C at 176 MHz) equipped with a TCI 
cryoprobe. The chemical shifts () are reported in parts per million (ppm) and are 
quoted relative to centre of the residual non-deuterated solvent peak for                           
δH (CDCl3: 7.26 ppm; MeCN: 1.94 ppm; D2O: 4.79 ppm; DMSO: 2.50 ppm) and 
δC (CDCl3: 77.16 ppm; MeCN: 1.32 ppm and 118.26 ppm; DMSO: 39.52 ppm). 
Chemical shifts δF are quoted relative to CFCl3 (δF CFCl3: 0.00 ppm). 
13
C NMR 
spectra were recorded using the DEPT Q or UDEFT pulse sequence with 
broadband 
1
H decoupling. 
19
F{
1
H} spectra were recorded with inverse-gating, to 
avoid errors on the integrals. Coupling constants (J) are given in Hertz (Hz). 
Signal splitting patterns are described as: br s (broad singlet), d (doublet),               
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s (singlet), sept (septet), t (triplet), dd (doublet of doublets), dm (doublet of 
multiplets) or m (multiplet). Spectroscopic data were assigned based on the 
combination of one- and two-dimensional experiments (HSQC and HMBC).             
 
4.1.4  X-ray crystallography 
 
Single crystal X-ray Diffraction analyses were carried out by Dr David B. Cordes 
and Professor Alexandra M. Z. Slawin at the University of St Andrews. All 
diffraction data except for (122) were collected by using a Rigaku FR-X Ultrahigh 
brilliance Microfocus RA generator/confocal optics and Rigaku XtaLAB P200 
system, with Mo Kα radiation (λ = 0.71075 Å). Data for (122) were collected at 
125 K by using a Rigaku MM-007HF High brilliance RA generator/confocal 
optics and Rigaku XtaLAB P200 system, with Cu Kα radiation (λ = 1.54187 Å). 
Intensity data for all samples were collected using ω steps accumulating area 
detector images spanning at least a hemisphere of reciprocal space. All data were 
corrected for Lorentz polarisation effects. A multiscan absorption correction was 
applied by using CrystalClear
2
 or CrysAlisPro.
3
 Structures were solved by 
Patterson (PATTY
4
) or direct (SIR2004,
5
 SIR2011
6
) methods and refined by     
full-matrix least-squares against F
2
 (SHELXL-2013
7
). Non-hydrogen atoms were 
refined anisotropically, and hydrogen atoms were refined using a riding model. 
All calculations were performed using the CrystalStructure
8
 interface. The 
Crystallographic Information Files (CIF) were analysed using CrystalMaker 
software and are attached on a CD disc.  
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4.1.5  Other analysis  
 
Melting points were obtained on an Electrothermal IA9100digital point apparatus 
without correction. IR spectra were recorded using the ATR technique on 
Shimadzu IRAffinity-1S FT-IR spectrometer with a diamond ATR attachment. 
HPLC analyses were performed using either a Waters system (600E multisolvent 
delivery system) or Shimadzu Prominence with reverse phase column as indicated 
in individual experiment. Amino acids (11), (64), (65) and (165) were freeze dried 
from solvent solution in water in a Chris Alpha 1-2 LO Plus freeze drier.  
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4.2  Experimental protocols 
 
4.2.1 Methyl 4-azido-3-oxobutanoate (86)
9
 
 
 
 
NaN3 (1.4 g, 21.6 mmol, 1.3 eq) was added to a solution of methyl                        
4-chloroacetoacetate (2.5 g, 16.6 mmol, 1.0 eq) in THF/water (3:1 v/v mixture,  
24 mL) at 0 C. The mixture was stirred at rt overnight. Water (30 ml) was added 
and the product was extracted into EtOAc (3 x 100 ml). The combined organic 
layers were washed with a saturated aqueous solution of Na2CO3 (60 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure affording 
yellowish oil which was purified silica by gel column chromatography 
(DCM/petroleum ether, 80:20) to afford  methyl 4-azido-3-oxobutanoate (86) 
(1.75 g, 67%) as a pale yellowish oil: Rf 0.82 (DCM/EtOAc, 90:10, PMA);          
H (500 MHz, CDCl3) 4.12 (2H, s, H-4), 3.76 (3H, s, H-5), 3.53  (2H, s, H-2);           
C (125 MHz, CDCl3) 197.1 (C-3), 166.8 (C-1), 57.7 (C-4), 52.9 (C-5), 46.4          
(C-2); HRMS m/z (ES
+
), found: [M+Na]
+
 180.0378, C5H7N3O3Na requires 
[M+Na]
+
 180.0385. These data are in accordance with the literature.
9
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4.2.2  () Methyl 4-azido-2-fluoro-3-oxobutanoate (85) 
 
 
 
Selectfluor (1.52 g, 4.29 mmol, 1.5 eq) was added in single portion to a solution 
of methyl 4-azido-3-oxobutanoate (86) (450 mg, 2.86 mmol, 1.0 eq) in MeCN    
(20 mL). After complete dissolution of Selectfluor, TiCpCl3 (57 mg, 0.26 mmol, 
0.1 eq) was added and the reaction mixture turned bright yellow. After 15 h 
stirring at rt, MTBE (10 mL) was added and the precipitate was removed by 
filtration. The filtrate was concentrated under reduced pressure, affording                   
a dark yellowish oil which was purified by silica gel column chromatography           
(DCM, 100) to afford methyl 4-azido-2-fluoro-3-oxobutanoate (85)                 
(185 mg, 37%) as a yellowish oil:  Rf 0.69 (DCM/EtOAc, 90:10, PMA);                
FT-IR (ATR, cm
-1
) 2922, 2108 (N3), 1741 (C=O), 1456, 1440, 1287, 1231,           
1138, 1099, 1015, 910; H (500 MHz, CDCl3) 5.39 (1H, d, 
2
JHF 48.4, H-2),                
4.31 (1H, dd, 
2
JHH 19.2, 
4
JHF 2.2, H-4a), 4.26 (1H, dd, 
2
JHH 19.2, 
4
JHF 1.6, H-4b), 
3.88 (3H, s, H-5); 
1
H{
19
F} (500 MHz, CDCl3) 5.39 (1H, s, H-2), 4.31               
(1H, d, 
2
JHH 19.2, H-4a), 4.26 (1H, d, 
2
JHH 19.2, H-4b), 3.88 (3H, s, H-5);                          
C (125 MHz, CDCl3) 195.5 (d 
2
JCF 24.2, C-3) 163.7 (d, 
2
JCF 23.6, C-1),           
90.5 (d, 
1
JCF 197.4, C-2), 55.1 (C-4), 53.8 (C-5), F (470 MHz, CDCl3) -199.5 
(dm, 
2
JHF 48.4, 1F, CHF); 
19
F{
1
H} (470 MHz, CDCl3) -199.5 (s, 1F, CHF); 
HRMS m/z (APCI
+
), found: [M+H]
+
 176.0461, C5H7N3O3F requires [M+H]
+
 
176.0466. 
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4.2.3  Methyl 3-hydroxyisoxazole-5-carboxylate (77)
10
 
 
 
 
DBU (11.7 mL, 77.4 mmol, 1.1 eq) was slowly added to a solution of 
hydroxyurea (5.35 g, 70.4 mmol, 1.0 eq) in MeOH (85 mL) at 0 C. After 15 min 
stirring at 0 C, dimethyl acetylenedicarboxylate (8.6 mL, 70.4 mmol, 1.0 eq) was 
added dropwise to the reaction mixture. The resulting dark orange reaction 
mixture was stirred at rt for 2.5 h and concentrated under reduced pressure. The 
resulting red oil was diluted with water (120 mL), acidified with conc. HCl under 
ice-cooling to obtain pH<2 and extracted into Et2O (3  80 mL). The aqueous 
layer was washed with saturated NaCl and extracted into Et2O (2  80 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow amorphous solid, which was purified by 
recrystallisation from CHCl3 to give methyl 3-hydroxyisoxazole-5-carboxylate 
(77) (4.1 g, 41%) as colourless crystalline solid: Rf 0.57 (Et2O/petroleum ether, 
80:20, UV/KMnO4); mp 165-166 C [Lit.
10
 164-165 C];  H (500 MHz, CDCl3) 
6.61 (1H, s, H-4), 3.98 (3H, s, H-7); C (125 MHz, CDCl3) 170.8 (C-3),              
160.1 (C-5), 156.9 (C-6), 101.4 (C-4), 53.2 (C-7); HRMS m/z (ESI
-
), found:           
[M-H]
-
 142.0140, C5H4NO4 requires [M-H]
-
 142.0146. These data are in 
accordance with the literature.
10
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4.2.4  Methyl 3-methoxyisoxazole-5-carboxylate (94)
11
 
 
 
 
K2CO3 (2.9 g, 21.0 mmol, 1.5 eq) and CH3I (1.3 mL, 21.0 mmol, 1.5 eq) were 
added to a solution of methyl 3-hydroxyisoxazole-5-carboxylate (77)                  
(2.0 g, 13.9 mmol, 1.0 eq) in DMF (10 ml) at 0 °C. After 14 h stirring at rt,        
the mixture was poured into an ice-cold aqueous solution of HCl (0.5 M, 100 mL) 
and extracted into Et2O (5  80 mL). The combined organic layers were washed 
with a saturated aqueous solution of Na2CO3 (80 mL), dried over MgSO4, filtered 
and concentrated under reduced pressure to afford a light yellow                             
crystalline solid, which was purified by silica gel column chromatography                       
(petroleum ether/Et2O, 80:20), affording methyl-3-methoxyisoxazole-5-
carboxylate (94) (1.45 g, 66%)  as colourless crystalline solid: Rf 0.71 (petroleum 
ether/Et2O, 70:30, UV/KMnO4); mp 72-73 °C [Lit.
11
 70 °C]; H (500 MHz, 
CDCl3) 6.53 (1H, s, H-4), 4.02 (3H, s, H-8), 3.94 (3H, s, H-7); C (125 MHz, 
CDCl3) 172.2 (C-3), 160.5 (C-5), 157.2 (C-6), 100.8 (C-4), 57.6 (C-8), 53.0 (C-7); 
HRMS m/z (ESI
+
), found: [M+Na]
+
 180.0266, C6H7NO4Na requires [M+Na]
+
 
180.0273. These data are in accordance with the literature.
11
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4.2.5  5-Hydroxymethyl-3-methoxyisoxazole (95)
12
 
 
 
 
NaBH4 (1.51 g, 40.0 mmol, 2.5 eq) was added to a solution of methyl                   
3-methoxyisoxazole-5-carboxylate (94) (2.50 g, 16.0 mmol, 1.0 eq) in MeOH    
(50 mL) at 0 °C. The mixture was stirred at rt overnight and quenched with 
saturated solution NH4Cl (40 mL). The reaction mixture was partitioned between 
water (50 mL) and EtOAc (50 mL). The aqueous layer was extracted with EtOAc             
(3 x 50 mL). The combined organic layers were washed with brine (40 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure to afford a pale 
yellowish oil, which was purified by silica gel column chromatography 
(petroleum ether/EtOAc, 60:40) to afford 5-hydroxymethyl-3-methoxyisoxazole 
(95) (1.75 g, 85%) as colourless oil: Rf 0.65 (petroleum ether/EtOAc 50:50, 
KMnO4); H (500 MHz, CDCl3) 5.88 (1H, s, H-4), 4.65 (2H, d, 
3
JHH 6.0, H-6), 
3.96 (3H, s, H-7), 2.20 (br s, 1H, -OH); C (CDCl3, 125 MHz) 172.5 (C-3),        
172.4 (C-5), 93.2 (C-4), 57.1 (C-6), 56.7 (C-7). HRMS m/z (APCI
+
),             
found: [M+H]
+
 130.0496, C5H8NO3 requires [M+H]
+
 130.0496. These data are in 
accordance with the literature.
12,13
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4.2.6  3-Methoxy-5-(methoxymethyl)isoxazole (96)
14
 
 
 
 
NaH (60% dispersion in mineral oil, 232 mg, 5.80 mmol, 1.1 eq) was added in 
single portion to a solution of 5-hydroxymethyl-3-methoxyisoxazole (95)          
(680 mg, 5.27 mmol, 1.0 eq) in THF (30 mL) at 0 °C. The reaction mixture was 
stirred at rt for 1 h, cooled to 0 °C and CH3I (0.36 mL, 5.80 mmol, 1.1 eq)         
was added. After 1 h stirring at rt, the reaction was quenched by slow addition of 
ice-cold water (30 mL). The aqueous layer was extracted into EtOAc (4  20 mL). 
The combined organic layers were washed with brine (20 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. The resulting yellow oil was 
purified by silica gel column chromatography (petroleum ether/Et2O, 80:20)        
to afford 3-methoxy-5-(methoxymethyl)isoxazole (96) (473 mg, 57%)                     
as a colourless oil: Rf 0.52 (petroleum ether/Et2O, 70:30, KMnO4);                    
FT-IR (ATR, cm
-1
) 2949, 1620, 1516, 1454, 1411, 1382, 1098, 1030, 966, 916, 
795; H (500 MHz, CDCl3) 5.88 (1H, s, H-4), 4.42 (2H, s, H-6), 3.97 (3H, s, H-8), 
3.42 (3H, s, H-7); C (CDCl3, 125 MHz) 172.5 (C-3), 170.3 (C-5), 94.4 (C-4), 
65.8 (C-6), 58.9 (C-7), 57.2 (C-8); HRMS m/z (ESI
+
), found: [M+H]
+
 144.0651, 
C6H10NO3 requires [M+H]
+
 144.0661. These data are in accordance with the 
literature.
14
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4.2.7  Methyl 3-methoxy-4-nitroisoxazole-5-carboxylate (100) 
 
 
 
Triflic anhydride (5.9 g, 21.0 mmol, 3.0 eq) was added to solution of 
tetramethylammonium nitrate (2.9 g, 21.0 mmol, 3.0 eq) in DCM (3 mL) at rt. 
The suspension was stirred for 2 h, then a solution of methyl 3-methoxyisoxazole-
5-carboxylate (94) (1.1 g, 7.0 mmol, 1.0 eq) in DCM (10 mL) was added. After   
48 h stirring under reflux, the mixture was cooled down to rt and partitioned 
between water (30 mL) and DCM (40 mL). The organic layer was separated and 
washed with water (50 mL). The aqueous layer was extracted with DCM                           
(3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The resulting 
yellow residue was purified by silica gel column chromatography (petroleum 
ether/DCM, 50:50) to afford methyl 3-methoxy-4-nitroisoxazole-5-carboxylate 
(100) (0.9 g, 70%) as yellowish oil: Rf 0.41 (petroleum ether/Et2O, 80:20, 
UV/KMnO4); FT-IR (ATR, cm
-1
) 1751 (C=O), 1628, 1541 (NO2), 1456, 1418, 
1371, 1288, 1221, 1202, 1161, 1051, 964, 918, 831, 808; H (500 MHz, CDCl3) 
4.14 (3H, s, H-8), 4.02 (3H, s, H-7); C (125 MHz, CDCl3) 164.0 (C-3),              
157.4 (C-5), 155.0 (C-6), 127.7 (C-4), 58.9 (C-8), 54.2 (C-7); HRMS                 
m/z (APCI
+
), found: [M+H]
+
 203.0295, C6H7N2O6 requires [M+H]
+
  203.0299. 
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4.2.8  Methyl 4-amino-3-methoxyisoxazole-5-carboxylate (101) 
 
 
 
Fe powder (267 mg, 4.86 mmol, 5.0 eq) was added to a solution methyl                  
3-methoxy-4-nitroisoxazole-5-carboxylate (100) (196 mg, 0.97 mmol, 1.0 eq) in 
AcOH/H2O (3:1 v/v mixture, 12 mL). After stirring at 50 °C for 2 h, the solution 
was cooled to rt and the solvent was removed under reduced pressure. The residue 
was partitioned between water (20 mL) and EtOAc (20 mL). The mixture was 
basified with a saturated aqueous solution of Na2CO3 and further extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine         
(20 mL), dried over MgSO4, filtered and concentrated under reduced pressure to 
afford a light pale yellow solid, which was purified by silica gel column 
chromatography (DCM, 100), affording methyl 4-amino-3-methoxyisoxazole-5-
carboxylate (101) (139 mg, 83%) as colourless crystalline solid: Rf 0.74 
(DCM/EtOAc, 90:10, UV/ninhydrin); mp 111-112 °C; FT-IR (ATR, cm
-1
)          
3499, 3397 (NH2), 2957, 1711 (C=O), 1665, 1572, 1545, 1501, 1433, 1416, 1333, 
1238, 1182, 1126, 1007, 986, 962, 901, 802, 764, 716; H (400 MHz, CDCl3)                   
4.15 (br s, 2H, -NH2), 4.05 (3H, s, H-8), 3.92 (3H, s, H-7); C (CDCl3, 125 MHz) 
164.5 (C-3), 159.1 (C-6), 138.4 (C-5), 125.6 (C-4), 57.5 (C-8), 51.9 (C-7);    
HRMS m/z (ESI
+
), found: [M+Na]
+
 195.0373, C6H8N2O4Na requires [M+Na]
+
 
195.0382.  
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4.2.9   Methyl 4-bromo-3-methoxyisoxazole-5-carboxylate (105) 
 
 
 
Methyl 3-methoxyisoxazole-5-carboxylate (94) (100 mg, 0.64 mmol, 1.0 eq),                       
NBS (170 mg, 0.96 mmol, 1.5 eq) and TFA (3 mL) were placed in a 10 mL glass 
microwave vessel. The reaction vessel was sealed with a rubber lid (CEM) and 
heated under microwave irradiation at 150 °C (50 W) for 3 h. The solvent was 
removed under reduced pressure and the residue was purified by silica gel column 
chromatography (petroleum ether/Et2O, 95:5), affording methyl 4-bromo-3-
methoxyisoxazole-5-carboxylate (105) (128 mg, 85%) as colourless crystalline 
solid: Rf 0.56 (petroleum ether/Et2O, 80:20, UV/KMnO4); mp 103-104 °C;        
FT-IR (ATR, cm
-1
) 2965, 1732 (C=O), 1527, 1450, 1433, 1414, 1277, 1217, 
1206, 1172, 1105, 1038, 978, 947, 918, 808, 733, 700, 613; H (500 MHz, CDCl3)                     
4.10 (3H, s, H-8), 3.98 (3H, s, H-7);  C (125 MHz, CDCl3) 169.7 (C-3), 156.5  
(C-5), 156.3 (C-6), 91.7 (C-4), 58.1 (C-8), 53.0 (C-7); HRMS m/z (NSI
+
), found: 
[M+H]
+
 235.9555, C6H7NO4
79
Br requires [M+H]
+
 235.9553.  
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4.2.10  4-Bromo-3-methoxy-5-(methoxymethyl)isoxazole (107) 
 
 
 
NBS (153 mg, 0.86 mmol, 2.0 eq) was added to a solution of 3-methoxy-5-
(methoxymethyl)isoxazole (96) (61 mg, 0.43 mmol, 1.0 eq) in TFA (2 mL).    
After stirring at rt for 48 h, the solvent was removed under reduced pressure and 
the residue was purified by silica gel column chromatography (petroleum 
ether/Et2O, 80:20), affording 4-bromo-3-methoxy-5-(methoxymethyl)isoxazole 
(107) (55 mg, 85%) as colourless crystalline solid:  Rf 0.55 (petroleum ether/Et2O, 
70:30, UV/KMnO4); FT-IR (ATR, cm
-1
) 2994, 1624, 1530, 1452, 1413, 1375, 
1283, 1192, 1101, 1057, 959, 947, 926, 781, 716, 689; mp 49-50 °C;                        
H (500 MHz, CDCl3) 4.45 (2H, s,H-6) 4.03 (3H, s, H-8), 3.39 (3H, s, H-7);                                 
C (CDCl3, 125 MHz) 169.2 (C-3), 166.5 (C-5), 85.3 (C-4), 63.9 (C-6),             
59.0 (C-7), 57.8 (C-8); HRMS m/z (NSI
+
), found: [M+H]
+
 221.9762, 
C6H9NO3
79
Br requires [M+H]
+
 221.9760.  
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4.2.11  5-Bromomethyl-3-methoxyisoxazole (109)
15
 
 
 
 
CBr4 (4.44 g, 13.4 mmol, 1.04 eq) and PPh3 (3.72 g, 14.2 mmol, 1.1 eq) were 
added to a solution of 5-hydroxymethyl-3-methoxyisoxazole (95) (1.66 g,          
12.9 mmol, 1.0 eq) in DCM at 0 °C. The reaction was stirred at 0 °C for 2 h and 
concentrated under reduced pressure. The resulting residue was purified by silica 
gel column chromatography (petroleum ether/EtOAc, 90:10) to afford                 
5-bromomethyl-3-methoxyisoxazole (109 (2.1 g, 83%) as a colourless oil:               
Rf 0.72 (petroleum ether/EtOAc, 80:20, UV/KMnO4); H (500 MHz, CDCl3)           
5.91 (1H, s, H-4), 4.30 (2H, s, H-6), 3.90 (3H, s, H-7); C (125 MHz, CDCl3) 
172.2 (C-3), 168.2 (C-5), 95.1 (C-4), 57.1 (C-7), 19.1 (C-6); HRMS m/z (NSI
+
), 
found: [M+H]
+
 191.9654, C5H7NO2
79
Br requires [M+H]
+
 191.9655. These data 
are in accordance with the literature.
16
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4.2.12  5-Azidomethyl-3-methoxyisoxazole (110) 
 
 
 
NaN3 (1.56 g, 24.0 mmol, 5.0 eq) was added to a solution of 5-bromomethyl-3-
methoxyisoxazole (109) (923 mg, 4.8 mmol, 1.0 eq) in DMF (21 mL). After 
stirring at 80 °C for 3.5 h, the resulting solution was diluted with water (50 mL), 
and the product was extracted into Et2O (5 x 50 mL). The combined organic 
layers were washed with a saturated solution of Na2CO3 (50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting yellowish 
oil was purified by silica gel column chromatography (petroleum ether/EtOAc, 
90:10) to afford 5-azidomethyl-3-methoxyisoxazole (110) (665 mg, 90%)               
as a colourless oil: Rf 0.62 (petroleum ether/EtOAc, 80:20, KMnO4);                         
FT-IR (ATR, cm
-1
) 2949, 2100 (N3), 1622, 1520, 1454, 1413, 1354, 1292, 1198, 
1142, 1031, 914; H (500 MHz, CDCl3) 5.91 (1H, s, H-4), 4.32 (2H, s, H-6), 3.97 
(3H, s, H-7); C (125 MHz, CDCl3) 172.4 (C-3), 167.5 (C-5), 94.9 (C-4),                   
57.3 (C-7), 45.9 (C-6); HRMS m/z (ESI
+
), found: [M+H]
+
 155.0563, C5H7N4O2 
requires [M+H]
+
 154.0569.  
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4.2.13  5-Azidomethyl-4-bromo-3-methoxyisoxazole (111)   
 
 
 
NBS (1.53 g, 8.6 mmol, 2.0 eq) was added to a solution of 5-azidomethyl-3-
methoxyisoxazole (110) (665 mg, 4.3 mmol, 1.0 eq) in TFA (18 mL). After 
stirring at 30 °C for 27 h, the solvent was removed under reduced pressure and the 
residue was purified by silica gel column chromatography (petroleum ether/Et2O, 
95:5), affording 5-azidomethyl-4-bromo-3-methoxyisoxazole (111) (847 mg, 
85%) as colourless oil: Rf 0.67 (petroleum ether/Et2O, 80:20, UV/KMnO4);                 
FT-IR (ATR, cm
-1
) 2957, 2097 (N3), 1622, 1531, 1449, 1410, 1337, 1287, 1250, 
1200, 1101, 1061, 961, 920, 881, 768; H (500 MHz, CDCl3) 4.36 (2H, s,H-6), 
4.06 (3H, s, H-7); C (125 MHz, CDCl3) 169.4 (C-3), 164.6 (C-5), 85.5 (C-4), 
57.9 (C-7), 44.4 (C-6); HRMS m/z (APCI
+
), found: [M+H]
+
 232.9667, 
C5H6N2O4
79
Br requires [M+H]
+
 232.9669. 
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4.2.14  5-Aminomethyl-4-bromo-3-methoxyisoxazole (112)  
 
 
 
PMe3 (1.0 M solution in THF, 4.5 mL, 4.5 mmol, 1.5 eq) was added to a solution 
of 5-azidomethyl-4-bromo-3-methoxyisoxazole (111) (700 mg, 3.0 mmol, 1.0 eq) 
in THF (20 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 30 min and 
was quenched by slow addition of water (40 mL). The organic phase was 
separated and the aqueous phase was extracted into EtOAc (3 x 40 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure and the residue was purified by silica gel 
column chromatography (EtOAc, 100), affording 5-aminomethyl-4-bromo-3-
methoxyisoxazole (112) (410 mg, 66%) as yellowish oil: Rf 0.20                
(EtOAc, ninhydrin); FT-IR (ATR, cm
-1
) 3375, 3320 (NH2), 2955, 1614, 1530, 
1451, 1408, 1194, 1099, 1032, 961, 939, 702; H (500 MHz, CDCl3) 4.02 (3H, s, 
H-7), 3.87 (2H, s, H-6), 1.58 (br s, 2H, -NH2); C (CDCl3, 125 MHz) 170.6 (C-5), 
169.4 (C-3), 81.8 (C-4), 57.7 (C-7), 37.7 (C-6); HRMS m/z (NSI
+
), found: 
[M+H]
+
 206.9764, C5H8N2O2
79
Br requires [M+H]
+
 206.9764. 
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4.2.15  5-(tert-butyloxycarbonyl)aminomethyl-4-bromo-3-methoxyisoxazole 
(113)  
 
 
 
Et3N (0.3 mL, 2.13 mmol, 1.1 eq) and di-tert-butyl dicarbonate (0.49 mL,            
2.13 mmol, 1.1 eq) were added to a solution of 5-aminomethyl-4-bromo-3-
methoxyisoxazole (112) (400 mg, 1.93 mmol, 1.0 eq) in DCM (30 mL). The 
resulting yellowish mixture was stirred at rt for 15 h, diluted with DCM (40 mL), 
and washed with water (50 mL). The aqueous layer was extracted into DCM             
(3 x 30 mL). The combined organic layers were combined, dried over MgSO4, 
filtered and concentrated under reduced pressure. The resulting yellow residue 
was purified by silica gel column chromatography (petroleum ether/Et2O, 70:30) 
to afford 5-(tert-butyloxycarbonyl)aminomethyl-4-bromo-3-methoxyisoxazole 
(113) (427 mg, 72%) as a colourless crystalline solid: Rf 0.41 (petroleum 
ether/Et2O, 70:30, ninhydrin); mp 91-92 [Lit.
14
 91-92 C]; FT-IR (ATR, cm-1) 
3314 (NH), 2978, 1678 (C=O), 1626, 1531 (NH), 1450, 1410, 1368, 1271, 1256, 
1155, 1103, 1053, 976; H (500 MHz, CDCl3) 4.96 (br s, 1H, -NH),                   
4.37 (2H, d, 
3
JHH 5.5, H-6), 4.02 (3H, s, H-7), 1.44 (9H, s, H-10); C (125 MHz, 
CDCl3) 169.3 (C-3), 166.7 (C-5), 155.4 (C-8), 83.2 (C-4), 80.5 (C-9), 57.7 (C-7), 
36.2 (C-6), 28.4 (C-10); HRMS m/z (NSI
+
), found: (M+NH4)
+ 
324.0557, 
C10H19N3O4
79
Br requires (M+NH4)
+ 
324.0553. These data are in accordance with 
the literature.
14
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4.2.16  5-Di(tert-butyloxycarbonyl)aminomethyl-4-bromo-3-methoxyisoxazole 
(108)
14
  
 
 
 
 
DMAP (32 mg, 0.26 mmol, 0.2 eq) and di-tert-butyl dicarbonate                        
(0.60 mL, 2.6 mmol, 2.0 eq) were added to a solution of 5-(tert-
butyloxycarbonyl)aminomethyl-4-bromo-3-methoxyisoxazole (113) (400 mg, 
1.30 mmol, 1.0 eq) in MeCN (20 mL). The reaction mixture was heated under 
reflux for 3 h and allowed to cool to rt. The reaction was diluted with DCM            
(30 mL), and washed with water (40 mL). The aqueous layer was extracted into 
DCM (3 x 30 mL). The combined organic layers were combined, dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting brown oil 
was purified by silica gel column chromatography (petroleum ether/Et2O, 80:20) 
to afford 5-di(tert-butyloxycarbonyl)aminomethyl-4-bromo-3-methoxyisoxazole 
(108) (497 mg, 91%) as a colourless crystalline solid: Rf 0.63 (petroleum 
ether/Et2O, 70:30, ninhydrin); mp 73-74 C [Lit.
14
 73-75 C]; FT-IR (ATR, cm-1) 
2981, 1730 (C=O), 1694 (C=O), 1616, 1533, 1452, 1414, 1385, 1369, 1337, 1261, 
1229, 1163, 1142, 1125, 1103, 1040, 968; H (500 MHz, CDCl3)                        
4.84 (2H, s, H-6), 4.02 (3H, s, H-7), 1.49 (18H, s, H-10); C (125 MHz, CDCl3) 
169.3 (C-3), 166.2 (C-8), 151.6 (C-5), 83.6 (C-9), 82.2 (C-4), 57.7 (C-7), 41.8   
(C-6), 28.1 (C-10); HRMS m/z (NSI
+
), found: [M+Na]
+
 429.0631, 
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C14H17N9O1
79
BrNa requires [M+Na]
+
 429.0632. These data are in accordance 
with the literature.
14
  
 
4.2.17 Methyl 3-isopropoxyisoxazole-5-carboxylate (115)
17
 
 
 
 
Isopropyl bromide (3.9 mL, 42.0 mmol, 1.5 eq) was added to a mixture of                             
methyl 3-hydroxyisoxazole-5-carboxylate (77) (4.0 g, 28.0 mmol, 1.0 eq) and 
K2CO3 (4.3 g, 31.0 mmol, 1.1 eq) in DMF (50 mL). The mixture was stirred for    
1 h at 60 °C then at 55 °C overnight. After cooling down to rt, water (80 mL) was 
added and the aqueous phase was extracted into Et2O (3 x 50 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting yellow residue was purified by silica gel column 
chromatography (petroleum ether/Et2O, 90:10) to afford methyl                           
3-isopropoxyisoxazole-5-carboxylate (115) (4.0 g, 77%) as colourless oil:                    
Rf 0.61 (petroleum ether/Et2O, 80:20, UV/KMnO4); H (500 MHz, CDCl3)              
6.48 (1H, s, H-4), 4.93 (1H, sept, 
3
JHH  6.1, H-8), 3.92 (3H, s, H-7),                  
1.38 (6H, d, 
3
JHH 6.1, H-9); C (125 MHz, CDCl3) 170.9 (C-3), 160.0 (C-5), 157.3 
(C-6), 101.5 (C-4), 74.2 (C-8), 52.9 (C-7), 21.9 (C-9); HRMS m/z (NSI
+
), found: 
[M+H]
+
 186.0758, C8H12NO4 requires [M+H]
+
 186.0761.The data were in good 
agreement with the literature values.
17
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4.2.18  5-Hydroxymethyl-3-isopropoxyisoxazole (116) 
 
 
 
NaBH4 (1.53 g, 40.5 mmol, 2.5 eq) was added to a solution of methyl                   
3-isopropoxyisoxazole-5-carboxylate (115) (3.00 g, 16.2 mmol, 1.0 eq) in MeOH 
(80 mL) at 0 °C. The mixture was stirred at rt overnight and quenched with a 
saturated solution NH4Cl (50 mL). The reaction mixture was partitioned between 
water (60 mL) and EtOAc (60 mL). The aqueous layer was extracted into EtOAc             
(3 x 80 mL). The combined organic layers were washed with brine (50 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure to afford                           
a pale yellowish oil, which was purified by silica gel column                            
chromatography (petroleum ether/EtOAc, 80:20) to afford 5-hydroxymethyl-3-
isopropoxyisoxazole (116) (2.29 g, 90%) as colourless  oil: Rf 0.79 (petroleum 
ether/EtOAc, 70:30, KMnO4); FT-IR (ATR, cm
-1
) 3367 (OH), 2982, 1622, 1504, 
1456, 1386, 1375, 1338, 1111; H (500 MHz, CDCl3) 5.83 (1H, s, H-4),            
4.85 (1H, sept, 
3
JHH 6.1, H-7), 4.63 (2H, s, H-6), 2.61 (br s, 1H, -OH),              
1.36 (6H, d, 
3
JHH 6.1, H-8); C (125 MHz, CDCl3) 171.9 (C-5), 171.2 (C-3),         
94.1 (C-4), 73.5 (C-7), 56.9 (C-6), 22.0 (C-8); HRMS m/z (NSI
+
), found: [M+H]
+
 
158.0809, C7H12NO3 requires [M+H]
+
 158.0812.  
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4.2.19 5-Bromomethyl-3-isopropoxyisoxazole (117) 
 
 
 
CBr4 (7.26 g, 21.9 mmol, 2.2 eq) and PPh3 (7.82 g, 29.8 mmol, 3.0 eq) were 
added to a solution of 5-hydroxymethyl-3-isopropoxyisoxazole (116)                   
(1.56 g, 9.94 mmol, 1.0 eq) in DCM (100 mL) at 0 °C. The reaction mixture was 
stirred at rt for 12 h and concentrated under reduced pressure. The resulting 
residue was purified by silica gel column chromatography (petroleum ether/Et2O, 
95:5) to afford 5-bromomethyl-3-isopropoxyisoxazole (117) (1.27 g, 58%) as a 
colourless oil: Rf 0.66 (petroleum ether/Et2O, 80:20 UV/KMnO4); FT-IR           
(ATR, cm
-1
) 2980, 1618, 1504, 1447, 1387, 1373, 1340, 1287, 1109, 1030, 916, 
667; H (500 MHz, CDCl3) 5.90 (1H, s, H-4), 4.89 (1H, sept, 
3
JHH 6.1, H-7), 4.33 
(2H, s, H-6), 1.38 (6H, d, 
3
JHH 6.1,  H-8);  C (125 MHz, CDCl3) 171.0 (C-3),                
167.8 (C-5), 95.9 (C-4), 73.6 (C-7), 22.0 (C-8), 19.2 (C-6); HRMS m/z (ESI
+
), 
found: [M+H]
+
 219.9969,  C7H11NO2
79
Br requires [M+H]
+
 219.9968. 
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4.2.20 5-Azidomethyl-3-isopropoxyisoxazole (118) 
 
 
 
NaN3 (1.6 g, 25.0 mmol, 5.0 eq) was added to a solution of 5-bromomethyl-3-
isopropoxyisoxazole (117) (1.1 g, 5.0 mmol, 1.0 eq) in DMF (50 mL). After 
stirring at  80 °C for 3.5 h, the resulting solution was diluted with water (60 mL) 
and the product was extracted into Et2O (5 x 60 mL). The combined organic 
layers were washed with a saturated solution of Na2CO3 (60 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting yellowish 
oil was purified by silica gel column chromatography (petroleum ether/Et2O, 
95:5) to give 5-azidomethyl-3-isopropoxyisoxazole (118) (828 mg, 91%)            
as a colourless oil: Rf 0.64 (petroleum ether/Et2O, 80:20, KMnO4);                              
FT-IR (ATR, cm
-1
) 2980, 2100 (N3), 1622, 1506, 1456, 1446, 1339, 1111, 1029;                          
H (500 MHz, CDCl3) 5.87 (1H, s, H-4), 4.89 (1H, sept, 
3
JHH 6.1, H-7),                   
4.31 (2H, s, H-6), 1.38 (6H, d, 
3
JHH 6.1, H-8); C (CDCl3, 125 MHz) 171.1 (C-3), 
166.9 (C-5), 95.5 (C-4), 73.7 (C-7), 45.9 (C-6), 22.0 (C-8); HRMS m/z (NSI
+
), 
found: [M+H]
+
 183.0876, C7H11N4O2 requires [M+H]
+
 183.0877. 
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4.2.21 5-Aminomethyl-3-isopropoxyisoxazole (119) 
 
 
 
PMe3 (1.0 M solution in THF, 13.2 mL, 13.2 mmol, 3.0 eq) was added to a 
solution of 5-azidomethyl-3-isopropoxyisoxazole (118) (800 mg, 4.40 mmol,      
1.0 eq) in THF (30 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h 
and was quenched by slow addition of water (50 mL). The organic phase was 
separated and the aqueous phase was extracted into EtOAc (3 x 80 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The resulting residue was purified by silica 
gel column chromatography (EtOAc, 100) affording 5-aminomethyl-3-
isopropoxyisoxazole (119) (446 mg, 65%) as yellowish oil: Rf 0.40 
(EtOAc/MeOH, 80:20, ninhydrin); FT-IR (ATR, cm
-1
) 3383, 3315 (NH2), 2980, 
1616, 1499, 1449, 1385, 1373, 1340, 1111, 1028; H (500 MHz, CDCl3)              
5.70 (1H, t, 
4
JHH 0.7, H-4), 4.85 (1H, sept, 
3
JHH 6.1, H-7), 3.82 (2H, s, H-6),           
1.56 (br s, 2H, -NH2), 1.35 (6H, d, 
3
JHH 6.1, H-8); C (125 MHz, CDCl3) 174.3 
(C-5), 171.2 (C-3), 92.6 (C-4), 73.2 (C-7), 38.8 (C-6), 22.0 (C-8); HRMS m/z 
(NSI
+
), found: [M+H]
+
 157.0967, C7H13N2O2 requires [M+H]
+
 157.0972. 
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4.2.22 5-(tert-Butyloxycarbonyl)aminomethyl-3-isopropoxyisoxazole (120)
18
  
 
 
 
Na2CO3 (543 mg, 5.12 mmol, 2.0 eq) was added to a solution of 5-aminomethyl-
3-isopropoxyisoxazole (119) (400 mg, 2.56 mmol, 1.0 eq) in dioxane/water        
(3:1 v/v mixture, 8 mL) at 0 °C, followed by dropwise addition of di-tert-butyl 
dicarbonate (0.65 mL, 2.82 mmol, 1.1 eq) in dioxane (2 mL). After stirring at rt 
overnight, dioxane was removed under reduced pressure and the residue was 
diluted with Et2O (30 mL) and washed with water (50 mL). The aqueous layer 
was extracted into Et2O (3 x 30 mL). The combined organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. 
The resulting yellow residue was purified by silica gel column chromatography 
(petroleum ether/Et2O, 70:30) to afford 5-(tert-butyloxycarbonyl)aminomethyl-3-
isopropoxyisoxazole (120) (590 mg, 90%) as a colourless viscous oil that 
crystallised in time: Rf 0.74 (petroleum ether/Et2O, 50:50, ninhydrin);               
mp 49-50 °C; FT-IR (ATR, cm
-1
) 3306 (NH), 2980, 1712 (C=O), 1616, 1522 
(NH), 1497, 1449, 1384, 1366, 1271, 1254, 1138, 1036, 901; H (500 MHz, 
CDCl3) 5.74 (1H, s, H-4), 5.00 (br s, 1H, -NH), 4.85 (1H, sept, 
3
JHH 6.1, H-7),                
4.29 (2H, d, 
3
JHH 5.9, H-6), 1.44 (9H, s, H-11), 1.36 (6H, d, 
3
JHH 6.1,  H-8);         
C (125 MHz, CDCl3) 171.2 (C-3), 170.2 (C-5), 155.6 (C-9), 94.0 (C-4), 80.4     
(C-10), 73.4 (C-7), 37.1 (C-6), 28.4 (C-11), 22.0 (C-8); HRMS m/z (NSI
+
), found: 
[M+H]
+
 257.1496, C12H21N2O4 requires [M+H]
+
 257.1496.  
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4.2.23 5-(tert-Butyloxycarbonyl)aminomethyl-4-fluoro-3-isopropoxyisoxazole 
(121) 
 
 
 
n-BuLi (1.7 mL, 2.5 M in hexanes, 4.29 mmol, 2.2 eq) was added dropwise            
to a solution of 5-(tert-butyloxycarbonyl)aminomethyl-3-isopropoxyisoxazole 
(120) (500 mg, 1.95 mmol, 1.0 eq) at -78 °C. The mixture was stirred for 1.5 h at           
-78 °C and added a solution of NFSI (676 mg, 2.15 mmol, 1.1 eq) in THF (2 mL). 
The mixture was stirred for 2 h at -78 °C and the temperature was allowed to 
warm to rt over 12 h. The reaction mixture was quenched with aqueous NH4Cl 
(10 mL) and the organic phase was extracted into EtOAc (3 x 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. The resulting residue was purified by silica gel                       
column chromatography (petroleum ether/Et2O, 80:20) to afford 5-(tert-
butyloxycarbonyl)aminomethyl-4-fluoro-3-isopropoxyisoxazole (121) (160 mg, 
30%) as a colourless viscous oil that crystallised in time: Rf 0.67 (petroleum 
ether/Et2O, 50:50, ninhydrin); mp 63-65 °C; FT-IR (ATR, cm
-1
) 3333 (NH), 
2983, 1680 (C=O), 1612, 1526 (NH), 1285, 1269, 1252, 1107, 1078,                      
916, 907; H (400 MHz, CDCl3) 4.97 (br s, 1H, -NH, overlapped with H-7),           
4.92 (1H, sept, 
3
JHH 6.1, H-7), 4.36 (2H, d, 
3
JHH 5.0, H-6), 1.44 (9H, s, H-11),  
1.40 (6H, d, 
3
JHH 6.1, H-8); C (125 MHz, CDCl3) 161.5 (d, 
2
JCF 12.5, C-3), 155.5 
(C-9), 152.3 (d, 
2
JCF 19.2, C-5), 134.3 (d, 
1
JCF 254.6, C-4), 80.5 (C-10), 74.6      
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(C-7), 35.0 (C-6), 28.4 (C-11), 22.0 (C-8); F (376 MHz, CDCl3)                             
-188.0 (1F, s, CF); HRMS m/z (NSI
+
), found: [M+H]
+
 275.1404, C12H20N2O4F 
requires [M+H]
+
 275.1402. 
 
4.2.24 5-Ammoniomethyl-4-fluoro-3-isopropoxyisoxazole  
trifluoroacetate (122) 
 
 
 
 
TFA (1.7 mL, 22.0 mmol, 40.0 eq) was added to a solution of 5-(tert-
butyloxycarbonyl)aminomethyl-4-fluoro-3-isopropoxyisoxazole (121) (150 mg, 
0.55 mmol, 1.0 eq) in DCM (8 mL). After stirring at rt overnight, the solvent was 
removed under reduced pressure and the resulting residue was purified by silica 
gel column chromatography (DCM/MeOH, 95:5) to afford 5-aminomethyl-4-
fluoro-3-isopropoxyisoxazole trifluoroacetate salt (122) (155 mg, 98%) as light 
yellow solid: Rf 0.54 (DCM/MeOH, 90:10, ninhydrin); mp 116-118 °C;            
FT-IR (ATR, cm
-1
) 2988, 2926, 2843, 2612, 1670 (C=O), 1541, 1516, 1508, 
1435, 1381, 1352, 1339, 1290, 1242, 1120, 1177, 1138, 1103, 1064, 986;                                                  
H (400 MHz, CD3CN) 6.76 (br s, 3H, -NH3), 4.91 (1H, sept, 
3
JHH 6.1, H-7),       
4.15 (2H, s, H-6), 1.38 (6H, d, 
3
JHH 6.1, H-8); C (100 MHz, CD3CN) 162.5        
(q, 
2
JCF 30.5, TFA), 162.3 (d, 
2
JCF 12.5, C-3), 150.8 (d, 
2
JCF 20.4, C-5), 136.3     
(d, 
1
JCF 255.7, C-4), 117.6 (q, 
1
JCF 291.9, TFA), 76.0 (C-7), 34.0 (C-6), 21.9      
(C-8); F (376 MHz, CD3CN) -76.4 (3F, s, TFA), -186.5 (1F, s, CF);                
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HRMS m/z (ESI
+
), found: [M-TFA+H]
+
 175.0876, C7H12N2O2F requires                                    
[M-TFA+H]
+
175.0877.  
 
4.2.25 5-Aminomethyl-4-fluoro-3-hydroxyisoxazole (64) 
 
 
 
A solution of HBr 33% in AcOH (0.79 mL, 4.5 mmol, 25 eq) was added to                             
5-aminomethyl-4-fluoro-3-isopropoxyisoxazole trifluoroacetate (122) (53 mg, 
0.18 mmol, 1.0 eq) and stirred at 60 °C for 17 h. The solvent was removed under 
vacuum and the residue was washed with water (3 x 2 mL). The residue was 
passed through a reverse phase C18 cartridge (Varian Mega Bond Elut C18, 
preconditioned with water) and the product was eluted with water (3 x 10 mL). 
The fractions were combined and concentrated under reduced pressure.              
The product was further purified by preparative HPLC (Waters system, using a 
Phenomenex Kingsorb C18 (250 x 21.2 mm, 5 ) column equipped with security 
guard cartridge), with an isocratic mobile phase of H2O at flow rate of 8.0 mL/min 
detected at 254 nm. Fractions containing product (tR = 7.80 min) were collected 
and concentrated under reduced pressure. Fluoromuscimol (64) was obtained as a 
colourless solid after freeze drying (11 mg, 36%). Analytical HPLC analysis             
was performed using Shimadzu system (Phenomenex Kingsorb C18                 
(150 x 4.6 mm, 5 ) column), with an isocratic mobile phase of H2O at flow rate 
of 0.8 mL/min detected at 254 nm (tR = 1.97 min, purity >99%);                                                       
mp >200 °C (dec.); FT-IR (ATR, cm
-1
) 3429, 2982, 2621 (br), 2237, 2099 (br), 
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1521, 1458, 1273, 1219, 1144, 1088, 1069, 988; H (400 MHz, D2O)                 
4.21 (2H, d, 
4
JHF 1.5, H-6); 
1
H{
19
F} (400 MHz, D2O) 4.21 (2H, s, H-6);               
C (176 MHz, D2O) 167.8 (d, 
2
JCF 11.0, C-3), 145.6  (d, 
2
JCF 21.8, C-5), 139.1    
(d, 
1
JCF 257.1, C-4), 32.5 (d, 
3
JCF 3.1, C-6); F (376 MHz, D2O)                               
-185.2 (1F, s, CF); HRMS m/z (ESI
+
), found: [M+H]
+
 133.0407, C4H6N2O2F 
requires [M+H]
+
133.0413. 
 
4.2.26 5-Aminomethyl-3-hydroxyisoxazole (11)  
 
 
 
A solution of HBr 33% in AcOH (1.8 mL, 10.3 mmol, 25 eq) was added to                     
5-aminomethyl-3-isopropoxyisoxazole (119) (64 mg, 0.41 mmol, 1.0 eq) and 
stirred at 60 °C for 17 h. The solvent was removed under vacuum and the residue 
was washed with water (3 x 2 mL). The residue was passed through a reverse 
phase C18 cartridge (Varian Mega Bond Elut C18, preconditioned with water) 
and the product was eluted with water (3 x 10 mL). The fractions were combined 
and concentrated under reduced pressure. The product was further purified by 
preparative HPLC (Waters system, using a Phenomenex Kingsorb C18               
(250 x 21.2 mm, 5 ) column equipped with security guard cartridge), with an 
isocratic mobile phase of H2O at flow rate of 8.0 mL/min detected at 254 nm. 
Fractions containing product (tR = 7.95 min) were collected and concentrated 
under reduced pressure. Muscimol (11) was obtained as a colourless solid after 
freeze drying (16 mg, 34%). Analytical HPLC analysis was performed using 
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Shimadzu system (Phenomenex Kingsorb C18 (150 x 4.6 mm, 5 ) column), with 
an isocratic mobile phase of  H2O at flow rate of 0.8 mL/min detected at              
254 nm (t R= 1.98 min, purity >99%); mp 171-173 C (dec.) [Lit.
19
 170-172 C 
(decomp)]; H (400 MHz, D2O) 4.15 (s, 2H, H-6), 5.87 (s, 1H, H-4);                    
C (176 MHz, D2O) 176.2 (C-3), 165.8 (C-5), 98.9 (C-4), 34.9 (C-6); HRMS m/z 
(ESI
+
), found: [M+H]
+
 115.0501, C4H7N2O2 requires [M+H]
+
 115.0508. These 
data are in accordance with the literature.
19
 
 
4.2.27 5-Azidomethyl-4-iodo-3-isopropoxyisoxazole (126) 
 
 
 
NIS (202 mg, 0.90 mmol, 1.5 eq) was added to a solution of 5-azidomethyl-3-
isopropoxyisoxazole (118) (110 mg, 0.60 mmol, 1.0 eq) in TFA (5 mL) at rt. 
After stirring at rt overnight, the solvent was removed under reduced pressure and 
the residue was purified by silica gel column chromatography (petroleum 
ether/Et2O, 95:5), affording 5-azidomethyl-4-iodo-3-isopropoxyisoxazole (126) 
(159 mg, 86%) as yellowish oil: Rf 0.87 (petroleum ether/Et2O, 90:10, 
UV/KMnO4); FT-IR (ATR, cm
-1
) 2980, 2095 (N3), 1607, 1506, 1427, 1387, 
1373, 1333, 1287, 1182, 1109, 1087, 914, 839, 768, 700; H (500 MHz, CDCl3) 
4.95 (1H, sept, 
3
JHH 6.2, H-7), 4.37 (2H, s, H-6), 1.42 (6H, d, 
3
JHH 6.2, H-8);        
C (125 MHz, CDCl3) 170.3 (C-3), 167.4 (C-5), 74.9  (C-7), 53.2 (C-4), 45.3     
(C-6), 21.9 (C-8); HRMS m/z (NSI
+
), found: [M+H]
+
 308.9846, C7H10N4O2
127
I 
requires [M+H]
+
 308.9843. 
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4.2.28 5-Aminomethyl-4-iodo-3-isopropoxyisoxazole (127) 
 
 
 
PMe3 (1.0 M solution in THF, 1.47 mL, 1.47 mmol, 3.0 eq) was added to a 
solution of 5-azidomethyl-4-iodo-3-isopropoxyisoxazole (126) (150 mg,            
0.49 mmol, 1.0 eq) in THF (8 mL) at 0 °C. The resulting mixture was stirred at     
0 °C for 1 h and was quenched by slow addition of water (10 mL). The organic 
phase was separated and the aqueous phase was extracted into EtOAc                   
(3 x 20 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated under reduced pressure and the residue was 
purified by silica gel column chromatography (EtOAc, 100), affording                  
5-aminomethyl-4-iodo-3-isopropoxyisoxazole (127) (114 mg, 83%) as yellowish 
oil: Rf 0.50 (EtOAc/MeOH, 90:10, UV/ninhydrin);  FT-IR (ATR, cm
-1
) 3397, 
3377 (NH2), 2978, 1593, 1502, 1431, 1385, 1373, 1335, 1107, 1084, 916, 837, 
754, 721, 691; H (500 MHz ,CDCl3) 4.91 (1H, sept, 
3
JHH 6.2, H-7),                  
3.85 (2H, s, H-6), 1.53 (br s, 2H, -NH2), 1.39 (6H, d, 
3
JHH 6.2, H-8);                     
C (125 MHz, CDCl3) 173.2 (C-5), 170.2 (C-3), 74.4 (C-7), 49.2 (C-4), 38.5          
(C-6), 21.9 (C-8); HRMS m/z (NSI
+
), found: [M+H]
+
 282.9935, C7H12N2O2
127
I 
requires [M+H]
+
 282.9938. 
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4.2.29 5-(tert-Butyloxycarbonyl)aminomethyl-4-iodo-3-isopropoxyisoxazole 
(128) 
 
 
 
Na2CO3 (541 mg, 5.10 mmol, 2.0 eq) was added to a solution of                            
5-aminomethyl-4-iodo-3-isopropoxyisoxazole (127) (720 mg, 2.55 mmol, 1.0 eq) 
in dioxane/water (3:1 v/v mixture, 16 mL) at 0 °C, followed by dropwise addition 
of di-tert-butyl dicarbonate (0.65 mL, 2.81 mmol, 1.1 eq) in dioxane (2 mL). 
After stirring at rt overnight, dioxane was removed under reduced pressure and 
the residue was diluted with Et2O (40 mL) and washed with water (50 mL). The 
aqueous layer was extracted into Et2O (3 x 40 mL). The combined organic layers 
were combined, dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting yellow residue was purified by silica gel column                               
chromatography (petroleum ether/Et2O, 70:30) to afford 5-(tert-
butyloxycarbonyl)aminomethyl-4-iodo-3-isopropoxyisoxazole (128) (788 mg, 
81%) as a colourless viscous oil: Rf 0.53 (petroleum ether/Et2O, 60:40, 
UV/ninhydrin); FT-IR (ATR, cm
-1
) 3352 (NH), 2980, 1699 (C=O), 1603, 1506 
(NH), 1433, 1387, 1368, 1337, 1281, 1250, 1167, 1090, 916;                                
H (500 MHz, CDCl3) 4.98 (br s, 1H, -NH), 4.90 (1H, sept, 
3
JHH 6.2, H-7), 4.37 
(2H, d, 
3
JHH 5.9, H-6), 1.44 (9H, s, H-11), 1.39 (6H, d, 
3
JHH 6.2, H-8);                  
C (125 MHz, CDCl3) 170.3 (C-3), 169.3 (C-5), 155.4 (C-9), 80.4 (C-10),            
74.5 (C-7), 50.5 (C-4), 37.1 (C-6), 28.5 (C-11), 21.9 (C-8); HRMS m/z (ESI
+
), 
found: [M+Na]
+
 405.0273, C12H19N2O4
127
INa requires [M+Na]
+ 
405.0282. 
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4.2.30 5-Di(tert-butyloxycarbonyl)aminomethyl-4-iodo-3-isopropoxyisoxazole 
(129) 
 
 
 
 
DMAP (34.2 mg, 0.28 mmol, 0.2 eq) and di-tert-butyl dicarbonate (0.65 mL, 2.82 
mmol, 2.0 eq) were added to a solution of 5-(tert-butyloxycarbonyl)aminomethyl-
4-iodo-3-isopropoxyisoxazole (128) (540 mg, 1.41 mmol, 1.0 eq) in MeCN               
(25 mL). The reaction mixture was heated under reflux for 3 h and allowed to cool 
to rt. The reaction was diluted with DCM (20 mL), and washed with water               
(30 mL). The aqueous layer was extracted into DCM (3 x 30 mL). The combined 
organic layers were combined, dried over MgSO4, filtered and concentrated under 
reduced pressure. The resulting brown oil was purified by silica gel                                  
column chromatography (petroleum ether/Et2O, 90:10) to afford 5-di(tert-
butyloxycarbonyl)aminomethyl-4-iodo-3-isopropoxyisoxazole (129) (592  mg, 
87%) as a colourless viscous oil: Rf 0.68 (petroleum ether/Et2O, 70:30, 
UV/ninhydrin);  FT-IR (ATR, cm
-1
) 2986, 1730 (C=O), 1688 (C=O), 1601, 1510, 
1435, 1416, 1383, 1368, 1337, 1227, 1165, 1140, 1121, 1090, 918, 858, 849, 791, 
760; H (500 MHz, CDCl3) 4.90 (1H, sept, 
3
JHH 6.2, H-7), 4.83 (2H, s, H-6),              
1.48 (18H, s, H-11), 1.39 (6H, d, 
3
JHH 6.2, H-8); C (125 MHz, CDCl3) 171.0          
(C-3), 169.7 (C-9), 151.7 (C-5), 83.5 (C-10), 74.4 (C-7), 48.8 (C-4), 42.7 (C-6), 
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28.2 (C-11), 21.9 (C-8); HRMS m/z (ESI
+
), found: [M+Na]
+
 505.0796, 
C17H27N2O6
127
INa requires [M+Na]
+
 505.0806. 
 
4.2.31 5-Di(tert-butyloxycarbonyl)aminomethyl-4-trifluoromethyl-3- 
isopropoxyisoxazole (130) 
 
 
 
Methyl 2,2-difluoro-2-(fluorosulfonyl) acetate (MFDSA) (945 mg, 4.92 mmol, 
4.0 eq) was added to a preformed solution of 5-di(tert-
butyloxycarbonyl)aminomethyl-4-iodo-3-isopropoxyisoxazole (129) (592 mg, 
1.23 mmol, 1.0 eq), copper(I) iodide (47.6 mg, 0.25 mmol, 0.2 eq) and HMPA    
(1 ml) in DMF (8 ml).  The reaction mixture was heated under reflux at 80 C for 
24 h. The clear, dark orange reaction mixture was cooled to room temperature and 
diluted with Et2O (10 ml), washed with a saturated aqueous solution of NH4Cl                                
(15 ml) and brine (15 ml). The aqueous layer was back-extracted into                                   
Et2O (3 x 20 ml) and the combined organic layers were combined,                                                 
dried over MgSO4, filtered and concentrated under reduced pressure. The 
resulting yellowish oil was purified by silica gel column chromatography 
(petroleum ether/Et2O, 90:10) to afford 5-di(tert-butyloxycarbonyl)aminomethyl-
4-trifluoromethyl-3-isopropoxyisoxazole (130) (177 mg, 34%) as a colourless 
viscous oil: Rf 0.66 (petroleum ether/Et2O, 80:20, ninhydrin);                                
200 
 
FT-IR (ATR, cm
-1
) 2982, 1761 (C=O), 1699 (C=O), 1647, 1516, 1472, 1718, 
1369, 1333, 1308, 1260, 1227, 1130, 1109, 1078, 1036, 918, 854, 843.764;           
H (400 MHz, CDCl3) 4.97 (2H, q, 
5
JHF 1.0, H-6), 4.91 (1H, sept, 
3
JHH 6.2, H-7), 
1.49 (18H, s, H-11), 1.40 (6H, d, 
3
JHH 6.2, H-8); 
1
H{
19
F} (400 MHz, CDCl3)         
4.97 (2H, s, H-6), 4.91 (1H, sept, 
3
JHH 6.2, H-7), 1.49 (18H, s, H-11),                       
1.40 (6H, d, 
3
JHH 6.2, H-8);  C (176 MHz, CDCl3) 169.4 (C-9), 167.4 (C-3), 
151.6 (C-5), 121.2 (q, 
1
JCF 254.6, CF3), 99.2 (q, 
2
JCF 39.4, C-4), 83.8 (C-10),           
74.9 (C-7), 42.2 (C-6), 28.1 (C-11), 21.8 (C-8); F (376 MHz, CDCl3)                     
-57.7 (3F, t, 
5
JHF 1.0, CF3); 
19
F{
1
H} (376 MHz, CDCl3) -57.7 (s, CF3);.                  
HRMS m/z (ESI
+
), found: [M+Na]
+
 447.1704, C18H27N2O6F3Na requires 
[M+Na]
+
 447.1713. 
 
4.2.32 5-Aminomethyl-4-trifluoromethyl-3-hydroxyisoxazole (65) 
 
 
 
TFA (0.17 mL, 2.2 mmol, 20.0 eq) was added to a solution of 5-di(tert-
butyloxycarbonyl)aminomethyl-4-trifluoromethyl-3-isopropoxyisoxazole (130) 
(45 mg, 0.11 mmol, 1.0 eq) in DCM (5 mL). After stirring at rt for 6 h, the solvent 
was removed under reduced pressure to afford a hygroscopic colourless 
crystalline solid contained (135) (35 mg), which was used in the subsequent step 
without further purification. A solution of HBr 33% in AcOH (0.9 mL, 5.0 mmol, 
50 eq) was added to crude (135) (35 mg, 0.10 mmol, 1.0 eq) and stirred at 60 °C 
for 48 h. The solvent was removed under vacuum and the residue was washed 
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with water (3 x 2 mL). The residue was passed through a reverse phase C18 
cartridge (Varian Mega Bond Elut C18, preconditioned with water) and the 
product was eluted with water (3 x 10 mL). The fractions were combined and 
concentrated under reduced pressure. The product was further purified by 
preparative HPLC (Waters system, using a Phenomenex Kingsorb C18             
(250 x 21.2 mm, 5 ) column equipped with security guard cartridge) with an 
isocratic mobile phase of H2O at flow rate of  8.0 mL/min detected at 254 nm. 
Fractions containing product (tR = 9.10 min) were collected and concentrated 
under reduced pressure. Trifluoromethylmuscimol (65) was obtained as a 
colourless solid after freeze drying (7.2 mg, 36% over 2 steps). Analytical HPLC 
analysis was performed using Shimadzu system (Phenomenex Kingsorb C18    
(150 x 4.6 mm, 5 ) column), with an isocratic mobile phase of H2O at flow rate 
of  0.8 mL/min detected at 254 nm (tR = 2.27 min, purity >98%); mp 165-168 C 
(dec); FT-IR (ATR, cm
-1
) 2997, 2891, 2631 (br), 1667, 1491, 1425, 1371,              
1344, 1161, 1109, 1042, 978, 745; H (400 MHz, D2O) 4.38 (s, H-6);                     
C (176 MHz, D2O) 172.2 (C-3), 163.7 (C-5), 121.6 (q, 
1
JCF 267.8, CF3),         
103.2 (q, 
2
JCF 39.5, C-4), 34.5 (C-6); F (376 MHz, D2O) -58.9 (s, CF3);      
HRMS m/z (ESI
+
), found: [M+H]
+
 183.0373, C5H6N2O2F3 requires  [M+H]
+
 
183.0381. 
 
 
 
 
 
 
 
 
 
202 
 
4.2.33 Methyl 4-iodo-3-methoxyisoxazole-5-carboxylate (166) 
 
 
 
Methyl-3-methoxyisoxazole-5-carboxylate (94) (680 mg, 4.33 mmol, 1.0 eq),                           
NIS (1.95 g, 8.66 mmol, 2.0 eq), and TFA (19 mL) were placed in a 10 ml glass 
microwave vessel. The reaction vessel was sealed with a rubber lid (CEM) and 
heated under microwave irradiation at 150 °C (50 W) for 3 h. The solvent was 
removed under reduced pressure and the residue was purified by silica gel column 
chromatography (petroleum ether/Et2O, 90:10), furnishing methyl 4-iodo-3-
methoxyisoxazole-5-carboxylate (166) (980 mg, 80%) as colourless crystalline 
solid: Rf 0.47 (petroleum ether/Et2O, 80:20, UV/KMnO4); mp 140-141 °C;           
FT-IR (ATR, cm
-1
) 2963, 1730 (C=O), 1518, 1445, 1431, 1406, 1269, 1211, 
1204, 1169, 1090, 1032, 978, 945, 918, 808, 773, 698, 606; H (500 MHz, CDCl3) 
4.08 (3H, s, H-8),  3.97 (3H, s, H-7); C (125 MHz, CDCl3) 172.1 (C-3), 159.2   
(C-5), 156.7 (C-6), 58.2 (C-8), 57.9 (C-4), 53.0 (C-7); HRMS m/z (NSI
+
), found 
[M+H]
+
 283.9419, C6H7NO4
127
I requires [M+H]
+
 283.9414.  
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4.2.34 Tributyl(4-methoxyphenyl)stannane (170)
20
 
 
 
 
4-Methoxyphenylmagnesium bromide (0.50 M in THF, 8.0 mL, 4.0 mmol, 2.0 eq) 
was added to a solution of tributyltin chloride (652 mg, 2.00 mmol, 1.0 eq) in 
THF (2 mL). After stirring for 2 h at 60 °C, the reaction mixture was cooled to       
0 °C and quenched with saturated aqueous solution of NH4Cl (10 mL) and Et2O 
(10 ml) was added. The phases were separated and the aqueous phase was 
extracted with Et2O (3 x 10 mL). The combined organic layers were washed with 
brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by fractional distillation to afford                       
tributyl(4-methoxyphenyl)stannane (170) (630 mg, 79%) as a colourless oil:         
H (500 MHz, CDCl3) 7.43-7.28 (m, 2H, H-3), 6.93-6.90 (m, 2H, H-4), 3.81            
(s, 1H, H-1), 1.57-1.51 (m, 6H, H-7), 1.37-1.30 (m, 6H, H-8), 1.04-1.02                    
(m, 6H, H-6), 0.89 (t, 
3
JHH 7.3, H-9); C (100 MHz, CDCl3) 159.8 (C-2),                  
137.6 (C-3), 132.1 (C-5), 114.1 (C-4), 55.1 (C-1), 29.2 (C-7), 27.5 (C-8), 13.8   
(C-9), 9.7 (C-6). These data are in accordance with the literature.
20
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4.2.35 (3-Methoxy-5-(methoxycarbonyl)isoxazol-4-yl)                                                
(4-methoxyphenyl)iodonium trifluoroacetate (171) 
 
 
 
mCPBA (70% active oxidant, 791 mg, 3.21 mmol, 1.3 eq) was added to a solution 
of methyl 4-iodo-3-methoxyisoxazole-5-carboxylate (166) (700 mg, 2.47 mmol, 
1.0 eq) in AcOH (20 ml). After stirring at 55 °C for 96 h, water (30 ml) was added 
to the reaction mixture and it was extracted into DCM (3 x 20 ml). The combined 
organic layers were washed with a saturated aqueous solution of Na2CO3              
(60 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to 
afford a colourless solid, which was used without further purification.  
 
Methyl (4-diacetoxyiodo)-3-methoxyisoxazole-5-carboxylate (167) (281 mg,           
0.7 mmol, 1.0 eq as a 40% mixture determined by 
1
H-NMR with methyl 4-iodo-3-
methoxyisoxazole-5-carboxylate (166)), was dissolved in DCM (10 ml)                    
and cooled to -30 °C, followed by dropwise addition of TFA (110 L, 1.40 mmol, 
2.0 eq). The solution was stirred with exclusion of light for 30 min,                       
followed by 1 h at rt. The reaction mixture was re-cooled to -30 °C and                                        
tributyl(4-methoxyphenyl)stannane (170) (278 mg, 0.70 mmol, 1.0 eq) was added.                 
The reaction was warmed to rt for the second time and left to stir overnight. The 
solvent was removed under vacuo, leaving the addition of Et2O to afford                                            
(3-methoxy-5-(methoxycarbonyl)isoxazol-4-yl)(4-methoxyphenyl)iodonium TFA 
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salt (171) (35 mg, 10%) as colourless crystalline solid: mp 150-153 C (dec.); 
FT-IR (ATR, cm
-1
) 1732 (C=O), 1655, 1523, 1487, 1294, 1260, 1145, 1132, 
1028, 819, 797, 719; H (500 MHz, d6-DMSO) 8.00 (2H, d, 
3
JHH 7.2,  H-10), 7.06 
(2H, d, 
3
JHH 7.2, H-11), 4.07 (3H, s, H-7), 4.01 (3H, s, H-8), 3.80 (3H, s, H-13); 
C (125 MHz, d6-DMSO) 170.1 (C-6), 162.0 (C-12), 161.0 (C-5), 155.3(C-3), 
137.0 (C-10), 117.5 (C11), 107.0 (C-9), 83.9(C-4), 59.0(C-7), 55.7(C-13), 54.0   
(C-8); F (470 MHz, d6-DMSO) -73.6 (3F, s, TFA); HRMS m/z (ESI
+
), found   
[M-TFA]
+ 
389.9819, C13H13 NO5
127
I requires [M-TFA]
+ 
389.9833.  
 
4.2.36 4-Iodo-3-methoxy-5-(methoxymethyl)isoxazole (173) 
 
 
 
NIS (997 mg, 4.43 mmol, 1.5 eq) was added to a solution of 3-methoxy-5-
(methoxymethyl)isoxazole (96) (422 mg, 2.95 mmol, 1.0 eq) in TFA (10 mL). 
After stirring at rt overnight, the solvent was removed under reduced pressure and 
the residue was purified by silica gel column chromatography (petroleum 
ether/Et2O, 90:10), affording 4-iodo-3-methoxy-5-(methoxymethyl)isoxazole 
(173) (696 mg, 88%) as colourless crystalline solid: Rf 0.50 (petroleum 
ether/Et2O, 70:30, UV/KMnO4); mp 88-89 °C; FT-IR (ATR, cm
-1
) 2990, 1609, 
1526, 1447, 1408, 1371, 1277, 1192, 1105, 1086, 1053, 959, 947, 928, 783, 716, 
546;  H (500 MHz, CDCl3) 4.47 (2H, s, H-6) 4.03 (3H, s, H-8), 3.40 (3H, s, H-7);                                                
C (125 MHz, CDCl3) 171.5 (C-3), 169.8 (C-5), 64.8 (C-6), 59.0 (C-7), 57.8           
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(C-8), 51.7 (C-4); HRMS m/z (ESI
+
), found: [M+H]
+
 269.9619, C6H9NO3
127
I 
requires [M+H]
+
 269.9627.  
 
4.2.37 (3-Methoxy-5-(methoxymethyl)isoxazol-4-yl)                                                
(4-methoxyphenyl)iodonium tetrafluoroborate (176) 
 
 
 
4-Iodo-3-methoxy-5-(methoxymethyl)isoxazole (173) (70 mg, 0.26 mmol, 1.0 eq) 
and BF3Et2O (80 L, 0.65 mmol, 2.5 eq) were added to a solution of mCPBA 
(70% active oxidant, 83 mg, 0.34 mmol, 1.3 eq) in DCM (1.5 mL) at rt. The 
resulting yellow solution was stirred at rt for 2 h and cooled to 0 °C,                           
4-methoxyphenylboronic acid (43 mg, 0.29 mmol, 1.1 eq) was added and the 
temperature was allowed to warm to rt. After 2 h of stirring, the crude mixture 
was applied on silica plug (0.8 g) and eluted with DCM (10 mL) to remove 
unreacted ArI (173) and mCBA followed by (DCM/MeOH) (20:1 v/v mixture,           
42 mL) to elute the product, leaving any boronic acid derivatives on the column. 
The latter solution was concentrated and Et2O (1 mL) was added to the residue to 
induce precipitation. The ether phase was decanted and the solid was washed 
twice more with Et2O (2 x 1 mL) and dried in vacuo to give (3-methoxy-5-
(methoxymethyl)isoxazol-4-yl)(4-methoxyphenyl)iodonium tetrafluoroborate salt 
(176) in (60 mg, 50%) as a pale yellow solid: mp 161-163 C (dec.);                  
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FT-IR (ATR, cm
-1
) 2945, 1601, 1497, 1408, 1246, 1088, 1039, 756, 692;                    
H (500 MHz, d6-DMSO) 8.00 (2H, d, 
3
JHH 8.9, H-10), 7.08 (2H, d, 
3
JHH 8.9,      
H-11), 4.79 (2H, s, H-6), 4.02 (3H, s, H-8), 3.80 (3H, s, H-13), 3.38 (3H, s, H-7);            
C (125 MHz, d6-DMSO) 174.4 (C-5), 169.6 (C-3), 162.0 (C-12), 136.9 (C-10), 
117.6  (C-11), 106.7 (C-9), 78.0 (C-4), 64.6 (C-6), 58.8 (C-7), 58.6 (C-8), 55.8 
(C-13); F (470 MHz, d6-DMSO) -148.17, -148.23 (4F, s, BF4
-
); HRMS m/z 
(ESI
+
), found: [M-BF4]
+ 
376.0028, C13H15NO4
127
I requires [M-BF4]
+
 376.0040]. 
 
4.2.38 Mesityl(3-methoxy-5-(methoxymethyl)isoxazol-4-yl)iodonium 
tetrafluoroborate (177) 
 
 
 
4-Iodo-3-methoxy-5-(methoxymethyl)isoxazole (173) (70 mg, 0.26 mmol, 1.0 eq) 
and BF3Et2O (80 L, 0.65 mmol, 2.5 eq) were added to a solution of mCPBA 
(70% active oxidant, 83 mg, 0.34 mmol, 1.3 eq) in DCM (1.5 mL) at rt. The 
resulting yellow solution was stirred at rt for 2 h and cooled to 0 °C,                
2,4,6-trimethylphenylboronic acid (48 mg, 0.29 mmol, 1.1 eq) was added and the 
temperature was allowed to warm to rt. After 2 h of stirring, the crude mixture 
was applied on silica plug (0.8 g) and eluted with DCM (10 mL) to remove 
unreacted ArI (173) and mCBA followed by (DCM/MeOH) (20:1 v/v mixture,     
42 mL) to elute the product, leaving any boronic acid derivatives on the column. 
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The latter solution was concentrated, and Et2O (1 mL) was added to the residue to 
induce precipitation. The ether phase was decanted and the solid was washed 
twice more with Et2O (2 x 1 mL) and  dried in vacuo to give mesityl(3-methoxy-
5-(methoxymethyl)isoxazol-4-yl)iodonium tetrafluoroborate salt (177) in                 
(55 mg, 45%) as a pale yellow solid: ; mp 157-160 C (dec.); FT-IR (ATR, cm-1) 
2916, 1607, 1470, 1377, 1032, 1003, 962, 835, 687; H (500 MHz, d6-DMSO)                    
7.20 (2H, s, H-12), 4.72 (2H, s, H-6), 3.96 (3H, s, H-8), 3.37 (3H, s, H-7),               
2.63 (6H, s, H-11), 2.29 (3H, s, H-14); C (125 MHz, d6-DMSO) 174.3 (C-5), 
169.9 (C-3), 143.0 (C-13), 141.5 (C-10), 129.6 (C-12), 123.9 (C-9), 75.9 (C-4), 
64.7 (C-6), 58.9 (C-7), 58.5 (C-8), 26.0 (C-11), 20.5 (C-14); F (470 MHz,          
d6-DMSO) -148.16, -148.21 (4F, s, BF4
-
); HRMS m/z (ESI
+
), found: [M-BF4]
+ 
388.0392, C15H19NO3
127
I requires [M-BF4]
+
 388.0404. 
 
4.2.39 5-Aminomethyl-4-iodo-3-hydroxyisoxazole (165) 
 
 
 
A solution of HBr 33% in AcOH (1.7 mL, 9.5 mmol, 25 eq) was added to                              
5-aminomethyl-4-iodo-3-isopropoxyisoxazole (127) (107 mg, 0.38 mmol, 1.0 eq) 
and stirred at 60 °C for 17 h. The solvent was removed under vacuum and the 
residue was washed with water (3 x 2 mL). The residue was passed through a 
reverse phase C18 cartridge (Varian Mega Bond Elut C18, preconditioned with 
water) and the product was eluted with water (3 x 10 mL). The fractions were 
combined and concentrated under reduced pressure. The product was further 
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purified by preparative HPLC (Waters system, using a Phenomenex Kingsorb 
C18 (250 x 21.2 mm, 5 ) column equipped with security guard cartridge), with 
an isocratic mobile phase of H2O at flow rate of 8.0 mL/min detected at 254 nm. 
Fractions containing product (tR = 8.97 min) were collected and concentrated 
under reduced pressure.  Iodomuscimol (165) was obtained as a colourless solid 
after freeze drying (17.3 mg, 19%). Analytical HPLC analysis was performed 
using Shimadzu system (Phenomenex Kingsorb C18 (150 x 4.6 mm, 5 ) 
column), with an isocratic mobile phase of H2O at flow rate of                             
0.8 mL/min detected at 254 nm (tR = 2.19 min, purity >99%); mp 161-162 C;                        
FT-IR (ATR, cm
-1
) 3350, 2990, 2637 (br), 2363, 1616, 1487, 1358, 1254, 1077, 
1037, 968; H (400 MHz, D2O) 4.21 (s, 2H, H-6); C (176 MHz, D2O) 176.4          
(C-3), 163.2 (C-5), 61.6 (C-4), 35.3 (C-6); HRMS m/z (ESI
+
), found: [M+H]
+
 
240.9466, C4H6N2O2
127
I requires  [M+H]
+
 240.9474. 
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Appendix 1.1-Crystallographic information for (101) 
 
 
 
 
 mmdh7 (101) 
Formula  C6H8N2O4 
Molecular weight  172.14 
Crystal description Colourless prism 
Crystal dimensions (mm) 0.27×0.06×0.06 
Crystal system Monoclinic 
Space group  P21/c  
a (Å) 7.0425(18) 
b (Å) 11.555(3) 
c (Å) 9.654(2) 
α (°)  
β (°) 106.629(6) 
γ (°)  
Volume (Å
3
) 752.7(3) 
Z 4 
Calculated density (g cm
-3
) 1.519 
Temperature (K) 173 
 (mm-1) 0.129 
F(000) 360 
Reflections collected 9048 
Unique reflections (Rint) 1388 (0.0511) 
Max./min. transmission 0.992, 0.695 
R1, wR2 [I>2(I)] 0.0300, 0.0813 
R1, wR2 (all data) 0.0345, 0.0833 
Goodness of fit 1.086 
Data/restraints/parameters 1388/2/119 
Max. difference peak/hole (e A
-3
) 0.17, -0.20 
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Appendix 1.2-Crystallographic information for (105) 
 
 
 
 
 mmdh1 (105) 
Formula  C6H6BrNO4 
Molecular weight  236.03 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.17×0.03×0.01 
Crystal system Monoclinic 
Space group  P21/n  
a (Å) 3.9658(10) 
b (Å) 15.912(4) 
c (Å) 12.881(3) 
α (°)  
β (°) 94.979(7) 
γ (°)  
Volume (Å
3
) 809.8(3) 
Z 4 
Calculated density (g cm
-3
) 1.936 
Temperature (K) 173 
 (mm-1) 5.064 
F(000) 464 
Reflections collected 8194 
Unique reflections (Rint) 1468 (0.1382) 
Max./min. transmission 0.951, 0.457 
R1, wR2 [I>2(I)] 0.0605, 0.1401 
R1, wR2 (all data) 0.0826, 0.1505 
Goodness of fit 0.925 
Data/restraints/parameters 1468/0/111 
Max. difference peak/hole (e A
-3
) 1.49, -0.83 
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Appendix 1.3-Crystallographic information for (107) 
 
 
 
 
 mmdh5 (107) 
Formula  C6H8BrNO3 
Molecular weight  222.04 
Crystal description Colourless prism 
Crystal dimensions (mm) 0.06×0.06×0.04 
Crystal system Orthorhombic 
Space group  P212121  
a (Å) 4.0901(5) 
b (Å) 7.0548(10) 
c (Å) 28.194(4) 
α (°)  
β (°)  
γ (°)  
Volume (Å
3
) 813.53(19) 
Z 4 
Calculated density (g cm
-3
) 1.813 
Temperature (K) 173 
 (mm-1) 5.025 
F(000) 440 
Reflections collected 9749 
Unique reflections (Rint) 1489 (0.0580) 
Max./min. transmission 0.818, 0.602 
R1, wR2 [I>2(I)] 0.0233, 0.0549 
R1, wR2 (all data) 0.0249, 0.0551 
Goodness of fit 0.976 
Data/restraints/parameters 1489/0/102 
Max. difference peak/hole (e A
-3
) 0.73, -0.22 
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Appendix 1.4-Crystallographic information for (108) 
 
 
 
 mmdh14 (108) 
Formula  C15H23BrN2O6 
Molecular weight  407.26 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.18×0.09×0.02 
Crystal system Monoclinic 
Space group  P21/c  
a (Å) 11.3612(13) 
b (Å) 9.2489(11) 
c (Å) 18.561(2) 
α (°)  
β (°) 97.991(3) 
γ (°)  
Volume (Å
3
) 1931.4(4) 
Z 4 
Calculated density (g cm
-3
) 1.400 
Temperature (K) 173 
 (mm-1) 2.164 
F(000) 840 
Reflections collected 23120 
Unique reflections (Rint) 3536 (0.0246) 
Max./min. transmission 0.958, 0.830 
R1, wR2 [I>2(I)] 0.0255, 0.0620 
R1, wR2 (all data) 0.0315, 0.0648 
Goodness of fit 1.019 
Data/restraints/parameters 3536/0/224 
Max. difference peak/hole (e A
-3
) 0.36, -0.37 
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Appendix 1.5-Crystallographic information for (120) 
 
 
 
 
 mmdh17 (120) 
Formula  C12H20N2O4 
Molecular weight  256.30 
Crystal description Colourless chip 
Crystal dimensions (mm) 0.04×0.04×0.02 
Crystal system Orthorhombic 
Space group  Pbcn  
a (Å) 14.177(12) 
b (Å) 8.920(8) 
c (Å) 22.562(19) 
α (°)  
β (°)  
γ (°)  
Volume (Å
3
) 2853(4) 
Z 8 
Calculated density (g cm
-3
) 1.193 
Temperature (K) 173 
 (mm-1) 0.090 
F(000) 1104 
Reflections collected 32287 
Unique reflections (Rint) 2606 (0.6336) 
Max./min. transmission 0.998, 0.515 
R1, wR2 [I>2(I)] 0.0926, 0.0953 
R1, wR2 (all data) 0.1442, 0.3157 
Goodness of fit 1.065 
Data/restraints/parameters 2606/19/187 
Max. difference peak/hole (e A
-3
) 0.21, -0.19 
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Appendix 1.6-Crystallographic information for (121) 
 
 
 
 
 mmdh20 (121) 
Formula  C12H19FN2O4 
Molecular weight  274.29 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.17×0.07×0.01 
Crystal system Monoclinic 
Space group  P21/c  
a (Å) 29.944(18) 
b (Å) 9.572(6) 
c (Å) 9.989(6) 
α (°)  
β (°) 99.228(12) 
γ (°)  
Volume (Å
3
) 2826(3) 
Z 8 
Calculated density (g cm
-3
) 1.289 
Temperature (K) 173 
 (mm-1) 0.105 
F(000) 1168 
Reflections collected 43304 
Unique reflections (Rint) 5154 (0.3362) 
Max./min. transmission 0.999, 0.796 
R1, wR2 [I>2(I)] 0.1049, 0.1219 
R1, wR2 (all data) 0.3055, 0.1761 
Goodness of fit 1.040 
Data/restraints/parameters 5154/2/361 
Max. difference peak/hole (e A
-3
) 0.24, -0.23 
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Appendix 1.7-Crystallographic information for (122) 
 
 
 
 
 mmdh23 (122) 
Formula  C9H12F4N2O4 
Molecular weight  288.20 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.05×0.05×0.01 
Crystal system Monoclinic 
Space group  P21/c  
a (Å) 12.7513(10) 
b (Å) 10.6475(5) 
c (Å) 10.3803(8) 
α (°)  
β (°) 112.145(9) 
γ (°)  
Volume (Å
3
) 1305.37(18) 
Z 4 
Calculated density (g cm
-3
) 1.466 
Temperature (K) 125 
 (mm-1) 1.342 
F(000) 592 
Reflections collected 14808 
Unique reflections (Rint) 2669 (0.0678) 
Max./min. transmission 0.987, 0.536 
R1, wR2 [I>2(I)] 0.0571, 0.1846 
R1, wR2 (all data) 0.0671, 0.2025 
Goodness of fit 0.830 
Data/restraints/parameters 2669/3/184 
Max. difference peak/hole (e A
-3
) 0.19, -0.33 
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Appendix 1.8-Crystallographic information for (64) 
 
 
 
 
 
 mmdh24 (64) 
Formula  C4H5FN2O2 
Molecular weight  132.09 
Crystal description Colourless prism 
Crystal dimensions (mm) 0.12×0.03×0.02 
Crystal system Monoclinic 
Space group  P21/n  
a (Å) 6.8563(18) 
b (Å) 6.6807(13) 
c (Å) 10.937(3) 
α (°)  
β (°) 92.905(7) 
γ (°)  
Volume (Å
3
) 500.3(2) 
Z 4 
Calculated density (g cm
-3
) 1.754 
Temperature (K) 173 
 (mm-1) 0.164 
F(000) 272 
Reflections collected 5826 
Unique reflections (Rint) 913 (0.0250) 
Max./min. transmission 0.997, 0.930 
R1, wR2 [I>2(I)] 0.0301, 0.0807 
R1, wR2 (all data) 0.0354, 0.0844 
Goodness of fit 1.066 
Data/restraints/parameters 913/3/94 
Max. difference peak/hole (e A
-3
) 0.27, -0.20 
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Appendix 1.9-Crystallographic information for (135) 
 
 
 
 mmdh26 (135) 
Formula  C10H12F6N2O4 
Molecular weight  338.21 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.16×0.12×0.02 
Crystal system Monoclinic 
Space group  P21/c  
a (Å) 17.240(4) 
b (Å) 10.355(2) 
c (Å) 7.9889(17) 
α (°)  
β (°) 101.840(6) 
γ (°)  
Volume (Å
3
) 1395.8(5) 
Z 4 
Calculated density (g cm
-3
) 1.609 
Temperature (K) 173 
 (mm-1) 0.172 
F(000) 688 
Reflections collected 16782 
Unique reflections (Rint) 2552 (0.0896) 
Max./min. transmission 0.997, 0.833 
R1, wR2 [I>2(I)] 0.0473, 0.0768 
R1, wR2 (all data) 0.1056, 0.0958 
Goodness of fit 1.035 
Data/restraints/parameters 2554/3/213 
Max. difference peak/hole (e A
-3
) 0.21, -0.22 
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Appendix 1.10-Crystallographic information for (166) 
 
 
 
 mmdh2 (166) 
Formula  C6H6INO4 
Molecular weight  283.02 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.21×0.12×0.02 
Crystal system Monoclinic 
Space group  P21/n  
a (Å) 4.1252(13) 
b (Å) 15.712(4) 
c (Å) 13.231(4) 
α (°)  
β (°) 95.941(9) 
γ (°)  
Volume (Å
3
) 853.0(4) 
Z 4 
Calculated density (g cm
-3
) 2.204 
Temperature (K) 173 
 (mm-1) 3.731 
F(000) 536 
Reflections collected 9717 
Unique reflections (Rint) 1549 (0.1853) 
Max./min. transmission 0.928, 0.181 
R1, wR2 [I>2(I)] 0.0964, 0.2438 
R1, wR2 (all data) 0.1131, 0.2514 
Goodness of fit 0.985 
Data/restraints/parameters 1549/0/112 
Max. difference peak/hole (e A
-3
) 3.89, -1.97 
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Appendix 1.11-Crystallographic information for (171) 
 
 
 
 mmdh10 (171) 
Formula  C15H13F3INO7 
Molecular weight  503.17 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.16×0.03×0.01 
Crystal system Triclinic 
Space group  P ̅  
a (Å) 8.436(2) 
b (Å) 10.750(3) 
c (Å) 11.338(3) 
α (°) 113.913(5) 
β (°) 97.392(4) 
γ (°) 98.975(5) 
Volume (Å
3
) 907.2(4) 
Z 2 
Calculated density (g cm
-3
) 1.842 
Temperature (K) 173 
 (mm-1) 1.833 
F(000) 492 
Reflections collected 11079 
Unique reflections (Rint) 3270 (0.0528) 
Max./min. transmission 0.982, 0.862 
R1, wR2 [I>2(I)] 0.0602, 0.1317 
R1, wR2 (all data) 0.0925, 0.1456 
Goodness of fit 1.045 
Data/restraints/parameters 3270/0/246 
Max. difference peak/hole (e A
-3
) 1.49, -0.66 
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Appendix 1.12-Crystallographic information for (173) 
 
 
 
 
 mmdh11 (173) 
Formula  C6H8INO3 
Molecular weight  269.04 
Crystal description Colourless platelet 
Crystal dimensions (mm) 0.12×0.04×0.01 
Crystal system Orthorhombic 
Space group  P212121  
a (Å) 4.1851(10) 
b (Å) 7.2364(19) 
c (Å) 28.331(8) 
α (°)  
β (°)  
γ (°)  
Volume (Å
3
) 858.0(4) 
Z 4 
Calculated density (g cm
-3
) 2.083 
Temperature (K) 173 
 (mm-1) 3.694 
F(000) 512 
Reflections collected 13556 
Unique reflections (Rint) 1560 (0.1144) 
Max./min. transmission 0.964, 0.629 
R1, wR2 [I>2(I)] 0.0657, 0.1427 
R1, wR2 (all data) 0.0833, 0.1498 
Goodness of fit 1.103 
Data/restraints/parameters 1560/0/102 
Max. difference peak/hole (e A
-3
) 1.99, -0.78 
 
